10.01.503: General Anesthesia and Facility Services Related to Dental Treatment Treatments: [General Anesthesia and Medical Monitoring, Facility Services for Dental Treatment with Monitored Anesthesia]; Indications: [Need for facility due to medical condition risk, Need for facility due to severity/extent of dental condition, Need for GA/Monitoring due to disability and failure of other sedation, Need for GA/Monitoring for child failing other management, Need for GA/Monitoring for child where other management is contraindicated, Anesthesia performed by licensed professional other than treating provider]
10.01.504: MEDICAL POLICY – 10.01.504 Technology Review Treatments: [Any New or Existing Technology/Service Under Review]; Indications: [Meets Medically Necessary Criteria, Fails Medically Necessary Criteria (Is Investigational), Cosmetic Services]
10.01.511: ADMINISTRATIVE GUIDELINE – Medical Policy and Clinical Guidelines: Definitions and Procedures Treatments: []; Indications: []
10.01.512: Ambulance and Medical Transport Services Treatments: [Any Ambulance or Medical Transport Service, Ground Emergency Medical Transport, Air Emergency Medical Transport, Sea Emergency Medical Transport, Non-Emergency Ground Transport (Hospital to Hospital), Non-Emergency Air Transport (Hospital to Hospital), Other Non-Emergency Ground Transport, Cabulance or Wheelchair Van Transport]; Indications: [Medical Emergency, Ground Emergency Transport Requirements Met, Examples of Medical Conditions Requiring Emergency Transport, Need for Specialized Medical Facility (Emergency Context), Air/Sea Emergency Transport Requirements Met, Non-Emergency Hospital Transfer Criteria Met, Other Non-Emergency Ground Transport Criteria Met, Death Occurring After Ambulance Called or En Route, Death Occurring Before Ambulance Called, Cabulance/Wheelchair Van Not Defined as Ambulance]
10.01.514: Cosmetic and Reconstructive Services Treatments: [Procedures Meeting Reconstructive Criteria (General), Chin Surgery (Genioplasty/Mentoplasty), Dermabrasion / Abrasion, Labiaplasty / Labial Reduction, Otoplasty / Pinnaplasty, Nonsurgical Infant Ear Molding, Rhytidectomy (Face Lift, Neck Lift), Scar Revision, Skin Tag Removal, Tattooing (Medical), Blepharoplasty, Breast Reduction (Reduction Mammaplasty), Gynecomastia Surgery, Orthognathic Surgery, Panniculectomy, Rhinoplasty, Breast Reconstruction, Breast Symmetry Surgery (Contralateral), Breast Prostheses, Facial Prostheses, Ear (Auricular) Prostheses, Eye (Ocular) Prostheses, Testicular Prostheses, Procedures Listed As Cosmetic (General), Abdominoplasty (Tummy Tuck), Arm Lift (Brachioplasty), Breast Augmentation (Implants), Breast Lift (Mastopexy), Buttock / Thigh Lift, Canthopexy / Canthoplasty, Diastasis Recti Repair, Excessive Skin Removal (Limbs/Body), Facial Bone Reduction / Enhancement, Fat Grafts / Injections, Injectable Fillers / Collagen / Volumizers, Inverted Nipple Correction, Lip Augmentation, Liposuction, Lipectomy (Belt, Circumferential), Lower Body Lift, Penis Enhancement Surgery, Tattoo Removal (Salabrasion), Torsoplasty (Body Lift), Skin Wrinkle Treatment, Spider Vein Treatment, Vaginal Rejuvenation Procedures, Botox Cosmetic (OnabotulinumtoxinA), Bellafill (Polymethylmethacrylate Microspheres), Belotero (Non-Animal Hyaluronic Acid Gel), Daxxify (DaxibotulinumtoxinA-lanm), Egrifta SV (Tesamorelin), Jeuveau (PrabotulinumtoxinA-xvfs), Juvederm (Hyaluronic Acid Gel), Kybella (Deoxycholic Acid), Latisse (Bimatoprost), LaViv (Azficel-T), Leqselvi (Deuruxolitinib), Litfulo (Ritlecitinib), Mirvaso (Brimonidine Topical Gel), Olumiant (Baricitinib), Opzelura (Ruxolitinib) Cream, Radiesse (Calcium Hydoxylapatite), Restylane (Hyaluronic Acid Gel), Revanesse (Hyaluronic Acid Gel), Rha Redensity (Resilient Hyaluronic Acid), Sculptra Aesthetic (Injectable Poly-L-lactic Acid), Rhofade (Oxymetazoline Hydrochloride) Topical Cream, Vaniqa (Eflornithine) Topical Cream, Xeomin (IncobotulinumtoxinA), Zyderm (Injectable Collagen), Zyplast (Injectable Collagen), Any Topical Non-Legend Drug for Cosmetic Purpose, Unclassified Drugs/Biologics (General)]; Indications: [Presence of Physical Functional Impairment, Absence of Physical Functional Impairment, Primary Purpose is to Improve Appearance, Maxilla or Mandible Defect (Trauma/Injury/Disease), Superficial Basal Cell Carcinoma, Actinic Keratoses, Chronic Labial Irritation (Pain from Friction), Atypical Genitalia (Previously Ambiguous Genitalia), Congenital Asymmetrical Labial Growth (CALME), Congenital Defect (General), Absent or Deformed Ears, Otoplasty Performed to Improve Hearing, Congenital Auricular Anomalies (Infant), Severe Burns to the Face, Scar(s) Causing Symptoms or Functional Impairment, Scar Resulting from Accidental Injury, Trauma, Burn, or Medically Necessary Surgery, Skin Tag in Area of Friction Causing Irritation/Bleeding, As Part of Breast Reconstructive Surgery Post-Mastectomy, Breast Cancer or History of Breast Cancer, Loss or Impairment of External Body Part, Wrinkling / Aging Skin, Acne Scars, Acne Vulgaris, Pigmentation Issues (Freckles, Age Spots), Body Contouring for Alteration of Appearance, Large or Protruding Ears (To Improve Physical Appearance), Facial Lines / Wrinkles (Cosmetic Treatment), Spider Veins (Telangiectasia), Nonsegmental Vitiligo, Alopecia Areata, Cosmetic Use (Pharmaceuticals)]
10.01.517: BENEFIT COVERAGE GUIDELINE – 10.01.517 Non-covered Services and Procedures Treatments: [Therapeutic Drug Monitoring (Psychoactive, Pain, Anxiety, etc.), Low-Level Laser Therapy (LLLT), Scalp Cooling, Digitization of Glass Microscope Slides for Pathology, Hair Transplant, Electrolysis Epilation, Penile Function Testing, Penile Prosthesis (Insertion, Removal, Repair), Male Vacuum Erection System, Ear Piercing, MR Safety Assessment, Blood Typing for Paternity Testing, Hair Analysis (Excluding Arsenic), Autopsy/Necropsy, Psychiatric Administration and Reports/Exams/Testimony, Orthoptic Training, Audiology Testing (Specific Types), Athletic Training, Community/Work Reintegration Training, Work Hardening/Conditioning, Hospital Administrative/Convenience Services, Nonemergency Transportation, Personal Hygiene Supplies and Miscellaneous Items/Supplies, Incontinence Supplies, Blood Pressure Monitoring Equipment, Thermometers, Gradient Compression Stockings, Nonprescription Medications, Vitamins, Supplements, & Ophthalmic Items, Monitoring and Alert Devices (Not Otherwise Classified), Reaching/Grabbing Device, Wigs, Postmastectomy Camisole, Exercise Equipment, Health Club Membership, DME Delivery, Setup, and/or Dispensing, Bathroom, Toilet, and Mobility Aids (Specific Types), Bed Accessories, Nebulizers and Vaporizers, Manual Breast Pump, External Defibrillator with Integrated ECG Analysis, Patient Lifts, Safety and Restraint Equipment, Gravity Assisted Traction Device, Wheelchair Accessories and Components, Whirlpools, Adjustable Chair for ESRD Patients, Nonelectronic Augmentative/Alternative Communication Board, Home Suction Pump for External Urine Management, Community Health Integration Services, Principal Illness Navigation Services, SDOH Risk Assessment Tool Administration, Principal Illness Navigation - Peer Support, Activity and Recreational Therapy (Not for Recreation), Noncovered Clinical Trial Procedures, Case Management and Community/Behavioral Health Support Services, Behavioral Health Screening, Prevention, and Outreach Services, Behavioral Health and Home Care Training, Support, and Education, Alcohol and/or Other Drug Testing: Collection and Handling Only, Family Assessment by Licensed Behavioral Health Professional (State Defined Purposes), Behavioral Health Treatment Programs (Hourly/Daily), Developmental Delay Prevention Activities (Dependent Child), Sexual Offender Treatment Service, Coordinated Specialty Care for First Episode Psychosis, Pemivibart (COVID-19 Prophylaxis), Tocilizumab (COVID-19 Treatment), Disease Management Program Services, Refractive Eye Surgery and Lenses, Deluxe Item (Patient Aware), Performance Measurement - Patient Self-Assessment (Depression), Adult Day Care and Adult Foster Care, Chore Services, Attendant Care Services, Homemaker Service, Adult Companion Care, Therapeutic Foster Care (Child), Respite Care Services (Unskilled), Emergency Response System, Home Modifications, Home Delivered Meals, Laundry Service, Medication Reminder Service, Personal Care Item (Not Otherwise Specified), Enuresis Alarm, Equestrian/Hippotherapy, Physical or Manipulative Therapy for Maintenance, Back School, Services by Journal-Listed Christian Science Practitioner (Healing), Not Medically Necessary Service (Patient Aware), Clinical Trial Lodging, Meals, and Transportation Costs (Participant/Caregiver), Private Duty/Independent Nursing Services, Child Sitting Services (Children of Individual Receiving Substance Abuse Services), Meals for Individuals Receiving Substance Abuse Services (When Not Included in Program), Sign Language or Oral Interpretive Services, Clinic Visit/Encounter (All-Inclusive), School-Based Individualized Education Program (IEP) Services, Personal Care Services (Not Inpatient/Resident), Home Health Aide or Certified Nurse Assistant Visit, Contracted Home Health Agency Services (All Services), Screening for Program/Project/Treatment Protocol Participation, Assessment of Home, Physical, and Family Environment, Comprehensive Environmental Lead Investigation, Doula Birth Worker Services, Medicaid Certified Community Behavioral Health Clinic Services, Waiver Services (General), Human Breast Milk Processing, Storage, and Distribution, Hydrophilic Contact Lens with Blue-Violet Filter, Eyeglass Case, Assistive Listening Devices, Milieu Therapy (Revenue Code)]; Indications: [Services and Procedures Not Covered by Plan Policy, Benefit exclusion category, Cosmetic Services Category, Counseling, Education, or Training Services Not Covered Under Another Benefit Category, Custodial Care Category, Nonmedical Equipment (DME or HME) Category, Nonmedical Services Category, Nonprescription Drugs, Supplements, or Supplies Category, Personal Care/Convenience Items Category, Services Related to a Non-Covered Service or Supply, Benefit Limit Exhausted, Service Not Specifically Listed as Covered (Unless Preauthorized), Amount Exceeds Allowable Charge or Maximum Benefit, Experimental or Investigational Services, Covered by Other Sources (e.g., Liability Insurance)]
10.01.518: Clinical Trials Treatments: [Clinical Trial Participation]; Indications: [Cancer or other life-threatening disease or condition, Study approved/funded by qualifying entity or meets IND/exemption/WA IRB criteria, Individual meets eligibility requirements of the approved clinical trial, Individual's participation is appropriate for the treatment of the condition, Individual has provided signed informed consent, Patient registry participation, The drug, item, or service being studied is not covered, Items/services provided solely for data collection and analysis needs are not covered, Items/services provided free of charge by research sponsors are not covered, Service inconsistent with widely accepted/established standards of care is not covered, Travel and transportation expenses are not covered, Non-FDA approved drugs after trial ends are not covered, Any indication/context (unless specified otherwise)]
10.01.520: Review for Coverage in the Absence of a Medical Policy, Pharmacy Policy, or Utilization Management Guideline Treatments: []; Indications: []
10.01.521: Routine Vision Care Treatments: [Routine Vision Exam, Medical Vision Exam, Routine Vision Hardware (Age 19+), Medical Vision Hardware (Age 19+), Vision Hardware Fitting, Non-prescription Vision Items, Contact Lens Supplies, Smart Glasses / Augmented Reality Glasses, Vision Therapy / Orthoptics / Pleoptics]; Indications: [Routine Refractive Errors & Mild Vision Issues, Routine Vision Screening/Exam Encounter (Z Codes), General Medical Eye Conditions/Injuries, Long-term Treatment with High-Risk Medication, Specific Medical Conditions for Hardware (Age 19+), Routine Use for Corrective Lenses, No Routine Vision Benefit Exists, No Vision Hardware Benefit Exists (Age 19+), Hardware/Fitting Not Covered Under Routine Exam Benefit, Non-prescription Items NMN Rule, Smart Glasses NMN Rule, Contact Lens Supplies NMN Rule, Vision Therapy / Orthoptics / Pleoptics NMN Rule]
10.01.522: Routine Foot Care Services Treatments: [Routine Foot Care Services]; Indications: [Conditions Associated with Poor Blood Flow, Neuropathy, or Diabetes, Routine Foot Care - Default Exclusion]
10.01.523: Preventive Care Treatments: [Adult Aortic Aneurysm Screening Ultrasound, Alcohol Misuse Screening and Counseling, Unhealthy Drug Use Screening, Blood Pressure Screening, Cholesterol (Lipid) Screening, Colorectal Cancer Screening (Stool-based), Colorectal Cancer Screening (Sigmoidoscopy), Colorectal Cancer Screening (Colonoscopy - Visual), Colorectal Cancer Screening (Colonoscopy Pathology), Colorectal Cancer Screening (Colonoscopy Preoperative Assessment), Colorectal Cancer Screening (Barium Enema), Colorectal Cancer Screening (CT Colonography), Contraceptives (Condoms), Depression and Anxiety Screening (Adults, Children, Adolescents), Depression Screening (Perinatal/Post-partum), Psychotherapy (for Perinatal Depression), Diabetes and Prediabetes Screening (Type 2), Diet and Physical Activity Counseling (Intensive Behavioral), Statin Use for Primary Cardiovascular Disease Prevention, Fall Prevention (Exercise or Physical Therapy), Hepatitis B Screening, Hepatitis C Screening, HIV Screening, HIV Pre-Exposure Prophylaxis (PrEP) Oral Drug Coverage, HIV Pre-Exposure Prophylaxis (PrEP) Injectable Drug Coverage, HIV Pre-Exposure Prophylaxis (PrEP) Counseling Visit, HIV Pre-Exposure Prophylaxis (PrEP) Pregnancy Test, HIV Pre-Exposure Prophylaxis (PrEP) STI Screening, HIV Pre-Exposure Prophylaxis (PrEP) HIV Testing, HIV Pre-Exposure Prophylaxis (PrEP) Hepatitis B & C Screening, HIV Pre-Exposure Prophylaxis (PrEP) Creatinine Testing, Immunizations (ACIP Recommended), Lung Cancer Screening (Low-Dose CT), Obesity Screening and Counseling (Adults), Obesity Screening and Counseling (Children), Prostate Cancer Screening (PSA), Interpersonal and Domestic Violence Screening and Counseling, Sexually Transmitted Disease (STD) Counseling, Syphilis Screening, Tobacco Use Counseling and Interventions (Adults), Tobacco Use Counseling and Interventions (Under 18), Tobacco Use Counseling and Interventions (Pregnant Women), Tuberculosis (TB) Testing, Anemia Screening (Hematocrit or Hemoglobin), Bacteriuria Screening (Pregnant Women), Breastfeeding Counseling Interventions, Breast Pump (Hospital Grade Rental), Breast Pump (Other Purchase/Rental), Contraceptive Visits, Contraceptive Implantable Devices (Insertion and Removal), Contraceptive Injectables, Birth Control (Generic Pills - Pharmacy), Birth Control (Mobile Apps), Birth Control (IUD - Insertion/Removal/Supply), Birth Control (Female Sterilization Procedure), Birth Control (Female Sterilization Anesthesia), Folic Acid Supplementation, Gestational Diabetes Screening (Antenatal), Gestational Diabetes Screening (Postpartum), Gonorrhea Screening, Pre-eclampsia Prevention (Low-dose Aspirin), Rh Incompatibility Screening (Initial Prenatal), Rh Incompatibility Screening (Later Gestation), Rubella Screening (Serology), Breast Cancer Chemoprevention Counseling, BRCA Screening Risk Assessment, Genetic Counseling, and Testing, Breast Cancer Screening (Mammography), Cervical Cancer Screening (Pap Smear), HPV Testing (High-Risk), Chlamydia Screening, Osteoporosis Screening (Bone Density), Bilirubin Screening (Newborn), Dental Caries Prevention (Fluoride Varnish - Primary Care), Fluoride Chemoprevention Supplements (Oral), Developmental Screening (Including Autism), Dyslipidemia Screening (Children/Adolescents), Gonorrhea Prophylactic Medications (Newborn), Hearing Loss Screening (Children), Hemoglobinopathies (Sickle Cell) Screening (Newborn), Hypothyroidism Screening (Newborn), Iron Supplements (Children), Lead Screening (Children), Phenylketonuria (PKU) Screening (Newborn), Skin Cancer Behavioral Counseling (Ages 10-24), Vision Acuity Screening (Children), Wellness Preventive Examination (Comprehensive E&M)]; Indications: [Used as Preventive Screening per Guidelines, Used for Diagnostic, Monitoring, or Surveillance Purposes, Performed Incidentally in an Inpatient Setting, Men aged 65 to 75 years who have ever smoked, Individuals aged 18 years and older, Individuals aged 18 years and older engaged in risky or hazardous drinking, Individuals aged 18 years and older engaged in unhealthy drug use, Individuals aged 18 years and older (for high blood pressure screening), Men aged 35 years and older (for lipid disorders), Men aged 20 to 35 years at increased risk for coronary heart disease (for lipid disorders), Women aged 45 years and older at increased risk for coronary heart disease (for lipid disorders), Women aged 20 to 45 years at increased risk for coronary heart disease (for lipid disorders), Children aged 5 to 18 years (for lipid disorders), Individuals aged 45 to 75 years (for colorectal cancer screening), Individuals under age 45 at increased risk for colon cancer due to a strong family history, Individuals aged 45 and older with personal history of inflammatory bowel disease (Crohn disease or ulcerative colitis), Pregnant Persons (General), Pregnant women at higher risk of perinatal depression, Asymptomatic pregnant persons at or after 24 weeks of gestation (for gestational diabetes), Pregnant persons with a history of gestational diabetes that are not currently pregnant (postpartum), Pregnant persons who are at high risk for preeclampsia, Pregnant persons during their first visit for pregnancy-related care, Unsensitized Rh (D)-negative persons at 24 to 28 weeks' gestation, Pregnant persons at increased risk for sexually transmitted infections, Individuals aged 40 to 70 years who are overweight or obese (for abnormal blood glucose screening as part of CVD risk), Asymptomatic adults aged 35-70 years who are overweight or have obesity (for abnormal blood glucose screening), Individuals aged 18 and older who are overweight or obese (for intensive behavioral interventions), Individuals aged 6 years and older with obesity (for intensive behavioral interventions), Individuals aged 40-75 years who have one or more cardiovascular risk factors (for statin use), Individuals aged 65 and older who are at increased risk of falling, Individuals at high risk of Hepatitis B infection, Individuals at high risk of Hepatitis C infection, Individuals born between 1945 and 1965 (for Hepatitis C), Individuals aged 15 or older or any individual who is at increased risk (for HIV screening), Individuals who are at high risk of HIV exposure (for PrEP), Sexually active individuals who are at increased risk for sexually transmitted infections (for counseling), Individuals over age 18 (for tobacco use counseling/intervention), Individuals aged 18 and under (for tobacco use prevention), Pregnant women who use tobacco, Populations at increased risk for latent tuberculosis infection (LTBI) or if positive risk assessment, Asymptomatic pregnant women (for anemia), Individuals aged 18 or under (General Pediatric), Pregnant women at 12 to 16 weeks' gestation or at the first prenatal visit (for bacteriuria), During pregnancy and after birth (for breastfeeding counseling), Sexually active women aged 24 years or younger, Older women who are at increased risk for Gonorrhea/Chlamydia, Women who are at increased risk for breast cancer (for chemoprevention), Women who have a family history of breast/ovarian/tubal/peritoneal cancer or increased risk for BRCA mutations, Women aged 40 years and older (for mammography), Women aged 21 to 29 years (for cervical cancer screening with cytology), Women aged 30 to 65 years (for cervical cancer screening with hrHPV alone or co-testing), Women aged 65 years or older (for osteoporosis), Younger women who are at high risk of fractures (for osteoporosis), Newborns age 0 to 28 days, Newborns (General), Children aged 0-6 years (primary teeth eruption), Children starting at age 6 months whose water supply is fluoride deficient, Children aged 9 to 11 (for dyslipidemia), Children aged 17 to 21 (for dyslipidemia), Children up to age 21 (for hearing loss), Individuals aged 10 to 24 years (for skin cancer behavioral counseling), Individual of any age (for wellness preventive examination)]
10.01.524: Sleep Disorder Management: Services Reviewed by Carelon Medical Benefits Management Treatments: [Facility Sleep Study (Any Type), Polysomnography, Multiple Sleep Latency Testing, Maintenance of Wakefulness Testing, Positive Airway Pressure (PAP) Device (Any Type), Auto-Titrating Positive Airway Pressure (APAP) Device, Continuous Positive Airway Pressure (CPAP) Device, Bi-level Positive Airway Pressure (BPAP) Device, Positive Airway Pressure (PAP) Supplies, Oral Appliance]; Indications: [Obstructive Sleep Apnea, Nonrespiratory Sleep Disorders, PAP Adherence Monitoring for Supplies]
10.01.525: Right-to-Try Laws and Coverage of Services Treatments: [Investigational Product Accessed via Right-to-Try, Hospice or Palliative Care, Medical Product Under Emergency Use Authorization (EUA)]; Indications: [Serious or Immediately Life-Threatening Illness, Complications from Investigational Product Use (General), Life Threatening or Emergency Complications from Investigational Product Use, Patient Receiving Hospice or Palliative Care After Using Right-to-Try Product, Context: Under Emergency Use Authorization (EUA)]
10.01.526: Molecular Genetic Testing: Services Reviewed by Carelon Medical Benefits Management Treatments: [Any Molecular Genetic Testing, Single-Gene Genetic Testing, Multi-Gene Panel Testing, Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), Chromosomal Microarray Analysis, Cell-Free DNA Testing, Somatic Tumor Testing, Polygenic Risk Scores]; Indications: [Carrier Screening (Prenatal or Preimplantation), Cancer Management (General), Suspected Inherited Conditions (General), Hereditary Cancer Susceptibility Testing, Pharmacogenetic Testing, Prenatal Testing Using Cell-Free DNA, Somatic Tumor Testing, Evaluation for Inherited Cardiac Conditions, Lack of Pre-Test Genetic Counseling for WES/WGS, Lack of Genetic Counseling for Inherited Cardiac Evaluation, Lack of Genetic Counseling for Hereditary Cancer Testing, Genetic Counseling May Benefit Any Patient]
10.01.527: Radiation Oncology: Services Reviewed by Carelon Medical Benefits Management Treatments: [Radiation Oncology Services]; Indications: [Bone metastases, Breast cancer, Central nervous system cancers (intracranial, spinal, ocular, and neurologic [e.g., trigeminal neuralgia]), Colorectal and anal cancers, Gastrointestinal cancers, non-colorectal (cholangiocarcinoma, esophageal, gastric, liver, pancreatic), Genitourinary cancers (bladder, penile, testicular), Gynecologic cancers (cervical, fallopian tube, ovarian, uterine, and vulvar/vaginal), Head and neck cancers (including thyroid), Lung cancers: small cell and non-small cell, Lymphoma: Hodgkin and non-Hodgkin, Oligometastatic extracranial disease, Other tumor types (sarcoma, thymoma and thymic carcinoma, pediatric tumors, other malignancies), Prostate cancer, Skin cancer]
10.01.528: Imaging: Services Reviewed by Carelon Medical Benefits Management Treatments: [Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Magnetic Resonance Angiography (MRA), Nuclear Cardiology, Echocardiography (ECHO), Positron Emission Tomography (PET) Scan]; Indications: [Services Subject to Carelon Review]
10.01.531: ADMINISTRATIVE GUIDELINE – 10.01.531 InterQual Criteria: Services Reviewed for Medical Necessity Treatments: [Services Reviewed Using InterQual Criteria]; Indications: [Level of Care Services Reviewed, Rehabilitation Services Reviewed, Behavioral Health Services Reviewed]
10.01.532: ASAM Criteria: Services Reviewed for Medical Necessity Treatments: [Inpatient Substance Use Disorder Rehabilitation, Residential/Sub-Acute Detoxification, Residential Substance Use Disorder Treatment, Special Populations Substance Use Disorder Residential Treatment, Inpatient Substance Use Disorder Treatment, Inpatient Detoxification, Any ASAM-Reviewed SUD Treatment Service]; Indications: [Substance Use Disorder (Adults and Adolescents), Medical Necessity Reviewed Using ASAM Criteria]
10.01.533: Non-covered Experimental/Investigational Services Treatments: [Percutaneous transluminal coronary lithotripsy, Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy, Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; cervical, Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; thoracic, Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; lumbar, Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; each additional vertebral segment, Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrode, Retinal polarization scan, ocular screening with on-site automated results, bilateral, Device evaluation, interrogation, and initial programming of intraocular retinal electrode array (e.g., retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified health care professional, Device evaluation and interrogation of intraocular retinal electrode array (e.g., retinal prosthesis), in person, including reprogramming and visual training, when performed, with review and report by a qualified health care professional, Optical coherence tomography (OCT) of middle ear, with interpretation and report; unilateral, Optical coherence tomography (OCT) of middle ear, with interpretation and report; bilateral, Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; adipose tissue harvesting, isolation and preparation of harvested cells including incubation with cell dissociation enzymes, removal of non-viable cells and debris, determination of concentration and dilution of regenerative cells, Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; multiple injections in one or both hands, Osteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device, Temporary female intraurethral valve-pump (i.e., voiding prosthesis); initial insertion, including urethral measurement, Temporary female intraurethral valve-pump (i.e., voiding prosthesis); replacement, Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site, Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site, Glomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent, Glomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours, Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; initial device provision, set-up and patient education on use of equipment, Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; remote surveillance center technical support, data analyses and reports, with a minimum of 8 daily recordings, each 30 days, Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; review, interpretation and report by the prescribing physician or other qualified health care professional of remote surveillance center data analyses, each 30 days, Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (e.g., ECG data), transmitted to a remote 24-hour attended surveillance center; set-up and patient education on use of equipment, Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (e.g., ECG data), transmitted to a remote 24-hour attended surveillance center; analysis of data received and transmission of reports to the physician or other qualified health care professional, Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc, on biomarkers (i.e., lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs, Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis, Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for algorithmic analysis of biomarker data for determination of relative chemical differences between discs, Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); interpretation and report, Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed, Eye-movement analysis without spatial calibration, with interpretation and report, Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed, Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, Trabeculostomy ab interno by laser, Trabeculostomy ab interno by laser; with use of ophthalmic endoscope, Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report, Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography, Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report, Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity, Percutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance, Wireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed, Endovaginal cryogen-cooled, monopolar radiofrequency remodeling of the tissues surrounding the female bladder neck and proximal urethra for urinary incontinence, Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance, Laparoscopic insertion of new or replacement of permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including an implantable pulse generator and diaphragmatic lead(s), Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first lead, Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional lead, Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first repositioned lead, Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead, Laparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, Insertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s), Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads, Removal of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, Programming device evaluation (in-person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, Peri-procedural device evaluation (in-person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, Interrogation device evaluation (in-person) with analysis, review and report by a physician or other qualified health care professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, Histotripsy (i.e., non-thermal ablation via acoustic energy delivery) of malignant hepatocellular tissue, including image guidance (ultrasound ablation), Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (e.g., organ, gland, tissue, target structure), Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained with diagnostic ultrasound examination of the same anatomy (e.g., organ, gland, tissue, target structure), Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report, Therapeutic ultrafiltration, Comprehensive full body computer-based markerless 3D kinematic and kinetic motion analysis and report, 3-dimensional volumetric imaging and reconstruction of breast or axillary lymph node tissue, each excised specimen, 3-dimensional automatic specimen reorientation, interpretation and report, real-time intraoperative, Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of implant or replacement, Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow-up interrogation or programming device evaluation, Quantitative magnetic resonance for analysis of tissue composition (e.g., fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (e.g., organ, gland, tissue, target structure) during the same session; multiple organs, Quantitative magnetic resonance for analysis of tissue composition (e.g., fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (e.g., organ, gland, tissue, target structure); multiple organs, Molecular fluorescent imaging of suspicious nevus; first lesion, Molecular fluorescent imaging of suspicious nevus; each additional lesion, Injection(s), bone-substitute material (e.g., calcium phosphate) into subchondral bone defect (i.e., bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including imaging guidance and arthroscopic assistance for joint visualization, Intradermal cancer immunotherapy; preparation and initial injection, Intradermal cancer immunotherapy; each additional injection, Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; including data preparation and transmission, quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, data review, interpretation and report, Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data preparation and transmission, Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data review, interpretation and report, Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging, Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained with concurrent CT examination of any structure contained in the concurrently acquired diagnostic imaging dataset, Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained without diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (e.g., organ, gland, tissue, target structure) during the same session, Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained with diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (e.g., organ, gland, tissue, target structure), Augmentative Al-based facial phenotype analysis with report, Immunotherapy administration with electroporation, intramuscular, Remote body and limb kinematic measurement-based therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days, Remote body and limb kinematic measurement-based therapy ordered by a physician or other qualified health care professional; treatment management services by a physician or other qualified health care professional, per calendar month, Colonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including insertion of rectal catheter, Xenograft implantation into the articular surface, Bone strength and fracture risk using finite element analysis of functional data and bone mineral density (BMD), with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and BMD and classification of any vertebral fractures, with overall fracture-risk assessment, interpretation and report, Insertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance, when performed, including autogenous or nonautogenous patch graft (e.g., polyester, ePTFE, bovine pericardium), when performed, Cardiac focal ablation utilizing radiation therapy for arrhythmia; noninvasive arrhythmia localization and mapping of arrhythmia site (nidus), derived from anatomical image data (e.g., CT, MRI, or myocardial perfusion scan) and electrical data (e.g., 12-lead ECG data), and identification of areas of avoidance, Cardiac focal ablation utilizing radiation therapy for arrhythmia; conversion of arrhythmia localization and mapping of arrhythmia site (nidus) into a multidimensional radiation treatment plan, Cardiac focal ablation utilizing radiation therapy for arrhythmia; delivery of radiation therapy, arrhythmia, Injections of stem cell product into perianal perifistular soft tissue, including fistula preparation (e.g., removal of setons, fistula curettage, closure of internal openings), Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X-ray data, assessment of bone strength and fracture risk and BMD, interpretation and report;, Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X-ray data, assessment of bone strength and fracture risk and BMD, interpretation and report; with single-view digital X-ray examination of the hand taken for the purpose of DXR-BMD, Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (e.g., low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram, Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (e.g., low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram, Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve, Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve, Virtual reality technology to assist therapy, Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15 minutes of intraservice time, patient aged 5 years or older, Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; each additional 15 minutes intraservice time, Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of intraservice time, patient aged 5 years or older, Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; each additional 15 minutes intraservice time, Therapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-controlled cooling device to the neck over carotids and head, including monitoring (e.g., vital signs and sport concussion assessment tool 5 [SCAT5]), 30 minutes of treatment, Real-time pressure-sensing epidural guidance system, Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function, Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi, Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus, Percutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance, Patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately, Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report, Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with computed tomography (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report, Subretinal injection of a pharmacologic agent, including vitrectomy and 1 or more retinotomies, Remote multi-day complex uroflowmetry (e.g., calibrated electronic equipment); set-up and patient education on use of equipment, Remote multi-day complex uroflowmetry (e.g., calibrated electronic equipment); device supply with automated report generation, up to 10 days, Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral, Externally applied transcranial magnetic stimulation with concomitant measurement of evoked cortical potentials with automated report, Noncontact near-infrared spectroscopy (e.g., for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; each additional anatomic site, Noncontact near-infrared spectroscopy (e.g., for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), for screening for peripheral arterial disease, including provocative maneuvers, image acquisition, interpretation, and report, one or both lower extremities, Low-intensity extracorporeal shock wave therapy involving corpus cavernosum, low energy, Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion identification, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the brain during the same session, Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion detection, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the brain, Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50 mL, High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report, Injection(s), bone-substitute material for bone and/or soft tissue hardware fixation augmentation, including intraoperative imaging guidance, when performed, Implantation of subcutaneous peritoneal ascites pump system, percutaneous, including pump-pocket creation, insertion of tunneled indwelling bladder and peritoneal catheters with pump connections, including all imaging and initial programming, when performed, Replacement of a subcutaneous peritoneal ascites pump, including reconnection between pump and indwelling bladder and peritoneal catheters, including initial programming and imaging, when performed, Replacement of indwelling bladder and peritoneal catheters, including tunneling of catheter(s) and connection with previously implanted peritoneal ascites pump, including imaging and programming, when performed, Revision of a subcutaneously implanted peritoneal ascites pump system, any component (ascites pump, associated peritoneal catheter, associated bladder catheter), including imaging and programming, when performed, Removal of a peritoneal ascites pump system, including implanted peritoneal ascites pump and indwelling bladder and peritoneal catheters, Programming of subcutaneously implanted peritoneal ascites pump system by physician or other qualified health care professional, Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging, Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure, Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission, Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report, Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to treatment, and removal of the oral device, Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; initial nerve, Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; each additional nerve, End-tidal control of inhaled anesthetic agents and oxygen to assist anesthesia care delivery, Histotripsy (i.e., non-thermal ablation via acoustic energy delivery) of malignant renal tissue, including imaging guidance, Personalized target development for accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation derived from a structural and resting-state functional MRI, including data preparation and transmission, generation of the target, motor threshold-starting location, neuronavigation files and target report, review and interpretation, Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including target assessment, initial motor threshold determination, neuronavigation, delivery and management, initial treatment day, Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent treatment day, Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent motor threshold redetermination with delivery and management, per treatment day, Noninvasive assessment of blood oxygenation, gas exchange efficiency, and cardiorespiratory status, with physician or other qualified health care professional interpretation and report, Cannulation of the liver allograft in preparation for connection to the normothermic perfusion device and decannulation of the liver allograft following normothermic perfusion, Connection of liver allograft to normothermic machine perfusion device, hemostasis control; initial 4 hours of monitoring time, including hourly physiological and laboratory assessments, Connection of liver allograft to normothermic machine perfusion device, hemostasis control; each additional hour, including physiological and laboratory assessments, Noninvasive augmentative arrhythmia analysis derived from quantitative computational cardiac arrhythmia simulations, based on selected intervals of interest from 12-lead electrocardiogram and uploaded clinical parameters, including uploading clinical parameters with interpretation and report, Noninvasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report, Noninvasive determination of absolute quantitation of myocardial blood flow (AQMBF), derived from augmentative algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by a physician or other qualified health care professional, Noninvasive estimate of absolute quantitation of myocardial blood flow (AQMBF), derived from assistive algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by a physician or other qualified health care professional, Placement of bone marrow sampling port, including imaging guidance when performed, QTc interval derived by augmentative algorithmic analysis of input from an external, patient-activated mobile ECG device, Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; with interpretation and report, Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; tracing only, Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; interpretation and report only, Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care; first application, total wound(s) surface area less than or equal to 50 sq cm, Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care; each additional application, total wound(s) surface area less than or equal to 50 sq cm, Open implantation of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed, Replacement of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed, Removal of integrated neurostimulation system, vagus nerve, Electronic analysis of implanted integrated neurostimulation system, vagus nerve; without programming by physician or other qualified health care professional, Electronic analysis of implanted integrated neurostimulation system, vagus nerve; with simple programming by physician or other qualified health care professional, Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (e.g., drug-coated, drug-eluting), including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch, Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (e.g., drug-coated, drug-eluting) performed on a separate target lesion from the target lesion treated with balloon angioplasty, coronary stent placement or coronary atherectomy, including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch, Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator and dual transvenous electrodes/leads (pacing and defibrillation), Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator only, Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; single transvenous lead (pacing or defibrillation) only, Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; dual transvenous leads (pacing and defibrillation) only, Removal of a permanent cardiac contractility modulation-defibrillation system component(s); pulse generator only, Removal of a permanent cardiac contractility modulation-defibrillation system component(s); single transvenous pacing lead only, Removal of a permanent cardiac contractility modulation-defibrillation system component(s); single transvenous defibrillation lead only, Removal of a permanent cardiac contractility modulation-defibrillation system component(s); dual (pacing and defibrillation) transvenous leads only, Removal and replacement of permanent cardiac contractility modulation-defibrillation pulse generator only, Repositioning of previously implanted cardiac contractility modulation-defibrillation transvenous electrode(s)/lead(s), including fluoroscopic guidance and programming of sensing and therapeutic parameters, Relocation of skin pocket for implanted cardiac contractility modulation-defibrillation pulse generator, Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation-defibrillation system, Interrogation device evaluation (in person) with analysis, review, and report, including connection, recording, and disconnection, per patient encounter, implantable cardiac contractility modulation-defibrillation system, Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system with interim analysis and report(s) by a physician or other qualified health care professional, Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system, remote data acquisition(s), receipt of transmissions, technician review, technical support, and distribution of results, Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), at time of initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator, Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), separate from initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator, Noninvasive detection of heart failure derived from augmentative analysis of an echocardiogram that demonstrated preserved ejection fraction, with interpretation and report by a physician or other qualified health care professional, Transcatheter implantation of wireless left atrial pressure sensor for long-term left atrial pressure monitoring, including sensor calibration and deployment, right heart catheterization, transseptal puncture, imaging guidance, and radiological supervision and interpretation, Remote monitoring of a wireless left atrial pressure sensor for up to 30 days, including data from daily uploads of left atrial pressure recordings, interpretation(s) and trend analysis, with adjustments to the diuretics plan, treatment paradigm thresholds, medications or lifestyle modifications, when performed, and report(s) by a physician or other qualified health care professional, Cystourethroscopy with renal pelvic sympathetic denervation, radiofrequency ablation, retrograde ureteral approach, including insertion of guide wire, selective placement of ureteral sheath(s) and multiple conformable electrodes, contrast injection(s), and fluoroscopy, bilateral, Photobiomodulation therapy of retina, single session, External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; including recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional, External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; recording (including connection and initial recording), External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; scanning analysis with report, External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; review and interpretation by a physician or other qualified health care professional, Cystourethroscopy, flexible; with insertion and expansion of prostatic urethral scaffold using integrated cystoscopic visualization, Cystourethroscopy, flexible; with removal and replacement of prostatic urethral scaffold, Cystourethroscopy, flexible; with removal of prostatic urethral scaffold, 3D contour simulation of target liver lesion(s) and margin(s) for image-guided percutaneous microwave ablation, Intraoperative assessment for abnormal (tumor) tissue, in-vivo, following partial mastectomy (e.g., lumpectomy) using computer-aided fluorescence imaging, Orthopedic implant movement analysis using paired computed tomography (CT) examination of the target structure, including data acquisition, data preparation and transmission, interpretation and report (including CT scan of the joint or extremity performed with paired views), Magnetic resonance image guided low intensity focused ultrasound (MRgFUS), stereotactic blood-brain barrier disruption using microbubble resonators to increase the concentration of blood-based biomarkers of target, intracranial, including stereotactic navigation and frame placement, when performed, Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral, Comprehensive computer-based motion analysis by video-taping and 3D kinematics;, Comprehensive computer-based motion analysis by video-taping and 3D kinematics; with dynamic plantar pressure measurements during walking, Dynamic surface electromyography, during walking or other functional activities, 1-12 muscle, Dynamic fine wire electromyography, during walking or other functional activities, 1 muscle, Review and interpretation by physician or other qualified health care professional of comprehensive computer-based motion analysis, dynamic plantar pressure measurements, dynamic surface electromyography during walking or other functional activities, and dynamic fine wire electromyography, with written report, Exsufflation belt, includes all supplies and accessories, Electrode for external lower extremity nerve stimulator for restless legs syndrome, Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each, Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical, Expiratory positive airway pressure intranasal resistance valve, Injection, pegulicianine, 1 mg, Hemostatic agent, gastrointestinal, topical, Catheter(s), intravascular for renal denervation, radiofrequency, including all single use system components, Catheter(s), intravascular for renal denervation, ultrasound, including all single use system components, Joint fusion and fixation device(s), sacroiliac and pelvis, including all system components (implantable), Catheter, transluminal intravascular lithotripsy, coronary, Monitor, cardiac, including intracardiac lead and all system components (implantable), 3D anatomical segmentation imaging for preoperative planning, data preparation and transmission, obtained from previous diagnostic computed tomographic or magnetic resonance examination of the same anatomy, Implantation of medial knee extraarticular implantable shock absorber spanning the knee joint from distal femur to proximal tibia, open, includes measurements, positioning and adjustments, with imaging guidance (e.g., fluoroscopy), Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed, Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed, Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed, Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed, Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies), with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed, Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed, Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed, Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed, Esophageal mucosal integrity testing by electrical impedance, transoral, Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed, Instillation of antineoplastic pharmacologic/biologic agent into renal pelvis, any method, including all imaging guidance, including volumetric measurement if performed, Blinded or nonblinded procedure for symptomatic New York Heart Association (NYHA) Class II, III, IVA heart failure; transcatheter implantation of left atrial to coronary sinus shunt using jugular vein access, including all imaging necessary to intra procedurally map the coronary sinus for optimal shunt placement (e.g., transesophageal echocardiography (TTE), intracardiac echocardiography (ICE), fluoroscopy), performed under general anesthesia in an approved investigational device exemption (IDE) study, 3D predictive model generation for preplanning of a cardiac procedure, using data from cardiac computed tomographic angiography with report, Therapeutic radiology simulation-aided field setting; complex, including acquisition of PET and CT imaging data required for radiopharmaceutical-directed radiation therapy treatment planning (i.e., modeling), Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions, Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote, Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply, Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application, Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply, Non-pneumatic sequential compression garment, trunk, Nonpneumatic sequential compression garment, full leg, Nonpneumatic sequential compression garment, half leg, Nonpneumatic compression controller with sequential calibrated gradient pressure, Nonpneumatic compression controller without calibrated gradient pressure, Nonpneumatic sequential compression garment, full arm, Non-pneumatic, non-sequential, peristaltic wave compression pump, Intravaginal device intended to strengthen pelvic floor muscles during kegel exercises, Supplies and accessories for intravaginal device intended to strengthen pelvic floor muscles during kegel exercises, Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, include microprocessor, all components and accessories, Rehab system with interactive interface providing active assistance in rehabilitation therapy, includes all components and accessories, motors, microprocessors, sensors, External lower extremity nerve stimulator for restless legs syndrome, each, FDA approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomiting, Intrabuccal, systemic delivery of amplitude-modulated, radiofrequency electromagnetic field device, for cancer treatment, includes all accessories each, Speech volume modulation system, any type, including all components and accessories, Gait modulation system, rhythmic auditory stimulation, including restricted therapy software, all components and accessories, prescription only, Therapeutic radiology simulation-aided field setting; complex, including acquisition of PET and CT imaging data required for radiopharmaceutical-directed radiation therapy treatment planning (i.e., modeling), Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions, Traditional healing service, Speech volume modulation system, any type, including all components and accessories, Exsufflation belt, includes all supplies and accessories, Nonpneumatic compression controller with sequential calibrated gradient pressure, Nonpneumatic sequential compression garment, full arm, Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical, Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle for the reduction of snoring and obstructive sleep apnea, controlled by phone application, Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply, Nonpneumatic compression controller without calibrated gradient pressure, Nonpneumatic sequential compression garment, full leg, Nonpneumatic sequential compression garment, half leg, Addition to lower extremity prostheses, osseointegrated external prosthetic connector, Miscellaneous external component, supply or accessory for use with the Argus II Retinal Prosthesis System, External lower extremity sensory prosthesis, cutaneous stimulation of mechanoreceptors proximal to the ankle, per leg, Receptor sole for use with 18720, replacement, each, Red blood cells, leukocytes reduced, oxygen/ carbon dioxide reduced, each unit, Arthroscopy, shoulder, surgical; with thermally-induced capsulorrhaphy]; Indications: [Experimental/Investigational Services Status]
10.01.535: High-Risk Conditions (Oral Health) Dental Benefit Treatments: [Periodic Oral Evaluation, Prophylaxis (Cleaning), Topical Application of Fluoride, Periodontal Maintenance]; Indications: [Cardiovascular Disease, Chronic Obstructive Pulmonary Disease (COPD), Diabetes Mellitus, Oral Cancer, Pregnancy]
1.01.18: Pneumatic Compression Pumps for Treatment of Lymphedema and Venous Ulcers Treatments: [Nonprogrammable Single Compartment Lymphedema Pump, Multichamber Nonprogrammable Lymphedema Pump, Multichamber Programmable Lymphedema Pump, Any Pneumatic Compression Pump for Limb Lymphedema, Any Pneumatic Compression Pump]; Indications: [Lymphedema Failing Conservative Measures, Lymphedema of Trunk or Chest, Lymphedema of Head and Neck, Venous Ulcers, Lymphedema of Limb Not Meeting Medically Necessary Criteria]
1.01.24: Interferential Current Stimulation Treatments: [Interferential Current Stimulation]; Indications: [Any indication (General rule), Musculoskeletal conditions, Osteoarthritis, Gastrointestinal disorders, Constipation, Irritable bowel syndrome, Dyspepsia, Spasticity, Shoulder disorders, Low back pain, Sciatica, Knee disorders, postoperative]
1.01.27: Electrical and Electromagnetic Stimulation for the Treatment of Arthritis Treatments: [Electrical and Electromagnetic Stimulation]; Indications: [Arthritis, Osteoarthritis, Rheumatoid Arthritis]
1.01.29: Tumor Treating Fields Therapy Treatments: [Tumor Treating Fields Therapy]; Indications: [Newly diagnosed glioblastoma multiforme (Adjuvant therapy), Progressive or recurrent glioblastoma multiforme, Malignant pleural mesothelioma, Brain metastases, Cancer in areas other than the brain]
1.01.30: Artificial Pancreas Device Systems Treatments: [Any Artificial Pancreas Device System, Artificial Pancreas Device System with Low Glucose Suspend Feature, Hybrid Closed Loop Insulin Delivery System, Closed-Loop Insulin Delivery System]; Indications: [Type 1 Diabetes, Use when Medically Necessary criteria are not met, Use of Non-FDA Cleared/Approved System]
1.01.501: Wheelchairs (Manual or Motorized) Treatments: [Any Wheelchair or Stroller, Manual Wheelchair (Standard), Any Electric/Power/Motorized Wheelchair, Standard Electric/Power/Motorized Wheelchair, Non-standard Manual/Powered Wheelchair (Size, Weight, Special Feature), Push-rim Activated Power Assist Device, Standard Power Wheelchair Batteries, Any Wheelchair Option or Accessory, Custom Fabricated Wheelchair Seat/Back Cushion, Electronic Interface (Speech Device), Gear-reduction Drive Wheel (Manual Wheelchair), Lever-activated Wheel Drive (Manual Wheelchair), Mechanically Linked or Power Leg Elevation Systems, Manual Standing System (Manual Wheelchair), Non-standard Seat (Width, Depth, Height), Power Add-on Conversion (Manual to Motorized), Power Wheelchair Attendant Control, Powered Seat Cushion (Sequential Inflation), Reclining, Tilt, or Combination Power Seating System / Seat Back, Skin Protection Seat Cushion, Specialty Positioning Components, Any Convenience Item, Stair-climbing Wheelchairs / iBOT Mobility System, Dual Mode Battery Charger, Heavy Duty Shock Absorber (Manual Wheelchair), Heavy Duty Shock Absorber (Power Wheelchair), Non-sealed Battery (Power Wheelchair), Power Standing System Wheelchair Accessory, Power Wheelchair Insert for Pneumatic Drive Wheel Tire, Shock Absorber (Manual Wheelchair), Shock Absorber (Power Wheelchair), Transport Tie Downs]; Indications: [Any Indication, Personal mobility deficit sufficient to impair participation in mobility-related activities of daily living (MRADLs) in the home, Mobility deficit cannot be sufficiently resolved by an appropriately fitted cane or walker, Individual's home allows for adequate access between rooms with maneuvering space and surfaces for operation of a wheelchair, Individual is unable to self-propel a manual wheelchair, Caregiver is available and willing/able to provide assistance, Individual is able to safely walk with a cane or a walker far enough to allow access to all necessary rooms in their home and allow them to perform activities of daily living, Wheelchair is only for use outside the home, The specific configurational needs of the individual are unable to be met using standard wheelchair options or accessories, Specialty evaluation performed by a licensed/certified medical professional with specific training in rehabilitation wheelchair evaluations, and the evaluation documents the need, Wheelchair is provided by a supplier that specializes in wheelchairs with a specialist who has direct, in-person involvement, Individual has been self-propelling in a manual wheelchair for at least one year, Individual lacks the upper body arm strength to push (propel) the wheels of a manual wheelchair, Individual's medical condition does not allow the individual to push the wheels of a manual wheelchair, Individual is able to safely operate the controls of a power wheelchair, Coverage for more than one wheelchair/stroller at a time, Used as a backup to the primary device, Considered experimental or investigational or used for experimental or investigational therapy or interventions, Associated with athletic, scholastic, educational/vocational training of the individual, Available over the counter or off-the-shelf without a prescription, Accessory/option assists individual to perform at least ONE of the following: Maintain current physical functions in the home OR Perform essential activities of daily living, Accessory/option is used primarily for the performance and participation in leisure or recreational activities, Comprehensive written evaluation clearly explains why a prefabricated seating system is not sufficient to meet positioning needs, Needed to allow a medically necessary speech-generating device to be operated by the power wheelchair control interface, Documentation supports that propelling a manual wheelchair is stressing and/or straining the individual's shoulder muscles, Musculoskeletal condition or a cast or brace that prevents 90-degree flexion at the knee, Individual meets the criteria for a power recline seating system, Severe swelling (edema) in the lower extremities that requires elevation of the legs, Individual spends at least two hours a day in the wheelchair, Fixed hip angle, Trunk or lower extremity casts/braces that require the reclining back feature for positioning, Manage increased tone or spasticity, Resting in a recumbent position is required two or more times a day and transfer between wheelchair and bed is very difficult, Individual is at high risk for development of a pressure ulcer and is unable to perform a functional weight shift, Intermittent catheterization for bladder management is utilized and the individual is unable to independently transfer from the wheelchair to a bed, Individual's physical size justifies the need for a non-standard seat (at least two inches greater than or less than standard), Individual is unable to operate a manual or power wheelchair and has a caregiver who is unable to operate a manual wheelchair but is able to operate a power wheelchair, Individual has a manual wheelchair or a power wheelchair with a sling or solid seat/back, Current pressure ulcer or past history of a pressure ulcer on the area of contact with the seating surface, Absent or impaired sensation in the area of contact with the seating surface, Inability to carry out a functional weight shift due to specific diagnosis, Significant postural asymmetries due to specific diagnosis, Alzheimer's disease, Athetoid cerebral palsy, Childhood cerebral degeneration, Hemiplegia, Huntington's chorea, Idiopathic torsion dystonia, Muscular dystrophy, Spina bifida, Anterior horn cell diseases including amyotrophic lateral sclerosis (ALS), Cerebral palsy, Hemiplegia due to stroke, Monoplegia of the lower limb, Multiple sclerosis, Osteogenesis imperfecta, Other demyelinating disease, Paraplegia, Parkinson's disease, Post-polio paralysis, Quadriplegia, Spinocerebellar disease, Transverse myelitis, Traumatic brain injury resulting in quadriplegia, Traumatic brain injury (General), Item is considered an extra cost convenience item]
1.01.506: Adjustable Cranial Orthoses for Positional Plagiocephaly and Craniosynostoses Treatments: [Adjustable Cranial Orthosis (Helmet/Band)]; Indications: [Craniosynostosis (Following Cranial Vault Remodeling Surgery), Craniosynostosis (Without Cranial Vault Remodeling Surgery), Positional Plagiocephaly Without Synostosis (Persistent, Severe, Meeting Criteria), Positional Plagiocephaly Without Synostosis (Not Meeting Criteria), Cosmetic Use]
1.01.507: Electrical Stimulation Devices Treatments: [Neuromuscular Electrical Stimulator (Open Loop), Galvanic or High-Voltage Galvanic Stimulation, H-wave Stimulation, Microcurrent Electrical Nerve Stimulation (MENS), Multimodal Electrical Stimulation Device, Pulsed Electrical Stimulation and Pulsed Electromagnetic Therapy, Sympathetic Electrical Stimulation Therapy, External Trigeminal Nerve Stimulation (eTNS), Transcutaneous Electrical Modulation Pain Reprocessing (TEMPR), Transcutaneous Afferent Patterned Stimulation (TAPS), Transcutaneous Supraorbital Electrical Nerve Stimulator, Transcutaneous Tibial Nerve Stimulation (TTNS)]; Indications: [Disuse Atrophy (Nerve supply to muscle is intact), Disuse atrophy due to previous casting or splinting of a limb, Disuse atrophy due to contractures from soft tissue scarring from burns, Disuse atrophy due to previous major knee surgery with failure to respond to physical therapy, Disuse atrophy due to recent hip replacement surgery (until physical therapy begins), General muscle strengthening in healthy individuals, Cardiac conditioning, Treatment of denervated muscles, Treatment of idiopathic scoliosis, Chronic pain, All other indications, Neuropathic pain, Acute pain, Treatment of wounds and ulcers, Attention Deficit Hyperactivity Disorder (ADHD), Cancer pain, Essential tremor, Action tremor for Parkinson disease, Migraine headaches (prevention and treatment), Overactive bladder (including urinary incontinence, frequency, urgency, nocturia)]
1.01.519: Patient Lifts, Seat Lifts and Standing Devices Treatments: [Sling or seat, patient lift, Seat lift mechanism, nonelectric, Patient lift, hydraulic or mechanical, Combination sit-to-stand frame/table system, Standing frame system, one position, Patient lift, moveable from room to room, Patient lift, fixed system (Ceiling), Standing frame system, multi-position, Standing frame/table system, mobile (dynamic), Multi-positional patient transfer system, up to 300 lbs, Multi-positional patient transfer system, greater than 300 lbs, Spring-release seat lift device, Electric seat lift mechanisms or chairs, Electric patient lift mechanism, Bathroom/Toilet/Tub Lift, Stairway chair/stair lift or stair glider, Platform lift, Van lift, Vehicle ramp]; Indications: [Limited Mobility, Risk of bed confinement, Severe arthritis of hip or knee, Severe neuromuscular disease, Unable to ambulate or stand independently due to neuromuscular condition, Any indication, Transfer requires assistance of more than one individual, Adequately trained individual available to operate lift, Requires supine positioning for transfers, Prescribed to improve health status or arrest deterioration, Incapable of standing up from any chair in home, Has the ability to ambulate once standing, Has sufficient residual strength in lower extremities, Standing position not achievable with PT or other assistive devices, Completed appropriate standing device training and demonstrated safe use, Use expected to allow meaningful functional improvement, Ordered as a replacement for an approved equipment item, Considered a convenience item, A contractual exclusion, Considered a home/vehicle modification, Involves fixtures to real property, Used in a bathroom, Considered furniture, Facilitates transportation, Does not primarily serve a medical purpose, Does not meet definition of Durable Medical Equipment]
1.01.520: Hospital Beds and Accessories Treatments: [Hospital Bed (General), Fixed-Height Hospital Bed, Variable-Height Hospital Bed, Semi-Electric Hospital Bed, Total Electric Hospital Bed, Heavy Duty, Extra Wide/Bariatric Bed, Extra-Heavy-Duty Bed, Alternating Pressure Mattress, Air-Fluidized Hospital Bed, Trapeze Equipment, Bed Cradles, Side Rails and Pads, Continuous Lateral Rotation Bed, Institutional Type Bed, Kinetic Therapy Type Bed, Oscillating Bed, Stryker Frame Bed, Innerspring/Foam Rubber Replacement Mattress (Patient-Owned Bed), Bed Pans and Urinals (for Bed-Confined Patients), Adjustable Firmness/Support Mattress, Nonhospital Adjustable Bed, Bed Boards/Foot Boards, Bed Elevation Blocks, Overbed Tables/Trays, Positioning Pillow/Cushion/Wedge, Power/Manual Lounge Bed, Restraints (Body, Chest, Wrist, Ankle, etc.), Safety, Enclosure, or Canopy Type Bed, Safety Accessories (Belt, Harness, Vest), Vibrating Bed, Viscoelastic or Memory Foam Mattress, Water Bed]; Indications: [Medical condition requiring positioning not feasible in ordinary bed, Requires frequent changes in body positioning, Requires head of bed elevated more than 30 degrees most of the time, Medical condition makes it difficult to transfer, Requires traction equipment which can be attached only to a hospital bed, Meets criteria for a standard hospital bed, Individual's weight is more than 350 pounds but less than 600 pounds, Individual's weight is 600 pounds or more, Extensive burns, Individual is bed-ridden and unable to ambulate fully or partially, Has stage 3 (full thickness tissue loss) or stage 4 (deep tissue destruction) pressure sore, Has exhausted conservative treatment without improvement (pressure sores), Would require institutionalization in the absence of air fluidized bed, Has a trained adult caregiver available, Has a physician who directs home treatment regimen and re-evaluates and recertifies monthly, Has used and failed to get wound healing from other alternative equipment, Requires treatment with wet soaks or has moist wound dressings not protected, Caregiver is unable to provide the type of care required on air fluidized bed, Structural support is inadequate to support the weight of the air fluidized bed system, Home electrical system and ventilation are insufficient for air fluidized bed, Documentation supports the medical necessity of the accessory, Not appropriate for use in the home setting, Not primarily intended for medical use and contractually excluded, Any Indication/Use Case]
1.01.525: Postsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Treatments: [Postsurgical Home Use of Limb Compression Devices]; Indications: [Postsurgical major orthopedic surgery with documented contraindication to standard anticoagulants, Postsurgical major orthopedic surgery without documented contraindication to standard anticoagulants, Postsurgical major non-orthopedic surgery (moderate/high VTE risk) with contraindication to standard anticoagulants, Postsurgical major non-orthopedic surgery (moderate/high VTE risk) without documented contraindication to standard anticoagulants, Use for periods longer than 30 days postsurgery, All other situations than those specified as Medically Necessary]
1.01.526: Durable Medical Equipment Repair/Replacement Treatments: [Any Durable Medical Equipment, Wheelchairs, Positive Airway Pressure (PAP) Devices]; Indications: [Criteria for Medically Necessary Repair, Criteria for Medically Necessary Replacement (Damage/Deterioration), Criteria for Medically Necessary Replacement (Lost or Stolen), Criteria for Medically Necessary PAP Device Repair, Criteria for Medically Necessary PAP Device Replacement (After 5-Year RUL), Criteria for Medically Necessary PAP Device Replacement (During 5-Year RUL, Loss/Damage), Criteria for Medically Necessary Rental During Repair/Replacement, Accessory Add-ons/Upgrades When Current Item is Functional, Experimental or Investigational Use, Associated with Training (Athletic, Scholastic, etc.), Available Over-the-Counter, Resulting from Abuse or Neglect, Back-up or Duplicate Item, Repair of Rented Equipment, Item Still Under Manufacturer Warranty, For Comfort or Convenience]
1.01.527: Power Operated Vehicles (Scooters) (Excluding Motorized Wheelchairs) Treatments: [Power Operated Vehicle (Scooter)]; Indications: [Physical/functional deficit in mobility impairing home ADLs, Can safely ambulate with cane or walker for home ADLs, Only for use outside the home, Exceeds basic mobility requirements, Only used when primary mobility device requires repair, Individual already has a manual or power wheelchair, Used for convenience, Used solely for recreational/leisure activities, Unable to safely operate independently, Purchased without clinical evaluation and prescription, Accessory items (e.g., car/van lifts, vehicle ramps), Residential/Home modifications (e.g., ramps, stair lifts, elevators), Devices not serving a primarily medical purpose (e.g., for transportation), Backup POV that is not the primary electric mobility device]
1.01.528: Hearing Aids (Excludes Implantable Devices) Treatments: [Prescription Hearing Aid (Traditional), Non-implantable Intraoral Bone Conduction Hearing Aid, FDA Cleared Over-the-Counter Hearing Aid, Hearing Aid Feature Software (e.g., Apple AirPods Pro), Over-the-Counter Hearing Assistive Device/PSAP]; Indications: [Moderate Hearing Loss (40-60 dB PTA bone-conduction), Conductive Hearing Loss (unresponsive to medical/surgical intervention), Sensorineural Hearing Loss, Mixed Hearing Loss, Single Sided Deafness, Generally Investigational Status, Generally Not Covered by Policy, Subsequent Batteries or Ancillary Equipment]
1.01.529: Durable Medical Equipment Treatments: [Any Durable Medical Equipment (DME), Speech Generating Devices (SGDs), Software Program for Essential Communication (with Personal Device), Artificial Laryngeal Devices (Prosthetic), Accessory Add-ons and Upgrades (when basic meets needs), Deluxe Equipment (when basic is available and meets needs), Duplicate Equipment (meets the same functional need), Elastic Garments (e.g., Stabilizing Pressure Input Orthoses), Equipment for Leisure or Recreational Activities, Redundant or Back-up DME (not used as primary device), Athletic/Exercise/Physical Fitness Equipment, Altered Auditory Feedback (AAF) Devices, Comfort or Convenience Items (added to basic equipment), Equipment for Environmental Control or Enhancement, First Aid or Precautionary Equipment, Home Modifications, Institutional Equipment (not suitable for home use), Maintenance and Service Fees for DME, Multiple-Function Hardware Devices (not primarily medical), Remote Hand-held Intermittent Intraocular Pressure (IOP) Monitoring Devices, Vehicle Modifications, Walker, Battery Powered, Wheeled (E0152)]; Indications: [Any Condition or Use Case, Documented Physical Functional Impairment Requiring Accommodation for Basic ADLs, Medical Necessity Criteria Not Met, Basic (Standard) Equipment Meets Functional Needs, Same Functional Need Already Met by Existing Equipment, Primarily Used for Leisure or Recreational Activities, Used as Redundant or Back-up Device (Not Primary), Considered Experimental or Investigational / Used for Experimental Therapy, Associated with Athletic, Scholastic, Educational/Vocational Training, Dispensed by DME Supplier Without a Prescription, Stuttering or Speech Dysfluency, Serves No Medical Purpose / Primarily for Comfort/Convenience, Used for Environmental Control or to Enhance Surroundings, Not Primarily Intended for Medical Purposes, Glaucoma or Elevated Intraocular Pressure, Children with Neuromotor Deficits, Not Suitable for Use in the Home Setting (Institutional Use Only)]
1.01.530: Children's Therapeutic Positioning Equipment Treatments: [Any Therapeutic Positioning Equipment, Reflux wedges, Therapeutic positioning seats (General), Therapeutic positioning seats for vehicles, Bath and toilet positioning equipment, Other positioning cushions, pillows, wedges (Non-reflux), Conventional car seats, Feeding chairs/highchairs (No medical positioning need), Positioning chairs (General population), Bean bag positioning seats, Positioning seats (Non-medical purpose), Positioning seats (Convenience features), Positioning equipment (Leisure/R-creation/Sports), Vehicle modifications for positioning seats]; Indications: [Any Condition, Any Policy Rule or Context, Severe Gastroesophageal Reflux (Infants), Inability to sit safely in conventional chair/seat, Need for specialized positioning (ADL), Significant head/trunk instability or weakness, Significant hypotonicity, Significant hypertonicity, Athetosis, Ataxia, Significant spasticity, Muscle spasming (uncontrollable movement), Absence or latency of protective reactions, Inability to maintain unsupported sitting, Other significant positional needs (not met by conventional seats), Inability to be safely supported in vehicle, Severe seizure activity (uncontrollable movement), Orthopedic disease (bony fragility/contracture), Pierre Robin sequence or premature/small infant (airway), Inability to sit safely (Bath/Toilet), Need for specialized positioning (Hygiene ADL), Prescribed by a physician, Documentation of medical condition (Reflux wedge), Trial and failure of other positioning methods, Documentation of contraindication to other positioning methods, Specialized seating/mobility evaluation, Successful equipment trial documented, Considered duplication of service, No medical purpose / primarily for comfort or convenience / general use, Required by law/community practice, No medical positioning needs, Vehicle modifications]
1.01.537: Low Intensity Pulsed Ultrasound Fracture Healing Device Treatments: [Low-intensity Pulsed Ultrasound]; Indications: [Fresh Fractures (Surgically or Nonsurgically Managed), Fracture Nonunion and Delayed Union, Stress Fractures, Osteotomy, and Distraction Osteogenesis, Concurrent use with other noninvasive osteogenic devices]
1.01.538: Cooling Devices Used in the Outpatient Setting Treatments: [Cooling Devices (Circulating and Noncirculating)]; Indications: [Used in the Outpatient Setting]
1.01.539: Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions Treatments: [Oscillatory Positive Expiratory Pressure (OPEP) Device, High-Frequency Chest Wall Compression (HFCWC) Device, Intrapulmonary Percussive Ventilation (IPV) Device, High-Frequency Chest Wall Compression and/or Intrapulmonary Percussive Ventilation Devices, Oscillation and Lung Expansion (OLE) Device]; Indications: [Hypersecretory Lung Disease, Cystic Fibrosis, Chronic Diffuse Bronchiectasis, Failed Standard Chest Physical Therapy, Standard Chest Physical Therapy Unavailable or Not Tolerated, Adjunctive Use of HFCWC/IPV with Chest Physical Therapy, Chronic Obstructive Pulmonary Disease (COPD), Respiratory Conditions Associated with Neuromuscular Disorders]
1.01.540: Continuous Passive Motion in the Home Setting Treatments: [Continuous Passive Motion]; Indications: [Total Knee Arthroplasty or TKA Revision, Articular Cartilage Repair of the Knee, Inability to Ambulate or Comply with Rehabilitation, During Non-Weight-Bearing Rehabilitation Period, For All Other Conditions Not Listed]
1.03.04: Powered Exoskeleton for Ambulation in Patients With Lower-Limb Disabilities Treatments: [Powered Exoskeleton]; Indications: [Lower-Limb Disabilities (for ambulation), Spinal Cord Injury, Stroke, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Guillain-Barré Syndrome, Spina Bifida, Acquired Brain Injury (including TBI), Cannot use hands and shoulders with crutches/walker, Poor bone density or fractures, Cannot stand using a standing frame, Not in general good health, Outside specified height or weight limits, Use for sports or stair climbing]
1.03.501: Custom-made Knee Orthoses (Braces), Ankle-Foot-Orthoses, and Knee-Ankle-Foot-Orthoses Treatments: [Custom-made Unloader Knee Orthosis/Brace, Custom-made Functional Knee Orthosis/Brace, Prophylactic Knee Orthosis/Brace (Custom or Prefabricated), Custom-made Ankle-Foot Orthosis, Custom-made Knee-Ankle-Foot Orthosis]; Indications: [Painful osteoarthritis involving the medial compartment of the knee (causing a varus deformity), Painful osteoarthritis involving the lateral compartment of the knee (causing a valgus deformity), Knee instability due to a knee injury (fracture, ligament tear), Knee instability due to recent knee surgery (rehabilitation), Knee instability due to a knee deformity (contracture, genu varum/valgum), Disorders of ankle dorsiflexion/plantar flexion/inversion/eversion, spastic diplegia (CP), lower motor neuron weakness (poliomyelitis), spastic hemiplegia (cerebral infarction), Need for additional support to the knee for stability (specific context for KAFOs), Criteria for AFO/KAFO Medical Necessity (Ambulatory + any of 5 specific rules), Prefabricated knee brace (unloader or functional) can be custom fit and adjusted, Condition other than specified osteoarthritis (unloader) or instability (functional), Use for prophylactic purposes (prevention of injury), Does not meet the specified criteria for AFO/KAFO medical necessity]
1.04.502: Myoelectric Prosthetic and Orthotic Components for the Upper Limb Treatments: [Any Myoelectric Upper Limb Prosthesis or Component, Conventional Grip Myoelectric Prosthetic Hand, Multiarticulating Myoelectric Hand Prosthesis, Myoelectric Partial Hand Prosthesis, Intent Decoding Modules (IDMs) / Pattern Recognition Control, Advanced Sensor and Myoelectric Controlled Upper-Limb Prosthetic Components, Myoelectric Controlled Upper Limb Orthosis, Custom Fabricated Glove for Upper Extremity Prosthesis]; Indications: [Amputation or Missing Limb at Wrist or Above, Standard Body-Powered Devices Insufficient or Cannot Be Used, Sufficient Remaining Musculature Microvolt Threshold, Sufficient Neurologic and Cognitive Function to Operate, Comorbidities Interfering with Function, Functional Evaluation Indicates Likely Success, Specific Medical Necessity Criteria Met for Upper Limb Myoelectric Prostheses, Policy Coverage Criteria Not Met, Requested Primarily Based on Appearance, Not Primarily Medical in Nature, Amputation or Missing Limb Distal to the Wrist (Partial Hand), Upper-Extremity Weakness or Paresis, Any Indication Not Otherwise Specified]
1.04.503: Microprocessor-Controlled and Powered Prostheses and Orthoses for the Lower Limb Treatments: [Microprocessor-controlled knee, Powered knee, Microprocessor-controlled or powered ankle-foot, Microprocessor stance-controlled knee-ankle-foot orthosis, Orthotics, prosthetics, or prosthetic components added to a conventional prosthesis, Any/All indications (default rule)]; Indications: [Transfemoral amputation (above the knee), Specific criteria for microprocessor-controlled knee are met, Condition preventing socket fitting (complicated wound, intractable pain), Inability to tolerate the weight of the prosthesis, Medicare K0 level (CMS criteria), Medicare K1 level (CMS criteria), Medicare K2 level (CMS criteria), Medicare K3 level (CMS criteria), Medicare K4 level (CMS criteria), Medicare Level K0, K1, or specific K2 criteria not met (VHA), Inability to use swing and stance features, Poor balance or ataxia that limits ambulation, Significant hip flexion contracture (> 20 degrees), Significant deformity of remaining limb, Limited cardiovascular and/or pulmonary reserve or profound weakness, Limited cognitive ability to understand gait sequencing or care requirements, Long distance or competitive running, Falls outside manufacturer weight or height guidelines, Specific environmental factors (excessive moisture or dust, inability to charge), Extremely rural conditions where maintenance ability is limited, Used for experimental or investigational therapy or interventions, Used only for recreational, sports or athletic activities, Available over-the-counter or off-the-shelf without prescription/consultation, Does not meet least costly alternative criteria, New amputees, Bilateral lower extremity amputees, Transfemoral or bilateral lower extremity amputees, Transtibial amputees (below the knee), Individuals with neuromuscular lower-limb deficits]
11.01.508: Skilled Home Health Care Services Treatments: [Skilled Home Health Care Services (Overall), Skilled Nursing Services in the Home, Skilled Medical Social Worker Services in the Home, Skilled Rehabilitation Services in the Home, Skilled Nursing: Post-partum Services, Maintenance Therapy Programs, Non-Skilled Care Services]; Indications: [General Medical Necessity Criteria for Skilled Home Health are met, Specific Medical Necessity Criteria for Skilled Nursing are met, Specific Medical Necessity Criteria for Medical Social Work are met, Specific Medical Necessity Criteria for Rehabilitation are met, Up to 2 Visits for Early Post-partum Care (regardless of homebound status), Maintenance Therapy Programs in the Home Setting, Non-Skilled Care Services in the Home, Skilled Home Health Services Duplicate Others, Not Ordered by Qualified Provider or Not Related to Plan of Care, Care is Deemed Skilled Simply Because of Provider Type or Order, Visits Solely to Reiterate Mastered Teaching, Ongoing Intermittent Straight Catheterization for Chronic Conditions, Visits Solely for Observation in Uncomplicated Wound Care, No Willing and Able Caregiver Available After Training]
11.01.510: Skilled Nursing Facility (SNF): Admission, Continued Stay, and Transition of Care Guideline Treatments: [Skilled Nursing Services, Skilled Therapy Services, Skilled Care in Skilled Nursing Facility]; Indications: [Admission Criteria Met, Continued Stay Criteria Met, Meeting Transition of Care Criteria, Post-Acute Recovery or Rehabilitation Needs, Care Possible at Lower Level, Custodial or Maintenance Care, Unable or Unwilling to Participate in Treatment, Routine Care Needs Only, Confused/Disoriented on Established, Stable Meds, ADL Assistance is Primary Need]
11.01.522: Skilled Hourly Nursing Care in the Home Treatments: [Skilled Hourly Nursing Care in the Home]; Indications: [General Criteria for Medical Necessity Met, Unstable Medical Condition Requiring Frequent Assessment/Change, Technological Dependence Requiring Skilled Monitoring/Intervention, Home Ventilator and/or Tracheostomy Care (Specific Criteria), Transitional Care (Specific Criteria for >16 hours), Care Provided in the School Setting, Chronic Illness Requiring Extensive Skilled Nursing Care, Prolonged IV Nutrition or Drug Therapy Needs Beyond Infusion Services, Severe Impairment Requiring Observation with Possible Intervention, No Caregiver Able/Available for Training, Caregiver Trained and Capable, Condition Stabilized/Predictable/Controlled, NG or G Tube Feedings Only (No Other Skilled Need), Stable, Established Tracheostomy Only (Routine Care), Care Provided by Supply, Infusion, or Home Health Company, Custodial or Maintenance Care, Care Solely for Caregiver Respite, Care Solely to Allow Caregiver Work/School, Patient Receiving Care in a Facility Setting, Nurse Providing Care is a Family Member, Administrative Exclusions, Specific Non-Skilled Services]
11.01.523_2025-05-06: Site of Service: Infusion Drugs and Biologic Agents Treatments: [Infusion Drugs and Biologic Agents (Any), Keytruda (pembrolizumab), Opdivo (nivolumab)]; Indications: [Age 13 and Older, Age Under 13, Alaska Fully-Insured Members, Physician's Office, Infusion Center, Home Infusion, Hospital-Based Outpatient Setting, Initial Course or Re-initiation (>6 months), No Outpatient Site within 50 miles or Home Agency Available, Increased Risk of Complications (Clinical Conditions), Cytokine Release Syndrome (CRS) Grade 3 or 4, Concurrent with Other IV Cancer Treatment]
11.01.523: Site of Service: Infusion Drugs and Biologic Agents Treatments: [Applicable IV Infusion and Injectable Therapy Services]; Indications: [Physician's Office Site of Service, Infusion Center Site of Service, Home Infusion Site of Service, Hospital-based Outpatient Site of Service, Hospital Outpatient - Initial 90 Days or Re-initiation, Hospital Outpatient - Geographic Barrier or Access Issue, Hospital Outpatient - Increased Risk of Complications (Clinical Factors), Cytokine Release Syndrome (CRS) Grade 3 or 4 Requiring Admission, Hospital Outpatient - Site Criteria Not Met, Age Under 13 - Excluded from Site Review Scope, Alaska Fully-Insured Members - Excluded from Site Review Scope, Keytruda/Opdivo Concurrent with Other IV Cancer Meds - Excluded from Site Review]
11.01.524: UTILIZATION MANAGEMENT GUIDELINE – 11.01.524 Site of Service: Select Surgical Procedures Treatments: [Any Elective Surgical Procedure Subject to Site of Service Policy]; Indications: [Patient meets criteria for inpatient site of service medical necessity, Patient does not meet criteria for inpatient site of service medical necessity]
13.01.500: Prescription Digital Therapeutics Treatments: [Any Prescription Digital Therapeutic, BlueStarRx System, Canvas Dx autism diagnosis aid, CureSight CS 100 System, DaylightRx, d-Nav Insulin Management Program, EndeavorRx, EpiMonitor, Halo AF Detection System, Insulia Diabetes Management Companion, leva Pelvic Digital Health System, Luminopia One, Mahana for irritable bowel syndrome, MamaLift Plus, MindMotion GO, My Dose Coach, NightWare, Regulora for irritable bowel syndrome, Rejoyn, RelieVRx, Revital Vision, Professional Services for PDT Management]; Indications: [Any Medically Necessary Purpose/Indication, Criteria Not Met or Other Non-Covered Use, Over-the-Counter or Non-Prescription Use, Professional Services Related to Managing PDTs, Associated PDT Device is Not Medically Necessary, Type 1 Diabetes, Type 2 Diabetes, Autism Diagnosis Aid, Amblyopia, Generalized Anxiety Disorder (GAD), Attention-Deficit Hyperactivity Disorder (ADHD), Epilepsy or at Risk of Having Epilepsy (Seizure Monitoring), Atrial Fibrillation (Detection/Monitoring), Urinary Incontinence (Stress, Mixed, Mild-Moderate Urgency), Overactive Bladder, Irritable Bowel Syndrome (IBS), Postpartum Depression (PPD), Stroke Recovery (Motor Function Rehabilitation), Brain Injury Recovery (Motor Function Rehabilitation), Nightmares (Sleep Disturbance Reduction), Nightmares from Posttraumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD) Symptoms, Chronic Low Back Pain, Adjunctive Treatment Use, Used Under Clinician Supervision/Management]
2.01.100: Dry Needling of Trigger Points for Myofascial Pain Treatments: [Dry Needling of Trigger Points]; Indications: [Myofascial Pain (associated with trigger points)]
2.01.106: Percutaneous Electrical Nerve Field Stimulation for Irritable Bowel Syndrome Treatments: [Percutaneous Electrical Nerve Field Stimulation]; Indications: [Irritable Bowel Syndrome]
2.01.107: Fractional Carbon Dioxide (CO2) Laser Ablation Treatment of Hypertrophic Scars or Keloids for Functional Improvement Treatments: [Fractional Carbon Dioxide (CO2) Laser Ablation]; Indications: [Hypertrophic Scars (for functional improvement), Keloids (for functional improvement)]
2.01.17: Sublingual Immunotherapy as a Technique of Allergen-Specific Therapy Treatments: [Sublingual Immunotherapy (Any), Oralair, Grastek, Ragwitek, Odactra]; Indications: [Pollen-induced Allergic Rhinitis/Rhinoconjunctivitis, House Dust Mite-induced Allergic Rhinitis/Rhinoconjunctivitis, Contraindication: Severe Asthma, Contraindication: History of Severe Allergic Reaction to SLIT, Contraindication: History of Eosinophilic Esophagitis, All Other Uses/Indications]
2.01.26: Prolotherapy Treatments: [Prolotherapy]; Indications: [Musculoskeletal Pain]
2.01.38: Transesophageal Endoscopic Therapies for Gastroesophageal Reflux Disease Treatments: [Transoral Incisionless Fundoplication (TIF), Transesophageal Radiofrequency Ablation (Stretta), Endoscopic Submucosal Implantation of Prosthesis, Endoscopic Injection of Bulking Agent, Surgical Fundoplication]; Indications: [Gastroesophageal Reflux Disease (GERD), Requirement for PPI Response/Failure, Hiatal Hernia Size Restriction, GERD Severity Limitation]
2.01.40: Extracorporeal Shock Wave Treatment for Plantar Fasciitis and Other Musculoskeletal Conditions Treatments: [Extracorporeal Shock Wave Therapy (ESWT)]; Indications: [Achilles Tendinopathy, Avascular Necrosis of the Femoral Head, Delayed Union and Nonunion of Fractures, Patellar Tendinopathy, Plantar Fasciitis, Spasticity, Stress Fractures, Tendinitis of the Elbow (Lateral Epicondylitis), Tendinopathies Including Tendinitis of the Shoulder, Medial Tibial Stress Syndrome, Coccydynia, Painful Stump Neuromas, Refractory Greater Trochanteric Pain Syndrome]
2.01.49: Transurethral Water Vapor Thermal Therapy and Transurethral Water Jet Ablation (Aquablation) for Benign Prostatic Hyperplasia Treatments: [Transurethral Water Vapor Thermal Therapy, Transurethral Waterjet Ablation (Aquablation)]; Indications: [Benign Prostatic Hyperplasia]
2.01.505: Hyperbaric Oxygen Therapy Treatments: [Systemic Hyperbaric Oxygen Pressurization Therapy, Topical Hyperbaric Oxygen Therapy]; Indications: [Acute traumatic ischemia, Anemia from exceptional blood loss (profound), Carbon monoxide poisoning, acute, Central retinal artery occlusion (CRAO), Compromised skin grafts or flaps, Cyanide poisoning, acute, Decompression sickness, Gas embolism, acute, Gas gangrene (i.e., clostridial myonecrosis), Idiopathic sudden sensorineural hearing loss, Necrotizing soft tissue infections, Non-healing diabetic wounds of the lower extremities (with specific criteria), Osteomyelitis, chronic refractory, Pre-and posttreatment for dental surgery (non-implant-related) of an irradiated jaw, Soft tissue radiation necrosis, Osteoradionecrosis, Acute peripheral arterial insufficiency, Acute coronary syndromes and as an adjunct to coronary interventions, Acute ischemic stroke, Acute surgical and traumatic wounds not meeting criteria, Acute thermal burns, Autism spectrum disorder, Bell's palsy, Bisphosphonate-related osteonecrosis of the jaw, Bone grafts, Brown recluse spider bites, Carbon tetrachloride poisoning, acute, Cerebral edema, acute, Cerebral palsy, Cerebrovascular disease, acute (thrombotic or embolic) or chronic, Chronic arm lymphedema following radiotherapy for cancer, Chronic wounds, other than those in individuals with diabetes who meet criteria, Delayed-onset muscle soreness, Demyelinating diseases, Early treatment (beginning at completion of radiotherapy) to reduce adverse events of radiotherapy, Fibromyalgia, Fracture healing, Herpes zoster, Hydrogen sulfide poisoning, Idiopathic femoral neck necrosis, In vitro fertilization, Inflammatory bowel disease (Crohn disease or ulcerative colitis), Intra-abdominal and intracranial abscesses, Lepromatous leprosy, Meningitis, Mental illness (i.e., posttraumatic stress disorder, generalized anxiety disorder, or depression), Migraine, Motor dysfunction associated with stroke, Pseudomembranous colitis (antimicrobial agent-induced colitis), Pyoderma gangrenosum, Radiation myelitis, Radiation-induced injury in the head and neck, except as noted, Refractory mycoses (grouped list), Actinomycosis, Retinopathy, adjunct to scleral buckling procedures in individuals with sickle cell peripheral retinopathy and retinal detachment, Sickle cell crisis and/or hematuria, Spinal cord injury, Traumatic brain injury, Tumor sensitization for cancer treatments, Vascular dementia, Avascular necrosis (aseptic osteonecrosis), Any Indication]
2.01.526: Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders Treatments: [Standard/Conventional and Deep Transcranial Magnetic Stimulation, Allowed Theta Burst Stimulation (Excluding Accelerated/SAINT), Accelerated Theta Burst Stimulation (General), SNT/SAINT Protocol, Accelerated TMS (3 or More Treatments Per Day), Any TMS Type with Biomarkers, Computer-assisted Transcranial Magnetic Stimulation, Functional MRI-guided TMS, Low Field Magnetic Stimulation, Magnetic Seizure Therapy, MeRT (Magnetic e-Resonance Therapy), MRI-guided TMS, Multiarray TMS, Navigated TMS, Single Pulse TMS, Synchronized TMS, Cerena TMS Device, Any Type of Transcranial Magnetic Stimulation]; Indications: [Major Depressive Disorder (Unipolar Depression), Major Depression as a component of Bipolar Disorder (Bipolar Depression), Obsessive-Compulsive Disorder, All Other Psychiatric Disorders or Conditions, Neurologic Disorders and Conditions, Substance Abuse Disorders and Conditions, Mixed Episodes of Bipolar Disorder, Acute Treatment of Pain Associated with Migraine Headache with Aura, Cluster Headache or Chronic Migraine Headache, Headaches Due to Underlying Pathology or Trauma, Medication Overuse Headaches, Presence of a Brain Tumor, History of Brain Tumor Without Clearance, History of Head Trauma Without Clearance, Unspecified Brain Lesion Without Clearance, Acute or Chronic Psychotic Disorder/Symptoms, Condition with Increased Intracranial Pressure, Current Substance Abuse/Excessive Substance Use, Magnetic Sensitive Dental Implants on Side of Head, Non-Removable Conductive/Magnetic Implants in Head/Neck, Uncontrolled Seizure Disorder/History, Severe Dementia, Required Medical Clearance Not Obtained, Criteria Met for Unipolar Depression Coverage, Criteria Met for Bipolar Depression Coverage, Criteria Met for OCD Coverage, Full Intensive Course Parameters, Excessive Initial Mapping/Threshold Sessions (NMN), Excessive Threshold Re-determination Sessions (NMN), Extended Intensive Course (Medically Necessary), Extended Intensive Course (Not Medically Necessary), Extended Taper (Medically Necessary), Extended Taper (Not Medically Necessary), Accelerated TMS (2 sessions/day, Medically Necessary), Accelerated TMS (> 2 sessions/day, Not Medically Necessary), Maintenance TMS (Medically Necessary), Maintenance TMS (Not Medically Necessary), Repeat Full Intensive Course (Medically Necessary), Repeat Full Intensive Course (Not Medically Necessary), Short/Brief Intensive Course (Booster, Medically Necessary), Short/Brief Intensive Course (Booster, Not Medically Necessary), Consecutive or Overlapping Courses for Different Conditions (NMN), TMS with More Than One Provider Simultaneously (NMN), Conjunction with Psychedelics (Investigational), Conjunction with Vagus Nerve Stimulation (Medically Necessary), Conjunction with Vagus Nerve Stimulation (Not Medically Necessary), Conjunction with Other Neuromodulation (NMN), Continuation of Non-Company TMS (Medically Necessary), Individuals Under Age 18 (Generally Investigational), Cerena for Cluster/Chronic Migraine (Investigational), Cerena for Aura Phase Treatment (Not Medically Necessary), Cerena for Migraine Associated Symptoms (Not Medically Necessary), Cerena for Pregnant/Under 18/Over 65 (Investigational), Any Indication, Contraindication, or Rule]
2.01.533: Upper Gastrointestinal (UGI) Endoscopy for Adults Treatments: [Upper Gastrointestinal Endoscopy (EGD)]; Indications: [Policy applies only to adults (Age 19+), Barrett esophagus (Metaplastic columnar or glandular epithelium), Dysplasia, Esophageal cancer, Familial adenomatous polyposis (FAP), Gastric cancer, Head/neck cancer, History of Lynch Syndrome or hereditary nonpolyposis colorectal cancer (HNPCC), Suspicious clinical features for UGI malignancy (e.g., epigastric mass on x-ray, abnormal barium study), Prior adenomatous gastric polyps or sessile polyps, Positive CDH1 mutation, Family history of gastric, esophageal, or duodenal cancer in a first degree relative, Tylosis, Iron deficiency anemia (suspected UGI source), GI bleeding (rectum or in stool that may be bright red or dark colored), Epigastric mass (found on examination), Persistent vomiting of unknown cause (including vomiting blood), Difficulty swallowing (dysphagia), Unintentional weight loss of 3 kg (approx. 6.6 lbs.) or more, Anorexia of unknown cause, Suspected portal hypertension or cirrhosis (initial evaluation to document varices), Follow-up of known eosinophilic esophagitis, Follow-up of known erosive esophagitis, Therapeutic banding (ligation) or sclerotherapy of esophageal varices and follow-up, Treatment of bleeding from lesions such as ulcers (e.g., electrocoagulation, heater probe, laser photocoagulation, or injection therapy), History of gastric surgery, UGI symptoms continue after NSAID use is stopped, Persistent non-cardiac chest pain (after cardiac rule out), Painful swallowing (odynophagia), Persistent GERD or dyspepsia symptoms (>= 3 months, failed 8-week daily PPI), Recurrent GERD or dyspepsia symptoms (after PPI discontinuation), Achalasia, Barrett esophagus surveillance (with dysplasia), Barrett esophagus surveillance (no dysplasia), Cirrhosis (initial diagnosis screening for esophageal varices), Cirrhosis (ongoing screening or surveillance for varices), Crohn disease that involves the esophagus, stomach, or duodenum, Eating or drinking (ingestion) of a caustic agent (acute injury assessment), Known or suspected foreign body removal, Gastric, peptic, or esophageal ulcer confirmation (failed or contraindicated conservative management), Gastric, peptic, or esophageal ulcer follow-up (until healed), Individuals planned for organ transplantation (UGI pathology might modify management), Performed for endoscopic ultrasound guided fine needle aspiration/biopsy(s) of adjacent organs or structures, Performed for preoperative endoscopic evaluation prior to bariatric surgery, Pernicious anemia symptoms (when blood tests are inconclusive), Post cardiac ablation for treatment of arrhythmias, Barrett esophagus screening (male 50+ with 5+ years GERD symptoms and risk factors), Assess diarrhea (suspected small-bowel disease like celiac disease or inflammatory bowel disease), UGI tract stricture or obstruction, Any other condition not addressed in this policy criteria, Symptoms considered functional in origin (chronic, non-progressive, atypical, responsive to therapy), Uncomplicated heartburn that responds to conservative medical management, Evaluation of UGI conditions/diagnoses when the endoscopy results will not alter management, Radiographic findings that are asymptomatic or have responded to therapy (deformed duodenal bulb, uncomplicated ulcer, sliding hiatal hernia), Performed as routine screening of the UGI tract in the absence of a clinical indication, Surveillance of healed benign disease (e.g., esophagitis, gastric or duodenal ulcer), Surveillance of individuals with gastric intestinal metaplasia, Metastatic adenocarcinoma of unknown primary site (when results will not alter management), Surveillance for malignancy in patients with gastric atrophy, pernicious anemia, or fundic gland or hyperplastic polyps, Surveillance during repeated dilation of benign strictures (unless there is a change in status)]
2.01.534: Intra-Articular Hyaluronan Injections for Osteoarthritis Treatments: [Intra-Articular Hyaluronan Injection]; Indications: [Osteoarthritis of the Knee, Osteoarthritis of Other Joints]
2.01.535: Temporomandibular Joint Disorder Treatments: [Diagnostic X-ray, Tomograms, and Arthrography (Radiological), Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI), Cephalograms, Pantograms, Injection Procedure for Temporomandibular Joint Arthrography, Arthrocentesis, Manipulation for Reduction of Fracture or Dislocation, Arthroscopic Surgery, Open Surgical Procedures, One Intraoral Removable Prosthetic Device or Appliance, Pharmacologic Treatment, Physical Therapy, Trigger Point Injections, Two-Piece Intraoral Prosthetic Device or Appliance, Arthroscopy (Purely Diagnostic), Computerized Mandibular Scan, Electromyography (EMG), Joint Vibration Analysis, Kinesiography, Muscle Testing, Neuromuscular Junction Testing, Range-of-Motion Measurements, Somatosensory Testing, Standard Dental Radiographic Procedures, Thermography, Transcranial or Lateral Skull X-rays, Intraoral Tracing or Gnathic Arch Tracing, Ultrasound Imaging/Sonogram (Diagnostic), Biofeedback, Botulinum Toxin A, Dental Restorations/Prostheses, Devices Promoted to Maintain Joint Range of Motion and Develop Muscles, Dextrose Prolotherapy, Electrogalvanic Stimulation, Hyaluronic Acid, Iontophoresis, Orthodontic Services, Percutaneous Electrical Nerve Stimulation (PENS), Platelet Concentrates (e.g., Platelet Rich Plasma), Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound (Therapeutic)]; Indications: [Temporomandibular Joint Disorder (TMJD), Diagnosis of Temporomandibular Joint Disorder, Treatment of Temporomandibular Joint Disorder, Purely Diagnostic Use (for Arthroscopy)]
2.01.543: Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions Treatments: [Recombinant Platelet-Derived Growth Factor (Becaplermin), Platelet-Rich Plasma (Autologous)]; Indications: [Neuropathic Diabetic Ulcers Extending into Subcutaneous Tissue, Pressure Ulcers Extending into Subcutaneous Tissue, Ischemic Ulcers, Venous Stasis Ulcers, Ulcers Not Extending to Subcutaneous Tissue, Acute or Chronic Wounds (General), Fat Graft Retention, All Other Indications Not Explicitly Listed]
2.01.57: Electrostimulation and Electromagnetic Therapy for Treating Wounds Treatments: [Electrical Stimulation (Electrostimulation), Electromagnetic Therapy]; Indications: [Wounds (Any Type), Use in Home Setting]
2.01.71: Nonpharmacologic Treatment of Rosacea Treatments: [Nonpharmacologic Treatment of Rosacea]; Indications: [Rosacea]
2.01.73: Actigraphy Treatments: [Actigraphy]; Indications: [Sleep-Wake Cycles, Sleep Disorders, Insomnia Disorder, Circadian Rhythm Sleep-Wake Disorder, Sleep-Disordered Breathing, Central Disorders of Hypersomnolence, Insufficient Sleep Syndrome, Restless Legs Syndrome, Periodic Limb Movement Disorder, Other Sleep-Wake Disturbances, Used as Sole Technique, Used as Component of Portable Sleep Monitoring]
2.01.91: Peroral Endoscopic Myotomy for Treatment of Esophageal Achalasia and Gastroparesis Treatments: [Peroral endoscopic myotomy (POEM), Gastric peroral endoscopic myotomy (G-POEM)]; Indications: [Esophageal Achalasia (Adult and Pediatric), Gastroparesis]
2.01.98: Orthopedic Applications of Platelet-Rich Plasma Treatments: [Platelet-Rich Plasma]; Indications: [All Orthopedic Indications, Achilles Tendinopathy, Lateral Epicondylitis, Osteochondral Lesions, Osteoarthritis (Any Site), Osteoarthritis (Knee), Osteoarthritis (Hip), Plantar Fasciitis, Non-Tendon Soft Tissue Injury or Inflammation, Dupuytren Contracture, Adjunctive Use in Surgical Procedures, Adjunctive Use: ACL Reconstruction, Adjunctive Use: Hip Fracture Surgery, Adjunctive Use: Long-Bone Nonunion Surgery, Adjunctive Use: Patellar Tendon Repair, Adjunctive Use: Rotator Cuff Repair, Adjunctive Use: Spinal Fusion, Adjunctive Use: Subacromial Decompression Surgery, Adjunctive Use: Total Knee Arthroplasty]
2.02.09: Closure Devices for Patent Foramen Ovale and Atrial Septal Defects Treatments: [Transcatheter ASD Closure, Transcatheter PFO Closure]; Indications: [Secundum Atrial Septal Defect, Patent Foramen Ovale, PFO with Cryptogenic Ischemic Stroke, PFO with Migraine Headache, PFO with Other Conditions, Secundum ASD Meeting Medical Necessity Criteria, Secundum ASD Not Meeting Medical Necessity Criteria, PFO with Cryptogenic Stroke Meeting All Medical Necessity Criteria, PFO with Cryptogenic Stroke Not Meeting Positive MN Criteria, Contraindication: Uncontrolled Vascular Risk Factors, Contraindication: Other Sources of Right-To-Left Shunts, Contraindication: Active Endocarditis or Untreated Infection, Contraindication: Inferior Vena Cava Filter, Contraindication: ASD with Severe Pulmonary Hypertension]
2.02.24: Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting Treatments: [Any Cardiac Hemodynamic Monitoring Device (Outpatient Setting), Arterial Pressure during Valsalva Maneuver, Implantable Direct Pulmonary Artery Pressure Monitoring, Inert Gas Rebreathing, Thoracic Bioimpedance]; Indications: [Heart Failure, In Outpatient or Ambulatory Setting, Hypertension, Drug-Resistant Hypertension, Integrated into Other Implantable Cardiac Devices, Acute Dyspnea (Differentiation of cause), Atrioventricular Interval Optimization (Pacemakers), Monitoring Continuous Inotropic Therapy (Terminal HF), Evaluation for Heart Transplant Rejection, Optimization of Fluid Management (Congestive Heart Failure)]
2.02.26: Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Treatments: [FDA-Approved Percutaneous Left Atrial Appendage Closure Device, Other Investigational Percutaneous Left Atrial Appendage Closure Device]; Indications: [Atrial Fibrillation Requiring Stroke Prevention, Increased Risk of Stroke/Systemic Embolism, Systemic Anticoagulation Therapy Recommended, Long-term Anticoagulation Risks Outweigh Device Risks]
2.02.30: Transcatheter Mitral Valve Repair or Replacement Treatments: [Transcatheter Mitral Valve Edge-to-Edge Repair, Transcatheter Mitral Valve-in-Valve Replacement]; Indications: [Symptomatic Primary Mitral Regurgitation at High/Prohibitive Surgical Risk, Symptomatic Moderate-to-Severe/Severe Secondary MR in Heart Failure Despite Maximally Tolerated GDMT, Failed Surgical Bioprosthetic Mitral Valve (Stenosed/Insufficient) with Symptomatic NYHA Class II-IV and High Surgical Risk/Inoperable, Other Situations for Transcatheter Mitral Valve Repair, Other Situations for Transcatheter Mitral Valve-in-Valve Replacement]
2.02.506: Wearable Cardioverter-Defibrillators as a Bridge to Implantable Cardioverter-Defibrillator Placement Treatments: [Wearable Cardioverter-Defibrillator]; Indications: [Systemic infection causing delay in ICD implantation, ICD removed due to infection or malfunction causing delay in replacement, LVEF <= 35% and recent MI (< 40 days) causing delay in ICD implantation, LVEF <= 35% and newly diagnosed non-ischemic dilated cardiomyopathy with GDMT initiated, causing delay in ICD implantation, LVEF <= 35% and recent revascularization (< 90 days) causing delay in ICD implantation, Familial or inherited arrhythmia condition being evaluated for medical therapy effectiveness, causing delay in ICD implantation, Documented VT/VF episode being evaluated for anti-arrhythmia medication effectiveness, causing delay in ICD implantation, High-risk individual awaiting heart transplant, Women with peripartum cardiomyopathy, All other indications]
2.02.507: Coronary Angiography for Known or Suspected Coronary Artery Disease in Adults Treatments: [Coronary Angiography]; Indications: [Congenital Heart Disease, Heart Failure, Hypertrophic Cardiomyopathy, Kawasaki Disease, Pulmonary Artery Extrinsic Compressions of Left Main Coronary Artery, Valvular Disease, Post Cardiac Transplant (Angiography not performed in preceding 6 months), Coronary Artery Disease (Known or Suspected), Stable Angina (meeting specific criteria), Unstable Angina or NSTEMI (High/Intermediate Risk), Suspected Prinzmetal's Angina, Echocardiographic Wall Motion Abnormality (> 2 segments), High-Risk Duke Treadmill Score (≤ -11), Left Ventricular Ejection Fraction ≤ 35% (at rest), High Risk Stress Electrocardiogram Findings, Stress-Induced Large or Multiple Moderate Perfusion Defects, Stress-Induced Left Ventricular Dysfunction (Exercise LVEF < 35%), Significant Stenosis (> 50%) in Unprotected Left Main Coronary Artery on Recent CCTA, Large, Fixed Perfusion Defect with LV Dilatation or Increased Lung Uptake (MPI), Stress-Induced Moderate Perfusion Defect with LV Dilatation or Increased Lung Uptake (MPI), Left Ventricular Enlargement or Transient Post-Stress Ischemic LV Dilatation (MPI), After Acute Myocardial Infarction (for Risk Stratification, meeting criteria), Clinically Significant Heart Failure during Hospital Course (Post-MI), Ischemia Provoked by Minimal Exercise on Noninvasive Testing (Post-MI), Left Ventricular Ejection Fraction ≤ 45% (Post-MI) and Unable to Undergo Noninvasive Testing, Recurrent Ischemia within 12 months of CABG, Suspected Pericarditis (when Acute MI cannot be definitively ruled out), Survived Sudden Cardiac Arrest or Sustained Ventricular Tachycardia, Cardiac Risk Assessment Prior to High-Risk Non-Cardiac Surgery (when non-invasive testing precluded), Suspected Stent Thrombosis following PCI, Reevaluation with Same Imaging Modality (due to change, procedural need, or interval reassessment), Inpatient Site of Service Criteria Met, Inpatient Site of Service Criteria Not Met]
2.02.510: Mobile Cardiac Outpatient Telemetry Treatments: [Mobile Cardiac Outpatient Telemetry (MCOT)]; Indications: [Infrequent Arrhythmia Symptoms after Non-Diagnostic Event Monitor, Suspected Atrial Fibrillation in Cryptogenic Stroke after Non-Diagnostic Event Monitor, Criteria for Medical Necessity not met, All other indications or uses]
2.02.515: Leadless Cardiac Pacemakers Treatments: [Micra Transcatheter Pacing System, Micra Model MC1VR01 (Micra VR), Micra Model MC1AVR1 (Micra AV), Aveir VR Leadless Pacemaker, Aveir DR Dual Chamber Leadless System, Any Leadless Cardiac Pacemaker]; Indications: [Symptomatic paroxysmal or permanent high-grade arteriovenous block, Symptomatic bradycardia-tachycardia syndrome, Sinus node dysfunction (sinus bradycardia or sinus pauses), Normal sinus rhythm with only rare episodes of AV block or sinus arrest, Chronic atrial fibrillation, Bradycardia, Syncope, Pre-syncope, Fatigue, Disorientation (as symptoms of bradycardia), Sick sinus syndrome, Chronic, symptomatic second- and third-degree atrioventricular block, Recurrent Adams-Stokes syndrome, Symptomatic bilateral bundle branch block, Chronotropic incompetence, Need for increased stimulation rates concurrent with physical activity, Sinus node dysfunction (condition where dual-chamber transvenous is preferred over Micra AV VDD mode), High sinus rates requiring atrial tracking (condition where dual-chamber transvenous is preferred over Micra AV VDD mode), Weak atrial contraction (condition where dual-chamber transvenous is preferred over Micra AV VDD mode), Symptoms during loss of atrioventricular (AV) synchrony (condition where dual-chamber transvenous is preferred over Micra AV VDD mode), Frequent premature atrial or ventricular contractions (condition where dual-chamber transvenous is preferred over Micra AV VDD mode), Any indication or condition, History of CIED infection or high risk for infection, Limited access for transvenous pacing, Presence of a bioprosthetic tricuspid valve, Implanted device that would interfere with implant, Implanted inferior vena cava filter, Mechanical tricuspid valve, Implanted cardiac device providing active therapy which may interfere with sensing, Femoral venous anatomy unable to accommodate sheath or implant, Morbid obesity preventing telemetry communication, Known intolerance or sensitivity to device materials or medical contrast, Cannot tolerate a single dose of 1.0 mg dexamethasone acetate, Meets Micra single chamber MN criteria (Specific bradyarrhythmias AND specific contraindications to conventional leads), Any other indication or situation not meeting specific criteria, Medically ineligible for a conventional pacing system, Medically eligible for a conventional pacing system]
2.02.516: Catheter Ablation as Treatment for Atrial Fibrillation Treatments: [Radiofrequency Ablation (RFA), Cryoablation, Catheter Ablation (RFA or Cryoablation)]; Indications: [Any Atrial Fibrillation, Symptomatic paroxysmal recurrent atrial fibrillation (>= 2 episodes) as alternative to medical therapy, Symptomatic persistent atrial fibrillation refractory or intolerant to antiarrhythmic medications, Repeat procedure due to recurrence of AF or development of atrial flutter, Atrial fibrillation not meeting specific coverage criteria, Cannot be treated with anticoagulant therapy, Sole intent is to obviate the need for anticoagulation]
2.03.07: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Select Intra-Abdominal and Pelvic Malignancies Treatments: [Cytoreductive surgery plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the time of surgery]; Indications: [Pseudomyxoma peritonei (malignant tumor of the appendix), Diffuse malignant peritoneal mesothelioma, Newly diagnosed Stage III epithelial ovarian or fallopian tube cancer at time of interval cytoreductive surgery (meeting specific criteria), Peritoneal carcinomatosis from colorectal cancer, Peritoneal carcinomatosis from gastric cancer, Peritoneal carcinomatosis from endometrial cancer, Goblet cell tumors of the appendix, Ovarian cancer (other settings), All other indications not specifically listed]
2.03.502: Monoclonal Antibodies for the Treatment of Lymphoma Treatments: [Rituximab (IV formulations), Rituxan Hycela (rituximab and hyaluronidase human), Arzerra (ofatumumab), Adcetris (brentuximab vedotin), Columvi (glofitamab-gxbm), Epkinly (epcoritamab-bysp), Lunsumio (mosunetuzumab-axgb), Monjuvi (tafasitamab-cxix), Polivy (polatuzumab vedotin-piiq), Any Rituximab Product, All Medications Listed in Policy]; Indications: [Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), High-Grade B-cell Lymphoma (HGBL), Systemic Anaplastic Large Cell Lymphoma (sALCL), Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or CD30-expressing Mycosis Fungoides (MF), Any B-cell or other Lymphoid malignancy with documented CD20 antigen expression, Posttransplant Lymphoproliferative Disorder (PTLD), Previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), Pediatric previously untreated high risk classical Hodgkin lymphoma (cHL), Classical Hodgkin lymphoma at high risk of relapse/progression as post-autologous HSCT consolidation, Classical Hodgkin lymphoma after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens (not auto-HSCT candidates), As first-line therapy, As second-line therapy, As maintenance therapy, Relapsed or Refractory (R/R), Individual has had an inadequate response or intolerance to Ruxience or Truxima, Lymphoid B-cell malignancy that does not express CD20 antigen, All other uses unless listed in this medical policy, All other uses beyond those listed in this policy, Adult individuals, Not eligible for autologous stem cell transplant (ASCT), After two or more lines of systemic therapy, After at least one prior multi-agent chemotherapy regimen, After prior systemic therapy, In combination with R-CHP, In combination with CHOP, In combination with FC, In combination with chlorambucil, In combination with fludarabine and cyclophosphamide, In combination with bendamustine and a rituximab product, In combination with lenalidomide and a rituximab product, In combination with lenalidomide, In combination with chemotherapy (unspecified), In combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVE-PC), International Prognostic Index (IPI) score of 2 or greater, Documentation of pretreatment with obinutuzumab, US Food and Drug Administration (FDA) labeled indication, Off-label indication]
2.04.119: Multibiomarker Disease Activity Blood Test for Rheumatoid Arthritis Treatments: [Multibiomarker Disease Activity Blood Test]; Indications: [Rheumatoid Arthritis]
2.04.123: Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases Treatments: [Serum Biomarker Panel Testing]; Indications: [Systemic Lupus Erythematosus, Other Connective Tissue Diseases]
2.04.125: Proteomic Testing for Systemic Therapy in Non-Small Cell Lung Cancer Treatments: [Proteomic Testing, Proteomic Testing (8-protein signature)]; Indications: [Non-Small Cell Lung Cancer (NSCLC)]
2.04.127: Multitarget Polymerase Chain Reaction Testing for Diagnosis of Bacterial Vaginosis Treatments: [Multitarget Polymerase Chain Reaction Testing]; Indications: [Bacterial Vaginosis]
2.04.136: Nutrient/Nutritional Panel Testing Treatments: [Nutrient/Nutritional Panel Testing]; Indications: [Nutritional Deficiencies (General), Mood Disorders, Fibromyalgia, Unexplained Fatigue, Healthy Individuals, Any Indication]
2.04.144: Gene Therapy for Inherited Retinal Dystrophy Treatments: [Luxturna (voretigene neparvovec-rzyl)]; Indications: [Biallelic RPE65 variant-associated retinal dystrophy, Pregnancy in females, Breastfeeding, Use of retinoid compounds or precursors, Prior intraocular surgery within 6 months, Preexisting eye conditions or complicating systemic diseases, Re-treatment of previously treated individuals, All other uses not explicitly listed as Medically Necessary]
2.04.152: Maternal Serum Biomarkers for Prediction of Adverse Obstetric Outcomes Treatments: [Maternal Serum Biomarker Tests]; Indications: [Prediction of Preeclampsia, Prediction of Spontaneous Preterm Birth]
2.04.26: Fecal Analysis in the Diagnosis of Intestinal Dysbiosis Treatments: [Fecal Analysis for Gastrointestinal Disorders]; Indications: [Intestinal Dysbiosis, Irritable Bowel Syndrome (IBS), Malabsorption, Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Dysbiosis, IBS, Malabsorption, or SIBO (Group)]
2.04.507: Testing Serum Vitamin D Levels Treatments: [Testing Serum Vitamin D Levels]; Indications: [Asymptomatic Individuals with Risk Factors, Asymptomatic Individuals without Risk Factors, Institutionalized Individuals, Symptomatic Vitamin D Deficiency, Symptomatic Vitamin D Toxicity (Hypervitaminosis D), Repeat Testing]
2.04.509: Cardiovascular Risk Panels Treatments: [Cardiovascular Risk Panels (Complex), Simple Lipid Panel]; Indications: [Assessment of Cardiac Risk, Diagnosis of Acute Myocardial Infarction (Not Addressed by Policy)]
2.04.513: Drug Testing in Pain Management and Substance Use Disorder Treatment Settings Treatments: [Presumptive Urine Drug Testing, Definitive Urine Drug Testing, Alcohol Breath Testing, Other Non-Urine Drug Testing (Hair, Oral Fluid, Nail, Sweat), Any Drug Testing or Screening]; Indications: [Pain Management Setting, Substance Use Disorder Treatment Setting, Initial evaluation/admission testing, Suspicion of non-compliance or aberrant behavior testing, Periodic monitoring testing (risk-stratified), SUD treatment: Stabilization phase testing, SUD treatment: Maintenance phase testing, SUD treatment: Inpatient/Residential setting testing, SUD treatment: Repeat testing following positive result, Suspicion of recent alcohol ingestion testing, Panel testing limitation (all components must meet criteria), Not Medically Necessary: Criteria not met, Not Medically Necessary: Routine/standard program/provider testing, Definitive testing trigger: Presumptive result concerning, Definitive testing trigger: Need to quantify substance level, Definitive testing trigger: Substance inadequately detected by presumptive test, Not Medically Necessary: Repeating definitive test for same presumptive result, Not Medically Necessary: Testing for employment issues, Any clinical setting or indication]
2.04.514: Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer Treatments: [Prostate Cancer Autoantibody Biomarkers, Prostate Cancer Kallikrein Markers]; Indications: [Diagnosis and Risk Assessment of Prostate Cancer, History of Prostate Cancer Diagnosis, Recent Digital Rectal Exam (within 4 days), Recent 5-alpha Reductase Inhibitor Therapy (within 6 months), Recent Treatment for Symptomatic BPH (within 6 months)]
2.04.515: Plasma-based Proteomic Screening in the Management of Pulmonary Nodules Treatments: [Plasma-based Proteomic Screening, Nodify XL2 (BDX-XL2), Nodify CDT, REVEAL Lung Nodule Characterization (MagArray)]; Indications: [Undiagnosed Pulmonary Nodules Detected by CT]
2.04.520: Laboratory Testing Investigational Services Treatments: [Oncology (colorectal), quantitative assessment of three urine metabolites, Oncology (bladder), mRNA, microarray gene expression profiling of 209 genes, Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray, Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene, Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins, Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (i.e., ELISA), Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1, Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55, Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1, Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4, Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1, Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2, Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1, Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC, Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA, Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB, Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44, Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1, Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2, Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL, KLF1 (Kruppel-like factor 1), targeted sequencing, Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM, Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4, Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP, Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK, Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE, Syphilis test, non-treponemal antibody, immunoassay, quantitative (RPR), Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis, Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, Red cell antigen (ABO blood group) genotyping (ABO), gene analysis, next-generation sequencing, Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins, Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, Oncology (solid tumor), circulating tumor cell selection, Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), Oncology (melanoma), artificial intelligence (Al)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments, Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of bladder cancer, Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer, Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence, Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, Oncology (ovarian), biochemical assays of 7 proteins, Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry, Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LC-MS/MS), Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as risk score, Oncology (lung), multi-omics (microbial DNA by shotgun next generation sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, Oncology (lung), flow cytometry, sputum, 5 markers, Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, Oncology (colorectal) screening, quantitative real-time target and signal amplification of 8 RNA markers and fecal hemoglobin, Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, Infectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, Infectious disease (respiratory infection), Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), fingerstick whole blood specimen, Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC-MS/MS), monoclonal paraprotein sequencing analysis, serum, Oncology (multiple myeloma), LC-MS/MS, peptide ion quantification, serum, Perfluoroalkyl substances (PFAS) (e.g., perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative, Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary, Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma, Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiqualitative, blood, Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular-weight melanoma-associated antigen, CD34 and CD45 protein biomarkers, peripheral blood, Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of estrogen receptor (ER) protein biomarker-expressing cells, peripheral blood, Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EPCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of PD-L1 protein biomarker-expressing cells, peripheral blood, Oncology (prostate), analysis of circulating plasma proteins (tPSA, fPSA, KLK2, PSP94, and GDF15), germline polygenic risk score (60 variants), clinical information, algorithm reported as risk of likelihood of detecting clinically significant prostate cancer, Oncology (colorectal), blood, quantitative measurement of cell-free DNA (cfDNA), Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA whole-transcriptome data, Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) status, Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood, Carbonic anhydrase VI, parotid specific/secretory protein and salivary protein 1 (SP1), IgG, IgM, and IgA antibodies, chemiluminescence, semiqualitative, blood, Oncology, spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian, fallopian, or peritoneal response prediction, Nephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial-resistance genes, amplified probe technique, Infectious disease (acid-fast bacteria and invasive fungi), DNA (673 organisms), next-generation sequencing, plasma, Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), by liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative, Cardiovascular disease (HDL reverse cholesterol transport), cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-bound apolipoproteins, Nephrology (renal transplant), urine, nuclear magnetic resonance (NMR) spectroscopy measurement of 84 urinary metabolites, combined with patient data, quantification of BK virus using real-time PCR and serum creatinine, Acetylcholine receptor (AChR), antibody identification by immunofluorescence, using live cells, Low-density lipoprotein receptor-related protein 4 (LRP4), antibody identification by immunofluorescence, using live cells, Glial fibrillary acidic protein (GFAP), chemiluminescent enzyme immunoassay, using plasma, Oncology (prostate), enzyme-linked immunosorbent assays (ELISA) for total prostate-specific antigen (PSA) and free PSA, serum, combined with age, previous negative prostate biopsy status, digital rectal examination findings, prostate volume, and image and data reporting of the prostate, Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers, Unlisted chemistry procedure (known error test, Prometheus precision-guided dosing PredictrPK test)]; Indications: [Any use of tests listed in this policy]
2.04.521: Evaluation of Biomarkers for Alzheimer Disease Treatments: [CSF testing for Amyloid Beta peptides and Tau protein, CSF testing for Neural Thread Proteins, Any CSF Biomarker Testing, Any Plasma/Serum Biomarker Testing, Any Urinary Biomarker Testing, Other Adjunct Biomarker Tests, Any AD Biomarker Testing]; Indications: [Mild Cognitive Impairment or Mild Dementia due to Alzheimer Disease, Evaluation for Initiation of Amyloid Beta Targeting Therapy in MCI/Mild Dementia due to AD, Adjunct to Clinical Diagnosis in MCI/Mild Dementia due to AD, Evaluation for Continuation of Amyloid Beta Targeting Therapy in MCI/Mild Dementia due to AD, Any Other Indication or Patient Group/Context]
2.04.62: Multimarker Serum Testing Related to Ovarian Cancer Treatments: [OVA1 Test, Overa Test, ROMA Test]; Indications: [Preoperative evaluation of adnexal masses to triage for malignancy, Screening for ovarian cancer, Selecting individuals for surgery for an adnexal mass, Evaluation of individuals with clinical or radiologic evidence of malignancy, Evaluation of individuals with nonspecific signs or symptoms suggesting possible malignancy, Postoperative testing and monitoring, Detect recurrent malignant disease following treatment, Use as a stand-alone diagnostic test, Use to determine whether or not to proceed with surgery, Use in asymptomatic women without adnexal masses]
2.04.73: Intracellular Micronutrient Analysis Treatments: [Intracellular Micronutrient Analysis]; Indications: [Any covered indication or use case addressed by this policy, Screening for nutritional deficiencies in healthy individuals, Screening for nutritional deficiencies in individuals with chronic disease, Aiding diagnosis in individuals with nonspecific symptoms]
3.01.510: Applied Behavior Analysis (ABA) Treatments: [Applied Behavior Analysis]; Indications: [Autism Spectrum Disorder, Other Diagnoses or Conditions, Unnecessary Duplication of ABA Services, Concurrent Provision with Other Therapies, Individual Treatment in Group Setting (Excludes Bona-Fide Group/Family Therapy), Specific Non-Covered Activities or Services within ABA Program, ABA Activities Excluded in School/Educational Settings (Excluding Bona-Fide Direct ABA), ABA Activities Excluded in Camp Settings, Other Therapy Modalities Not Considered ABA]
3.01.515: Behavioral Health: Residential/Sub-Acute Detoxification Treatments: [Residential and Sub-Acute Detoxification, Ultra-Rapid Detoxification, Sauna or Sweat Lodge Detoxification, Hot Bath/Tub/Jacuzzi Detoxification (Without Active Medical Management), Herbal Detoxification, Exercise-Based Detoxification, Hydration/Nutrition Detoxification (Without Active Medical Management), Vitamin/Supplementation Detoxification (Without Active Medical Management)]; Indications: [Substance Use Disorder (Moderate or Severe, Not in Remission, Excluding Tobacco/Nicotine), Any Detoxification Indication, Programmatic Requirement for Detox Admission, Observation Without Active Medical Management (Social Detoxification), Post-Acute Withdrawal Syndrome (PAWS), Discharge Planning Incomplete, Waiting for Residence or Treatment Placement, Uncertainty about Support System, Patient or Family Non-Compliance, Admission Based Solely on Court Order, Isolated Incident of Acute Intoxication, Provided in Excluded Location]
3.01.521: Psychiatric and Other Specified Evaluations in Inpatient and Residential Behavioral Health Treatment Treatments: [Psychiatric evaluation, Medical evaluation (History and Physical), Nursing assessment, Nursing staff observation and monitoring, Nutritional assessment]; Indications: [Inpatient Mental Health Treatment (including Eating Disorder), Inpatient Substance Use Disorder Treatment, Substance Use Disorder Inpatient Rehabilitation, Inpatient Detoxification, Residential Mental Health Treatment (including Eating Disorder), Residential Substance Use Disorder Treatment, Evaluation performed by licensed clinical practitioner (Residential), Evaluation in addition to other assessments/therapies, Formal evaluation vs. documentation review]
3.01.522: Wilderness Therapy/Outdoor Behavioral Healthcare Residential Wilderness Programs Treatments: [Wilderness Therapy / Outdoor Behavioral Healthcare Residential Wilderness Programs]; Indications: [Psychiatric / Mental Health Disorders (Adults 18+), Psychiatric / Mental Health Disorders (Adolescents 13-17), Substance Use Disorders (Adolescents 13+ and Adults), Any Behavioral Health Disorder (Children 12 and younger), Wilderness Component within Residential Treatment Center/Facility]
3.03.01: Prescription Digital Health Diagnostic Aid for Autism Spectrum Disorder Treatments: [Prescription FDA-Cleared Software as a Medical Device (SaMD) for Diagnostic Use, Over-the-Counter or Non-Prescription Digital Health Technology]; Indications: [Autism Spectrum Disorder (ASD) Diagnosis, Any Indication]
3.03.03: Prescription Digital Therapeutics for Attention Deficit/Hyperactivity Disorder Treatments: [Prescription Digital Therapeutics for ADHD]; Indications: [Attention-Deficit/Hyperactivity Disorder (ADHD), Age 8 to 12 years old, Used as part of a therapeutic program]
4.01.502: Surgical Interruption of Pelvic Nerve Pathways for Chronic Pelvic Pain Treatments: [Uterine Nerve Ablation (UNA), Presacral Neurectomy (PSN)]; Indications: [Chronic Pelvic Pain]
4.02.06: Uterus Transplantation for Absolute Uterine Factor Infertility Treatments: [Uterus Transplantation]; Indications: [Absolute Uterine Factor Infertility]
4.02.503: Infertility and Assisted Reproduction Services Treatments: [Diagnostic Services for Infertility, Ovulation Induction, Intrauterine Insemination (IUI), In Vitro Fertilization (IVF) and related procedures, Gamete or Zygote Intra-Fallopian Transfer (GIFT/ZIFT), Intracytoplasmic Sperm Injection (ICSI) or Ovum Microsurgery, Sterilization Reversal Services]; Indications: [Potential Infertility, Established Infertility, Fertility Preservation (due to impending medical/surgical treatment), Context: Sterilization Reversal Services, Diagnostic services not solely for establishing etiology]
5.01.42: Gene Therapies for Thalassemia Treatments: [Casgevy (exagamglogene autotemcel), Zynteglo (betibeglogene autotemcel)]; Indications: [Transfusion-dependent beta-thalassemia, Availability of HLA-identical or HLA-matched donor, Severe iron overload, Advanced liver disease, Baseline estimated glomerular filtration rate less than 70 mL/min/1.73 m², History of receiving prior gene therapy or allogeneic hematopoietic stem cell transplant, Any prior or current malignancy (Casgevy), Contraindication to the use of conditioning agents, Any prior or current malignancy, myeloproliferative, or significant immunodeficiency disorder (Zynteglo), Immediate family member with a known Familial Cancer Syndrome (Zynteglo), Active, uncontrolled HCV or HBV infection (Zynteglo), White blood cell count less than 3 X 10⁹/L not related to hypersplenism (Zynteglo), Platelet count less than 100 X 10⁹/L not related to hypersplenism (Zynteglo), Uncorrected bleeding disorder (Zynteglo), Repeat treatment, Other uses or conditions not listed as medically necessary]
5.01.500: Growth Hormone Therapy Treatments: [Any Growth Hormone Therapy, Genotropin, Omnitrope, Serostim (somatropin), Humatrope, Norditropin, Nutropin / Nutropin AQ, Saizen, Zomacton, Ngenla (somatrogon-ghla), Skytrofa (lonapegsomatropin-tcgd), Sogroya (somapacitan-beco), Any Non-Preferred Growth Hormone Product]; Indications: [Growth hormone deficiency (GHD) in children/adolescents, Short stature born small for gestational age (SGA), Chronic renal failure (CRF) without functioning kidney transplant (Children), Gonadal Dysgenesis / Turner Syndrome (Children), Noonan Syndrome (Children), Infantile hypoglycemia associated with panhypopituitarism (Children), Prader-Willi Syndrome (PWS) (Children), Short stature due to SHOX deficiency (Children), Severe / Adult growth hormone deficiency (Adults), AIDS wasting syndrome / cachexia (Adults), Short bowel syndrome (Adults), Idiopathic short stature (ISS) without growth hormone deficiency, Prader-Willi Syndrome: severe obesity or severe respiratory impairment (Children), Acute critical illness, Cancer, Active or severe diabetic retinopathy, Chronic renal failure following functioning kidney transplantation (Children), Anabolic therapy for catabolic illness (except AIDS), Anabolic therapy for performance or social reasons, Constitutional delay, Geriatric individual therapy, Glucocorticoid-induced growth failure, Non-GH-deficient short stature (general/other), Post-polio syndrome, Short stature associated with Lupron therapy, Short stature due to Down's syndromes, Conditions not specifically addressed in this policy, Requirement for baseline lipid panel or bone density scan (Adults), Prescribed by or in consultation with an endocrinologist (Adult GHD), Non-formulary exception review criteria, Use of Second Line Agents after failure of preferred products, Subject to product's FDA dosage and administration information]
5.01.503: Migraine and Cluster Headache Medications Treatments: [Any Triptan Medication, Generic Triptans, Specific Brand Triptans, Sumatriptan/Naproxen Combination, Elyxyb (celecoxib oral solution), Any Ergot Derivative, Generic Dihydroergotamine, Specific Brand Ergot Derivatives, Any Acute CGRP Receptor Antagonist (Gepant), Nurtec ODT (rimegepant), Ubrelvy (ubrogepant), Zavzpret (zavegepant), Reyvow (lasmiditan)]; Indications: [Acute Treatment of Migraine, Acute Treatment of Cluster Headaches, Medication Overuse Headache, Contraindication to Triptans, Concurrent use of acute gepants (Nurtec, Ubrelvy, Zavzpret)]
5.01.512: Botulinum Toxins Treatments: [Botox (onabotulinumtoxinA), Daxxify (daxibotulinumtoxinA-lanm), Dysport (abobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Letybo (letibotulinumtoxinA-wlbg), Myobloc (rimabotulinumtoxinB), Xeomin (incobotulinumtoxina)]; Indications: [Chronic Migraine Headaches (Prophylaxis), Overactive Bladder (OAB) (Adults), Urinary Incontinence due to Detrusor Overactivity (Adults, Neurogenic), Neurogenic Detrusor Overactivity (NDO) (Pediatrics), Cervical Dystonia (Spasmodic Torticollis), Primary Focal Axillary Hyperhidrosis (Adults), Primary Focal Palmar Hyperhidrosis (Adults), Focal Upper-Limb Dystonia (e.g., Writer's Cramp) (Adults), Idiopathic (Primary or Genetic) Torsion Dystonia (Adults), Laryngeal Dystonia (Adductor Spasmodic Dysphonia) (Adults), Oromandibular Dystonia (Orofacial Dyskinesia, Meige Syndrome) (Adults), Symptomatic (Acquired) Torsion Dystonia (Adults), Blepharospasm (Adults), Blepharospasm (Pediatrics), Chronic Anal Fissure, Esophageal Achalasia, Hemifacial Spasms (Adults), Hirschsprung Disease (Obstructive Symptoms Post-pull-through), Lower Limb Spasticity (Adults), Lower Limb Spasticity (Pediatrics), Upper Limb Spasticity (Adults), Upper Limb Spasticity (Pediatrics), Strabismus (Pediatrics/Adolescents), Chronic Sialorrhea (Adults), Chronic Sialorrhea (Pediatrics), Cosmetic Indications, Moderate to Severe Glabellar Lines, Acute Cervical Dystonia caused by Dopamine Receptor-Blocking Drugs, Xeomin - Upper Limb Spasticity caused by Cerebral Palsy (Pediatrics), Chronic Motor Tic Disorder / Tics Associated with Tourette Syndrome, Essential Tremor, Headaches (Excluding Chronic Migraine Prophylaxis), Tinnitus, Benign Prostatic Hyperplasia, Chronic Prostatic Pain, Detrusor Sphincteric Dyssynergia (after spinal cord injury), Interstitial Cystitis, Chronic Low Back Pain, Joint Pain, Lateral Epicondylitis, Mechanical Neck Disorders, Myofascial Pain Syndrome, Neuropathic Pain after Neck Dissection, Pain after Hemorrhoidectomy or Lumpectomy, Prevention of Pain Associated with Breast Reconstruction after Mastectomy, Temporomandibular Joint Disorders, Trigeminal Neuralgia, Anismus, Internal Anal Sphincter Achalasia, Primary Focal Plantar Hyperhidrosis, Primary Focal Craniofacial Hyperhidrosis, Severe Secondary Gustatory Hyperhidrosis, Acquired Nystagmus, Brachial Plexus Palsy, Bruxism, Cricopharyngeal Dysphagia, Gastroparesis, Nasal Hypersecretion, Pelvic Floor Spasticity, Piriformis Syndrome, Proctalgia Fugax, Thyroid Associated Ophthalmopathy]
5.01.513: Xolair (omalizumab) Treatments: [Xolair (omalizumab)]; Indications: [Moderate to Severe Persistent Asthma, Severe Chronic Idiopathic Urticaria, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), IgE-Mediated Food Allergy, Allergic Rhinitis, Atopic Dermatitis, Other IgE-Mediated Allergic Conditions Not Listed, Latex Allergy, Bullous Pemphigoid, Eosinophilic Gastrointestinal Disorders, Used in combination with certain other biologics for Asthma, Used in combination with certain other biologics for CRSwNP, Used concomitantly with Palforzia for food allergy]
5.01.514: HER2 Inhibitors Treatments: [Generic lapatinib, Tykerb (lapatinib), Nerlynx (neratinib), Tukysa (tucatinib), Kanjinti (trastuzumab-anns) / Trazimera (trastuzumab-qyyp), Herceptin Hylecta (trastuzumab and hyaluronidase-oysk), Herceptin (trastuzumab) and other IV biosimilars (Hercessi, Herzuma, Ogivri, Ontruzant), Perjeta (pertuzumab), Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf), Kadcyla (ado-trastuzumab emtansine), Enhertu (fam-trastuzumab deruxtecan-nxki), Margenza (margetuximab-cmkb)]; Indications: [HER2-positive Breast Cancer (Advanced or Metastatic), HER2-positive, Hormone Receptor-positive Metastatic Breast Cancer (Postmenopausal), HER2-positive Breast Cancer (Stage III or Lower, Extended Adjuvant Setting), HER2-positive Breast Cancer (Advanced Unresectable or Metastatic, including Brain Metastases), HER2-positive Breast Cancer (Adjuvant, Neoadjuvant, or Metastatic Setting), HER2-positive Early Breast Cancer (Adjuvant Setting), HER2-positive Breast Cancer (Neoadjuvant Setting for Locally Advanced, Inflammatory, or Early Stage), HER2-positive Metastatic Breast Cancer (Previously Received Trastuzumab and Taxane), HER2-positive Early Breast Cancer (Adjuvant Setting with Residual Invasive Disease after Neoadjuvant Taxane and Trastuzumab), HER2-positive Breast Cancer (Unresectable or Metastatic), HER2-low Breast Cancer (Unresectable or Metastatic, Hormone Receptor-positive), HER2-low Breast Cancer (Unresectable or Metastatic), HER2-positive Colorectal Cancer (Unresectable or Metastatic), HER2-positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (Metastatic), Non-Small Cell Lung Cancer (Unresectable or Metastatic with Activating HER2 Mutations), HER2-positive (IHC 3+) Solid Tumors (Other Unresectable or Metastatic), All Other Uses Not Explicitly Listed]
5.01.517: Use of Vascular Endothelial Growth Factor Receptor (VEGF) Inhibitors and Other Angiogenesis Inhibitors in Oncology Treatment Treatments: [Mvasi (bevacizumab-awwb), Zirabev (bevacizumab-bvzr), Alymsys (bevacizumab-maly), Avastin (bevacizumab), Avzivi (bevacizumab-tnjn), Vegzelma (bevacizumab-adcd), Cyramza (ramucirumab), Zaltrap (ziv-aflibercept), Fruzaqla (fruquintinib), Revlimid (lenalidomide), generic lenalidomide, Pomalyst (pomalidomide)]; Indications: [Metastatic colorectal cancer, Unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer, Recurrent glioblastoma in adults, Metastatic renal cell carcinoma, Persistent, recurrent, or metastatic cervical cancer, Epithelial ovarian, fallopian tube, or primary peritoneal cancer, Unresectable or metastatic hepatocellular carcinoma, Advanced or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma, Myelodysplastic syndrome (MDS) with 5q (q31-33) cytogenetic abnormality, Multiple myeloma, Mantel cell lymphoma, Kaposi sarcoma, Anaplastic glioma, Endometrial carcinoma, AIDS-related B-cell lymphoma, CLL/SLL, Hodgkin lymphoma, Mesothelioma, Rectal cancer, Advanced adenocarcinoma of the pancreas, Use no earlier than 28 days following major surgery and until surgical wound is fully healed, Inadequate response or intolerance to preferred bevacizumab products (Mvasi/Zirabev), All other uses not explicitly listed as Medically Necessary]
5.01.518: BCR-ABL Kinase Inhibitors Treatments: [Any BCR-ABL Tyrosine Kinase Inhibitor, Bosulif (bosutinib), Danziten (nilotinib), Generic dasatinib, Gleevec (imatinib), Imkeldi (imatinib oral solution), Generic imatinib, Iclusig (ponatinib), Phyrago (dasatinib), Scemblix (asciminib), Sprycel (dasatinib), Tasigna (nilotinib)]; Indications: [Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) - Chronic phase, Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) - Accelerated phase, Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) - Blast phase, Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) - Any phase (Chronic, Accelerated, or Blast), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), Myelodysplastic/Myeloproliferative Disease (MDS/MPD) with PDGFR rearrangement, Aggressive Systemic Mastocytosis (ASM) without D816V c-Kit mutation or status unknown, Hypereosinophilic Syndrome (HES)/Chronic Eosinophilic Leukemia (CEL), Unresectable, Recurrent, or Metastatic Dermatofibrosarcoma Protuberans (DFSP), Aggressive Desmoid Tumors, Recurrent Chordoma, Pigmented Villonodular Synovitis / Tenosynovial Giant Cell Tumor (PVNS/TGCT), Kit (CD117) Positive Gastrointestinal Stromal Tumor (GIST), Kit (CD117) Positive Tumors (GIST, Melanoma, others), Philadelphia chromosome-positive (Ph+) NHL - Lymphoblastic Lymphoma, Resistance or Intolerance to Prior Generic Imatinib Therapy, Resistance or Intolerance to Prior Generic Dasatinib Therapy, Documented Drug Interactions with Generic Dasatinib, Resistance or Intolerance to Prior Additional TKI (Bosutinib, Dasatinib, or Nilotinib), T315I Mutation Positive, Newly Diagnosed, Pediatric Individuals, Adult Individuals, Used in Combination with Chemotherapy, Recurred After Stem Cell Transplant, Used as Single-Agent Therapy, Used in Combination with Cisplatin or Sirolimus, Any Use Not Listed as Medically Necessary]
5.01.519: Increlex (mecasermin); Recombinant Human Insulin-Like Growth Factor-1 Treatments: [Increlex (mecasermin)]; Indications: [Growth failure due to severe primary insulin-like growth factor-1 (IGF-1) deficiency OR growth hormone (GH) gene deletion with neutralizing antibodies to GH, Idiopathic short stature, Less severe forms of IGF-1 deficiency, Secondary forms of IGF-1 deficiency, Growth failure due to other identifiable causes, Diabetes mellitus, Acquired immunodeficiency syndrome (AIDS)-associated wasting, Anorexia nervosa, Obesity in postmenopausal women, Advanced chronic renal failure, Cystic fibrosis, Amyotrophic lateral sclerosis, Use in combination with Growth Hormone (GH), All other indications not listed as medically necessary, Closed epiphyses, Suspected or active neoplasia, Intravenous (IV) administration, Hypersensitivity to any component, Seizure disorder or a history of a seizure disorder]
5.01.520: Antidepressants: Pharmacy Medical Necessity Criteria for Brands Treatments: [Brand Second-Generation Antidepressants (General Group), Auvelity (dextromethorphan and bupropion), Exxua (gepirone)]; Indications: [Anxiety, Depression, Uses not specified as Medically Necessary]
5.01.521: Pharmacologic Treatment of Neuropathy, Fibromyalgia, and Seizure Disorders Treatments: [Lyrica (pregabalin), Lyrica CR (pregabalin extended-release), Qutenza (capsaicin), Savella (milnacipran)]; Indications: [Neuropathic Pain, Seizure Disorder, Fibromyalgia, Generalized Anxiety Disorder, Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, All other uses or conditions not outlined in this policy]
5.01.527: Ampyra (Dalfampridine) Treatments: [Dalfampridine (generic), Ampyra (dalfampridine), Any Dalfampridine (generic or brand)]; Indications: [Multiple Sclerosis, History of Seizures, Low Creatinine Clearance (CrCl <= 50 mL/min)]
5.01.529: Management of Opioid Therapy Treatments: [Short-Acting Opioids (General), Long-Acting Opioids (General), Transmucosal Fentanyl Citrate Products, Methadone]; Indications: [Pain (requiring opioid therapy), Cancer Pain, Sickle Cell Disease, Hospice, End-of-Life, or Palliative Care, Opioid Naive Individuals, Short-Acting Opioid Quantity > 7 Day Supply (Adults), Short-Acting Opioid Quantity > 3 Day Supply (Minors), Pain Severe Enough for Daily/Long-Term Opioid Therapy, Long-Acting Opioid Quantity Exceeding Policy Limits, Opioid Use Disorder (OUD), Breakthrough Cancer Pain]
5.01.530: Egrifta SV (tesamorelin) Treatments: [Egrifta SV (tesamorelin)]; Indications: [Reduction of excess abdominal fat in HIV-infected individuals with lipodystrophy, All other uses]
5.01.532: Cutaneous T-Cell Lymphomas (CTCL): Systemic Therapies Treatments: [Generic Bexarotene Capsules Oral, Zolinza (Vorinostat) Oral, Targretin (Bexarotene) Oral, Generic Bexarotene Topical Gel, Targretin (Bexarotene) Topical Gel, Valchlor (Mechlorethamine) Topical Gel, Beleodaq (Belinostat) IV, Istodax/Romidepsin IV, Lymphir (Denileukin Diftitox-cxdl) IV, Poteligeo (Mogamulizumab-kpkc) IV, Any Medication Listed in Policy]; Indications: [Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF), Sézary Syndrome (SS), Peripheral T-Cell Lymphoma (PTCL), Angioimmunoblastic T-cell Lymphoma (AITL), Anaplastic Large Cell Lymphoma (ALCL), Enteropathy-associated T-cell Lymphoma (EATCL), Simple Skin Involvement Context, Late-Stage Disease Context, Stage IA and IB CTCL Context, Relapsed or Refractory Disease Context, Requirement for Prior Systemic Therapy, Any Other Use Not Explicitly Listed]
5.01.533: mTOR Kinase Inhibitors Treatments: [Generic everolimus tablet (High Dose), Afinitor (everolimus tablet), Generic everolimus tablet for oral suspension, Afinitor Disperz (everolimus tablet for oral suspension), Hyftor (sirolimus topical gel), Fyarro (sirolimus protein-bound particles) IV, Torisel (temsirolimus) IV, Everolimus tablet / Zortress (Low Dose, Transplant), Prograf (tacrolimus), Rapamune (sirolimus)]; Indications: [Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (Postmenopausal), Advanced Renal Cell Carcinoma (RCC) after Failure of Sunitinib or Sorafenib, Progressive, Unresectable Neuroendocrine Tumors (NET) of Pancreatic, GI, or Lung Origin, Renal Angiomyolipoma with Tuberous Sclerosis Complex (TSC) not requiring immediate surgery, Subependymal Giant Cell Astrocytoma (SEGA) with Tuberous Sclerosis Complex (TSC) (Unresectable), TSC-Associated Partial-Onset Seizures, Facial Angiofibroma Associated with Tuberous Sclerosis Complex (TSC), Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa), Advanced Renal Cell Carcinoma (RCC) (Torisel Indication), Prophylaxis of Organ Rejection in Allogeneic Transplant, Lymphangioleiomyomatosis (LAM), Contraindication: Hormone-Producing Carcinoid Tumors (for Everolimus), Rule: Prior Failure or Intolerance to Generic Everolimus, Rule: Oral Everolimus Dose Limit (10 mg), Rule: Hyftor Topical Dose Limit]
5.01.534: Multiple Receptor Tyrosine Kinase Inhibitors Treatments: [Augtyro (repotrectinib), Ayvakit (avapritinib), Cabometyx (cabozantinib), Cometriq (cabozantinib), Caprelsa (vandetanib), Fotivda (tivozanib), Inlyta (axitinib), Lenvima (lenvatinib), Nexavar (sorafenib), Generic pazopanib, Qinlock (ripretinib), Generic sorafenib, Stivarga (regorafenib), Generic sunitinib, Sutent (sunitinib), Tabrecta (capmatinib), Tepmetko (tepotinib), Turalio (pexidartinib), Vanflyta (quizartinib), Votrient (pazopanib), Xospata (gilteritinib)]; Indications: [Locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), Solid tumor with NTRK gene fusion (advanced/metastatic or unresectable), Unresectable or metastatic gastrointestinal stromal tumor (GIST) with PDGFRA exon 18 mutation, Advanced systemic mastocytosis (AdvSM), Indolent systemic mastocytosis (ISM), Advanced renal cell carcinoma (RCC), Advanced RCC as first-line treatment in combination with nivolumab, Advanced RCC as first-line treatment in combination with avelumab, Advanced RCC as first-line treatment in combination with pembrolizumab, Advanced RCC after failure of one prior systemic therapy (single agent), Advanced RCC in combination with everolimus, following prior anti-angiogenic therapy, Relapsed or refractory advanced RCC after 2 or more prior systemic therapies, Adjuvant treatment for RCC at high risk of recurrence following nephrectomy, Unresectable hepatocellular carcinoma (HCC), Hepatocellular carcinoma (HCC) previously treated with sorafenib, Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC), Progressing desmoid tumors requiring systemic treatment, Advanced soft tissue sarcoma (STS) after prior chemotherapy, Pazopanib: Efficacy not demonstrated for adipocytic soft tissue sarcoma or gastrointestinal stromal tumors, Advanced GIST after 3 or more prior kinase inhibitors, including imatinib, Locally advanced, unresectable or metastatic GIST after imatinib and sunitinib failure, GIST after imatinib mesylate progression or intolerance, Metastatic colorectal cancer (CRC) previously treated with standard regimens, Metastatic NSCLC with MET exon 14 skipping mutation, Symptomatic tenosynovial giant cell tumor (TGCT) unamenable to surgery, Newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD-positive (with induction/consolidation chemo), Relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation, Progressive, metastatic medullary thyroid cancer (MTC), Symptomatic or progressive unresectable locally advanced or metastatic medullary thyroid cancers (MTC), Advanced endometrial carcinoma post-systemic therapy (not surgery/radiation candidate, with pembrolizumab), Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) (unresectable/metastatic), All other uses / Indications not explicitly listed as Medically Necessary]
5.01.535: N/A Treatments: []; Indications: []
5.01.536: Nulojix (belatacept) for Adults Treatments: [Nulojix (belatacept)]; Indications: [Prophylaxis of organ rejection (adult kidney transplant), Prophylaxis of organ rejection (organs other than kidney), Contraindication: EBV seronegative or unknown serostatus, Contraindication: Age under 18, Not applicable in acute hospital setting, Site of Service: Preferred medically necessary locations, Site of Service: Hospital-based outpatient (when criteria met), Site of Service: Hospital-based outpatient (when criteria not met), Conversion from CNI-based maintenance regimen]
5.01.539: Pharmacologic Treatment of Cystic Fibrosis with Ivacaftor Products Treatments: [Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), Symdeko (tezacaftor/ivacaftor), Trikafta (elexacaftor/tezacaftor/ivacaftor), Any CFTR Modulator Product (Kalydeco, Orkambi, Symdeko, Trikafta)]; Indications: [Cystic Fibrosis, Cystic Fibrosis with CFTR Gene Mutations Responsive to Kalydeco (as listed), Cystic Fibrosis in individuals homozygous for the F508del mutation, Cystic Fibrosis in individuals homozygous for F508del or heterozygous for F508del with a residual function mutation, Cystic Fibrosis with CFTR Gene Mutations Responsive to Symdeko (as listed), Cystic Fibrosis in individuals with at least one F508del mutation, Cystic Fibrosis with CFTR Gene Mutations Responsive to Trikafta (as listed), Elevated Liver Function Tests (> 3X ULN), Kalydeco used in individuals homozygous for F508del, Kalydeco used in individuals with G970R without another responsive mutation, Any other indication or use not specified]
5.01.541: PHARMACY BENEFIT COVERAGE GUIDELINE – 5.01.541 Medical Necessity Exception Criteria for Dispense as Written (DAW) Exception Reviews Treatments: [Dispense as Written (DAW) Exception Review (for Brand Drug)]; Indications: [Documented adverse reaction, allergy, or sensitivity to generic equivalent, Documented therapeutic failure with generic equivalent, Transitioning to generic may result in destabilization or unnecessary risk, Any Indication or Context (Default)]
5.01.542: Medical Necessity Criteria for Medication Safety: Controlled Substances Utilization Service Program Treatments: [One-Provider Restriction (Controlled Substances)]; Indications: [Evidence of excessive use, misuse, non-medical use, or diversion, Failed attempts at appropriate management, Pattern of multiple prescribers and/or pharmacies, Long-term, unusually high and escalating doses, Frequent early refill requests, Altered or forged prescriptions, Multiple reports of lost/stolen/misplaced medication, Increasing symptoms despite controlled substances, Declining activity/functioning despite controlled substances, Missing medical appointments (except for refill), Unwillingness to try non-controlled treatments, Insistence on a specific controlled substance, Signs of intoxication or withdrawal, Abnormal drug screening results, Unwillingness/inability to take medications as prescribed, Concurrent buprenorphine and opioid prescriptions, Unwillingness/failure to engage in management methods, Attempts to taper controlled substance dosing resisted, Chronic use of carisoprodol (≥4 prescriptions in 6 mo), Continuous overlap of ≥2 benzodiazepines (incl. alprazolam) for ≥30 days, Estimated ≥4 g/d of acetaminophen, ≥2 Prescriptions for meperidine with >2-day supply, Chronic use of butorphanol (≥4 prescriptions in 6 mo), Continuous overlap of ≥2 benzodiazepines (incl. clonazepam) for ≥90 days, Continuous overlap of ≥2 benzodiazepines (incl. diazepam) for ≥90 days, Overlap of ≥2 sustained-release/long-acting opioids for ≥90 days]
5.01.544: Prostate Cancer Targeted Therapies Treatments: [Generic abiraterone oral, Akeega (niraparib and abiraterone acetate) oral, Erleada (apalutamide) oral, Nubeqa (darolutamide) oral, Xtandi (enzalutamide) oral, Yonsa (abiraterone) oral, Zytiga (abiraterone) oral, Jevtana (cabazitaxel) IV, Any medication listed in this policy]; Indications: [Metastatic castration-resistant prostate cancer, BRCA-mutated metastatic castration-resistant prostate cancer, Metastatic high-risk castration-sensitive prostate cancer, Metastatic castration-sensitive prostate cancer, Non-metastatic castration-resistant prostate cancer, Metastatic hormone-sensitive prostate cancer, Non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis, HRR gene-mutated metastatic castration-resistant prostate cancer, All other uses not explicitly listed as medically necessary]
5.01.545: Pharmacologic Treatment of Benign Prostatic Hyperplasia Treatments: [Avodart (dutasteride), Chewtadzy (tadalafil), Cialis (tadalafil), Entadfi (finasteride and tadalafil), Flomax (tamsulosin), Generic tadalafil, Tezruly (terazosin oral solution), Any listed medication]; Indications: [Benign Prostatic Hyperplasia (BPH), Erectile dysfunction (ED) without BPH, Hypertension, All other indications not specifically listed, Entadfi treatment duration > 26 weeks]
5.01.546: Medical Necessity Criteria for Compounded Medications Treatments: [Any Compounded Medication, Compounded Implantable Hormone Replacement Pellets or Granules]; Indications: [Any Covered Indication/Reason, Primary active ingredient is legend medication, Active ingredients in therapeutic amounts, Safety and effectiveness supported by evidence/FDA, Similar to commercial product, requires documentation for differences, Active ingredient requiring PA meets PA criteria, Difficulty or inability to swallow standard oral dosage forms, Documented allergies or sensitivities to inactive ingredients, Does not contain a legend drug otherwise covered by the plan, Cosmetic purposes, Performance enhancing purposes, Experimental or investigational purposes, Non-FDA approved indications or uses not supported by evidence, Uses not compliant with policy for off-label use, Using drugs withdrawn or removed from market for safety, Using unproven route of administration, Compounding for purposes of convenience only, Menopausal Disorder, Infused admixtures are excluded from this policy]
5.01.547: PHARMACY POLICY – 5.01.547 Medical Necessity Criteria and Dispensing Quantity Limits for Exchange Formulary Benefits Treatments: [Entresto, Entresto Sprinkle, Factive, Minitran, Nitro-Dur, Nucynta ER, U-Cort, Buprenorphine patch, Tazarotene, Alrex, Inveltys, Lotemax, Ranolazine extended-release, Emsam, Suprep, Carbinoxamine, Desloratadine, Abiraterone, Advair Diskus, Advair HFA, Akynzeo, Alora, Alvesco, Anastrozole, Androgel, Androderm, Arnuity Ellipta, Asmanex HFA, Asmanex Twisthaler, Atrovent HFA, Avonex, Axiron, Betaseron, Bicalutamide, Capecitabine, Climara, Climara Pro, Combivent Respimat, Copaxone, Divigel, Duetact, Dulera, Elestrin gel, Emend, Estraderm, Estrasorb, Estrogel, Evamist, Exemestane, Extavia, Flovent Diskus, Flovent HFA, Flutamide, Fortesta, Granisetron, Imatinib, Incruse Ellipta, Ipratropium/albuterol, Kesimpta, Letrozole, Mayzent, Megestrol, Melphalan, Menostar, Mercaptopurine, Minivelle, Natesto, Nilutamide, Plegridy, Pulmicort Flexhaler, Pulmicort Respules, Qvar HFA, Rebif, Relenza, Restasis, Sancuso, Sivextro, Spiriva, Spiriva Respimat, Striant, Symbicort, Tamiflu, Tamoxifen, Testim, Testosterone Gel/Pump (Various), Testosterone Packet (Various), Tudorza Pressair, Vivelle, Vivelle-Dot, Vogelxo, Xiidra, Zofran, Zofran ODT, Zubsolv, Zuplenz, Zinbryta, Abacavir, Abacavir-Lamivudine, Aptivus, Atazanavir, Atripla, Biktarvy, Cimduo, Combivir, Complera, Crixivan, Delstrigo, Didanosine dr, Dovato, Edurant, Efavirenz, Emtriva, Epivir, Evotaz, Fosamprenavir, Fuzeon, Genvoya, Intelence, Invirase, Isentress, Isentress HD, Juluca, Kaletra, Lexiva, Nevirapine, Nevirapine ER, Norvir, Odefsey, Pifeltro, Prezcobix, Prezista, Rescriptor, Retrovir, Reyataz, Selzentry, Stavudine, Stribild, Symfi, Symfi Lo, Symtuza, Tenofovir Disoproxil, Tivicay, Tivicay PD, Triumeq, Trizivir, Tybost, Videx, Viracept, Viread, Vitekta]; Indications: [Chronic Heart Failure (NYHA Class II to IV), Adult, Symptomatic Heart Failure with Systemic Left Ventricular Systolic Dysfunction, Pediatric, Plaque Psoriasis, Acne, Requires Step Therapy, Subject to Dispensing Quantity Limit, Subject to Antiretroviral Quantity Limit, Any Approved Indication]
5.01.548: Pharmacotherapy of Cushing's Disease and Acromegaly Treatments: [Bynfezia Pen (octreotide) SC, Isturisa (osilodrostat) oral, Korlym (mifepristone) oral, Somatuline Depot (lanreotide) SC, Generic mifepristone oral, Mycapssa (octreotide) oral, Generic octreotide SC/IV, Recorlev (levoketoconazole) oral, Sandostatin (octreotide) SC/IV, Sandostatin LAR Depot (octreotide) IM, Signifor (pasireotide) SC, Signifor LAR (pasireotide) IM, Somavert (pegvisomant) SC, Any listed medication]; Indications: [Cushing's Disease, Acromegaly, Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Carcinoid Syndrome, Profuse watery diarrhea associated with VIPomas, Hyperglycemia with Type 2 Diabetes Mellitus or Glucose Intolerance Secondary to Cushing's Syndrome, Endogenous Hypercortisolemia in Cushing's Syndrome, All other uses not explicitly listed]
5.01.549: Off-Label Use of Drugs and Biologic Agents Treatments: [Any Drug or Biologic Agent]; Indications: [General Off-label Use Context, Off-label Use Meets Medically Necessary Criteria, Off-label Use Meets Investigational Criteria (General), FDA Determined Contraindicated for Specific Off-label Use]
5.01.550_2025-05-06: Pharmacotherapy of Arthropathies Treatments: [Humira (adalimumab) (AbbVie) SC, Cyltezo (adalimumab-adbm) SC, Simlandi (adalimumab-ryvk) SC, Adalimumab-adaz (Hyrimoz unbranded) SC, Adalimumab-adbm (Cyltezo unbranded) SC, Adalimumab-ryvk (Simlandi unbranded) SC, Abrilada (adalimumab-afzb) SC, Humira (adalimumab) (Cordavis) SC, Adalimumab-aacf (Idacio unbranded) SC, Adalimumab-aaty (Yuflyma unbranded) SC, Adalimumab-fkjp (Hulio unbranded) SC, Amjevita (adalimumab-atto) SC, Hadlima (adalimumab-bwwd) SC, Hulio (adalimumab-fkjp) SC, Hyrimoz (adalimumab-adaz) SC, Idacio (adalimumab-aacf) SC, Yuflyma (adalimumab-aaty) SC, Yusimry (adalimumab-aqvh) SC, Inflectra (infliximab-dyyb) IV, Infliximab (Janssen – unbranded) IV, Remicade (infliximab) IV, Avsola (infliximab-axxq) IV, Renflexis (infliximab-abda) IV, Actemra (tocilizumab) IV/SC, Tofidence (tocilizumab-bavi) IV, Tyenne (tocilizumab-aazg) IV/SC, Orencia (abatacept) IV/SC, Simponi Aria (golimumab) IV, Enbrel (etanercept) SC, Taltz (ixekizumab) SC, Rinvoq (upadacitinib) oral tablet, Rinvoq LQ (upadacitinib) oral solution, Xeljanz (tofacitinib) oral tablet/solution, Xeljanz XR (tofacitinib extended-release) oral, Cimzia (certolizumab pegol) SC, Simponi (golimumab) SC, Kevzara (sarilumab) SC, Stelara (ustekinumab) SC, Skyrizi (risankizumab-rzaa) SC, Tremfya (guselkumab) SC, Otezla (apremilast) oral, Kineret (anakinra) SC, Olumiant (baricitinib) oral, Rituxan (rituximab) IV, Ruxience (rituximab-pvvr) IV, Truxima (rituximab-abbs) IV, Any IV Infusion Therapy Drug Listed, Any Agent Listed in this Policy]; Indications: [Ankylosing Spondylitis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Rheumatoid Arthritis, Polymyalgia Rheumatica, Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, Medically Necessary Site of Service, Hospital-Based Outpatient Site of Service (Default NMN), Hospital-Based Outpatient Site of Service (Criteria Met), Use in combination with each other, Use for conditions not outlined in this policy or related policies, Other uses for approved conditions where criteria are not met, Use for alopecia]
5.01.550_2025-07-01: Pharmacotherapy of Arthropathies Treatments: [Adalimumab (Preferred SC Biosimilars/Unbranded), Adalimumab (Alternative SC Biosimilars/Unbranded), Enbrel (etanercept) SC, Simponi Aria (golimumab) IV, Simponi (golimumab) SC, Remicade (infliximab) IV, Inflectra (infliximab-dyyb) IV, Infliximab (Janssen unbranded) IV, Avsola (infliximab-axxq) IV, Renflexis (infliximab-abda) IV, Cimzia (certolizumab pegol) SC, Actemra (tocilizumab) IV, Actemra (tocilizumab) SC, Tyenne (tocilizumab-aazg) IV, Tyenne (tocilizumab-aazg) SC, Tofidence (tocilizumab-bavi) IV, Kevzara (sarilumab) SC, Kineret (anakinra) SC, Orencia (abatacept) IV, Orencia (abatacept) SC, Xeljanz (tofacitinib) Oral, Rinvoq (upadacitinib) Oral, Olumiant (baricitinib) Oral, Taltz (ixekizumab) SC, Bimzelx (bimekizumab-bkzx) SC, Stelara (ustekinumab) SC, Skyrizi (risankizumab-rzaa) SC, Tremfya (guselkumab) SC, Otezla (apremilast) Oral, Rituxan (rituximab) IV, Ruxience (rituximab-pvvr) IV, Truxima (rituximab-abbs) IV, Any drug listed in this policy]; Indications: [Ankylosing Spondylitis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Rheumatoid Arthritis (Moderate to Severe), Polymyalgia Rheumatica (PMR), Psoriatic Arthritis (Active), Non-Radiographic Axial Spondyloarthritis (Adult, Inflammatory), Medically Necessary Site: Physician's Office, Infusion Center, or Home, Medically Necessary Site: Hospital Outpatient (Initial Course or Re-initiation), Medically Necessary Site: Hospital Outpatient (No Alternative Site Available), Medically Necessary Site: Hospital Outpatient (Increased Clinical Risk), Medically Necessary Site: Hospital Outpatient (Cytokine Release Syndrome), Not Medically Necessary Site: Hospital Outpatient (Criteria Not Met), Alopecia (Cosmetic Use), Any other condition not outlined in this policy or referenced policies, Used in combination with other agents listed in policy, Approved conditions listed in this policy (other uses)]
5.01.550: Pharmacotherapy of Arthropathies Treatments: [Actemra (tocilizumab) IV/SC, Avsola (infliximab-axxq) IV, Cosentyx (secukinumab) IV/SC, Inflectra (infliximab-dyyb) IV, Infliximab (Janssen – unbranded) IV, Orencia (abatacept) IV/SC, Remicade (infliximab) IV, Renflexis (infliximab-abda) IV, Rituxan (rituximab) IV, Simponi Aria (golimumab) IV, Tofidence (tocilizumab-bavi) IV, Enbrel (etanercept) SC, Cyltezo (adalimumab-adbm) SC, Humira (adalimumab) (AbbVie NDCs) SC, Simlandi (adalimumab-ryvk) SC, Adalimumab-adaz (Hyrimoz unbranded) SC, Adalimumab-adbm (Cyltezo unbranded) SC, Adalimumab-ryvk (Simlandi unbranded) SC, Taltz (ixekizumab) SC, Rinvoq (upadacitinib) oral, Xeljanz (tofacitinib) oral, Xeljanz XR (tofacitinib extended-release) oral, Abrilada (adalimumab-afzb) SC, Humira (adalimumab) (Cordavis NDCs) SC, Adalimumab-aacf (Idacio unbranded) SC, Adalimumab-aaty (Yuflyma unbranded) SC, Adalimumab-fkjp (Hulio unbranded) SC, Amjevita (adalimumab-atto) SC, Hadlima (adalimumab-bwwd) SC, Hulio (adalimumab-fkjp) SC, Hyrimoz (adalimumab-adaz) SC, Idacio (adalimumab-aacf) SC, Yuflyma (adalimumab-aaty) SC, Yusimry (adalimumab-aqvh) SC, Cimzia (certolizumab pegol) SC, Simponi (golimumab) SC, Bimzelx (bimekizumab-bkzx) SC, Rinvoq LQ (upadacitinib) oral solution, Xeljanz Oral Solution (tofacitinib) oral solution, Tyenne (tocilizumab-aazg) IV/SC, Kevzara (sarilumab) SC, Kineret (anakinra) SC, Olumiant (baricitinib) oral, Stelara (ustekinumab) SC, Skyrizi (risankizumab-rzaa) SC, Tremfya (guselkumab) SC, Otezla (apremilast) oral, Ruxience (rituximab-pvvr) IV, Truxima (rituximab-abbs) IV, Any listed agent or combination]; Indications: [Ankylosing Spondylitis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Moderate to Severe Rheumatoid Arthritis, Polymyalgia Rheumatica, Active Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, Alopecia, Site of Service Criteria, Investigational Use (General), Not Medically Necessary Use (General)]
5.01.551_2025-07-01: Use of Granulocyte Colony-Stimulating Factors (G-CSF) Treatments: [Any Granulocyte Colony-Stimulating Factor (G-CSF) Product, Granix (tbo-filgrastim), Nivestym (filgrastim-aafi), Neupogen (filgrastim), Releuko (filgrastim-ayow), Zarxio (filgrastim-sndz), Nypozi (filgrastim-txid), Fulphila (pegfilgrastim-jmdb), Udenyca (pegfilgrastim-cbqv) / Udenyca Onbody, Fylnetra (pegfilgrastim-pbbk), Neulasta (pegfilgrastim) / Neulasta Onpro, Nyvepria (pegfilgrastim-apgf), Stimufend (pegfilgrastim-fpgk), Ziextenzo (pegfilgrastim-bmez), Rolvedon (eflapegrastim-xnst), Ryzneuta (efbemalenograstim alfa-vuxw)]; Indications: [Febrile Neutropenia (FN) with Myelosuppressive Anti-Cancer Regimens, Autologous Peripheral Blood Progenitor Cell Collection and Therapy, Severe Chronic Neutropenia (Congenital, Cyclic, Idiopathic), Acute Radiation Syndrome (Hematopoietic Subsyndrome), Afebrile Neutropenia, History of Serious Allergic Reaction to G-CSFs, Combination with Chemotherapy where only Pegfilgrastim was used in trials, Any Indication Not Explicitly Addressed]
5.01.551: Use of Granulocyte Colony-Stimulating Factors (G-CSF) Treatments: [Any Granulocyte Colony-Stimulating Factor (G-CSF), Granix (tbo-filgrastim), Nivestym (filgrastim-aafi), Neupogen (filgrastim), Nypozi (filgrastim-txid), Releuko (filgrastim-ayow), Zarxio (filgrastim-sndz), Neulasta (pegfilgrastim) / Neulasta Onpro, Fulphila (pegfilgrastim-jmdb), Nyvepria (pegfilgrastim-apgf), Fylnetra (pegfilgrastim-pbbk), Stimufend (pegfilgrastim-fpgk), Udenyca (pegfilgrastim-cbqv) / Udenyca Onbody, Ziextenzo (pegfilgrastim-bmez), Rolvedon (eflapegrastim-xnst), Ryzneuta (efbemalenograstim alfa-vuxw)]; Indications: [Any Indication, Febrile Neutropenia (FN) with Anti-Cancer Regimens, Autologous Peripheral Blood Progenitor Cell Collection and Therapy, Severe Chronic Neutropenia, Acute Radiation Syndrome, Afebrile Neutropenia, History of Serious Allergic Reaction to G-CSFs, Chemotherapy Regimen Specific Use (Pegfilgrastim only in trials), Any Other Use Not Addressed in Policy]
5.01.552: PHARMACY POLICY – 5.01.552 Hetlioz (tasimelteon) Treatments: [Hetlioz (tasimelteon) capsules, Generic tasimelteon capsules, Hetlioz LQ (tasimelteon) oral suspension]; Indications: [Non-24-hour sleep-wake disorder, Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), All other indications (not N24SWD or SMS sleep disturbances)]
5.01.553: Myalept (metreleptin) Treatments: [Myalept (metreleptin)]; Indications: [Leptin Deficiency in Congenital or Acquired Lipodystrophy, Used as an adjunct to diet, Presence of specific metabolic abnormalities, Prescribed by or in consultation with endocrinologist, Dose prescribed <= 10 mg once daily, All other indications]
5.01.555: Pharmacologic Treatment of Interstitial Lung Disease Treatments: [Ofev (nintedanib) oral, Generic pirfenidone, Brand pirfenidone, Esbriet (pirfenidone) oral, Actemra (tocilizumab) SC, Tyenne (tocilizumab-aazg) SC, Tyvaso (treprostinil) oral inhalation solution, Tyvaso DPI (treprostinil) oral inhalation powder]; Indications: [Idiopathic Pulmonary Fibrosis (IPF), Systemic sclerosis-associated interstitial lung disease (SSc-ILD), Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a progressive phenotype, Pulmonary hypertension associated interstitial lung disease (PH-ILD), Combination Therapy: Ofev plus Pirfenidone (any form), Combination Therapy: Actemra/Tyenne plus Ofev for SSc-ILD, Interstitial Lung Diseases other than described]
5.01.556_2025-07-01: Rituximab: Non-oncologic and Miscellaneous Uses Treatments: [Ruxience / Truxima (First Line), Riabni / Rituxan IV (Second Line), Rituxan Hycela (Second Line, Subcutaneous), Any Rituximab Product (Non-Oncologic Uses)]; Indications: [Autoimmune Hemolytic Anemias (AIHA), Chronic Graft-Versus-Host Disease (GVHD), Cryoglobulinemic Vasculitis Associated with Hepatitis-C Virus (HCV), Desensitization of Human Leukocyte Antigen (HLA), Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome), Hemophilia with Factor Inhibitor, Idiopathic Membranous Nephropathy, Idiopathic (Immune) Thrombocytopenic Purpura (ITP), Lupus Nephritis, Microscopic Polyangiitis (MPA), Multicentric Castleman Disease, Neuromyelitis Optica Spectrum Disorders (NMOSD), Pemphigoid Diseases, Pemphigus Diseases, Primary Sjögren Syndrome, Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (Scleroderma), Thrombotic Thrombocytopenic Purpura (TTP), Wegener's Granulomatosis (Granulomatosis with Polyangiitis - GPA), Exclusion: Lymphoid Cancer Diagnosis, Medically Necessary Sites of Service, Hospital Outpatient Site: Initial Course or Re-initiation, Hospital Outpatient Site: Geographic Exception, Hospital Outpatient Site: Increased Clinical Risk, Hospital Outpatient Site: Cytokine Release Syndrome (CRS), Sites Considered Not Medically Necessary for Infusion, Investigational: Induction Immunosuppressive Therapy for Kidney Transplantation, Investigational: Induction Immunosuppressive Therapy for Heart Transplantation, Investigational: Mixed Connective Tissue Disease (MCTD), Investigational: Multiple Sclerosis (MS), Investigational: Paroxysmal Cold Hemoglobinuria, Investigational: Prophylaxis for Graft-Versus-Host Disease, Investigational: Antibody-Mediated Rejection (ABMR) after Pancreatic Islet Transplantation, Investigational: Antibody-Mediated Rejection (ABMR) in Solid Organ Transplant Recipients, Investigational: Minimal Change Disease, Investigational: Myasthenia Gravis, Investigational: All Other Non-oncologic Uses]
5.01.556: Rituximab: Non-oncologic and Miscellaneous Uses Treatments: [Any Rituximab Product (Non-Oncologic), Rituxan (rituximab), Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs), Rituxan Hycela (rituximab and hyaluronidase human)]; Indications: [Rheumatoid Arthritis (RA), ANCA-Associated Vasculitides (Wegener's, Microscopic), Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome), Cryoglobulinemic Vasculitis Associated with Hepatitis-C Virus (HCV), Idiopathic Membranous Nephropathy, Lupus Nephritis, Neuromyelitis Optica Spectrum Disorders (NMOSD), Primary Sjögren Syndrome, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (Scleroderma), Pemphigoid Diseases (Bullous, Mucous Membrane, Epidermolysis Bullosa Acquisita), Pemphigus Diseases (Vulgaris, Foliaceus, Paraneoplastic), Autoimmune Hemolytic Anemias (AIHA), Chronic Graft-Versus-Host Disease (GVHD), HLA Desensitization for Renal Transplant Candidates, Hemophilia (Factor Inhibitor), Idiopathic Thrombocytopenic Purpura (ITP), Thrombotic Thrombocytopenic Purpura (TTP), Multicentric Castleman Disease, Induction Immunosuppressive Therapy for Kidney Transplantation, Induction Immunosuppressive Therapy for Heart Transplantation, Mixed Connective Tissue Disease, Multiple Sclerosis, Paroxysmal Cold Hemoglobinuria, Prophylaxis for Graft-Versus-Host Disease, Treatment of Antibody-Mediated Rejection After Pancreatic Islet Transplantation, Treatment of Antibody-Mediated Rejection in Solid Organ Transplant Recipients, Treatment of Minimal Change Disease, Treatment of Myasthenia Gravis, Exclusion: Lymphoid Cancer Diagnosis, Medically Necessary Sites of Service (Office, Infusion Center, Home), Medically Necessary Hospital Outpatient Site of Service (Criteria Based), Not Medically Necessary Hospital Outpatient Site of Service (Criteria Not Met), Site of Service Review Age >= 13, Second-line Use Requirement, All Other Non-Oncologic Uses]
5.01.558: Pharmacologic Treatment of High Cholesterol Treatments: [Repatha (evolocumab), Praluent (alirocumab), Leqvio (inclisiran), Vascepa (icosapent ethyl), Generic icosapent ethyl, Lovaza (omega-3-acid ethyl esters), Nexletol (bempedoic acid), Nexlizet (bempedoic acid and ezetimibe), Evkeeza (evinacumab-dgnb), Tryngolza (olezarsen), Juxtapid (lomitapide), Altoprev (lovastatin), Crestor (rosuvastatin), Ezallor Sprinkle (rosuvastatin), Lescol XL (fluvastatin), Lipitor (atorvastatin), Livalo (pitavastatin), Pravachol (pravastatin), Zocor (simvastatin), Zypitamag (pitavastatin), Flolipid (simvastatin oral suspension), Simvastatin oral suspension (Brand), Roszet (rosuvastatin/ezetimibe), Brand rosuvastatin/ezetimibe, Vytorin (simvastatin-ezetimibe), Antara (fenofibrate), Brand fenofibrate, Fenoglide (fenofibrate), Fibricor (fenofibric acid), Lipofen (fenofibrate), Lopid (gemfibrozil), Tricor (fenofibrate), Triglide (fenofibrate), Trilipix (fenofibric acid), Niacor (niacin), Niaspan (niacin extended-release), Zetia (ezetimibe)]; Indications: [Atherosclerotic Cardiovascular Disease (ASCVD), Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Primary Hyperlipidemia, ASCVD Risk Reduction (for Vascepa), Severe Hypertriglyceridemia (TG >= 500 mg/dL), Hyperlipidemia (General), Familial Chylomicronemia Syndrome (FCS), Investigational Uses (Any Indication Not Listed as Medically Necessary), Not Medically Necessary Uses (Any Use Not Listed as Medically Necessary)]
5.01.559: IL-5 Inhibitors Treatments: [Cinqair (reslizumab) IV, Fasenra (benralizumab) SC, Nucala (mepolizumab) SC]; Indications: [Severe asthma with an eosinophilic phenotype, Eosinophilic granulomatosis with polyangiitis (EGPA), Hypereosinophilic syndrome (HES), Chronic rhinosinusitis with nasal polyps (CRSwNP), Administered at a Medically Necessary Site of Service, Administered at a Not Medically Necessary Site of Service, Used in combination with other specified biologics for Asthma, Used in combination with Dupixent or Xolair for CRSwNP, All other uses or conditions not explicitly outlined]
5.01.560: Excessively High Cost Drug Products with Lower Cost Alternatives Treatments: [Absorica and Absorica LD (isotretinoin), Alcortin-A, Allzital (butalbital/acetaminophen), Amrix (cyclobenzaprine extended-release), Auvi-Q (epinephrine injection), Brand name EpiPen (epinephrine injection), Lorzone (chlorzoxazone) and generic chlorzoxazone 250mg, 375mg, 750mg, Pennsaid (diclofenac sodium topical solution), Evzio (naloxone auto-injector), Bethkis, Kitabis Pak, and TOBI (tobramycin inhalation solution), TOBI Podhaler (tobramycin inhalation powder), Fluoxetine 60mg, Fortamet, Glumetza, and their generic extended-release, Brand metformin 625 mg, Mytesi (crofelemer), Natpara (parathyroid hormone), Northera (droxidopa), Excessively high cost Kits, Jublia (efinaconazole) and Kerydin (tavaborole) topical solutions, Generic tavaborole topical solution, Miscellaneous branded topical lidocaine products, Lidoderm, Synera, ZTlido topical patches, Paingo KFT, Rayos (prednisone delayed-release), Riomet (metformin oral solution), Riomet ER (metformin extended-release oral suspension), Sitavig (acyclovir buccal tablets), Zileuton products (Zyflo, Zyflo CR, Zileuton ER), Any drug listed in this policy]; Indications: [Severe, recalcitrant, nodular acne after generic isotretinoin trial failure, Condition treated by Alcortin-A after generic topical corticosteroid trial failure, Condition treated by Allzital after generic butalbital/acetaminophen trial failure, Condition treated by Amrix after generic cyclobenzaprine and other muscle relaxant trial failure, Risk of anaphylaxis, Risk of anaphylaxis requiring Auvi-Q (0.15/0.3mg) due to inability to use generic auto-injectors, Risk of anaphylaxis requiring Auvi-Q (0.1mg) due to inability of caregiver to use generic auto-injectors, Risk of anaphylaxis where individual is not a candidate for preferred epinephrine auto-injectors, Chlorzoxazone use requiring Brand Lorzone 750mg or generic chlorzoxazone 250/750mg after 500mg trial failure/intolerance, Chlorzoxazone use requiring Brand Lorzone 375mg after 500mg trial failure/intolerance, Osteoarthritis of the knee after generic topical diclofenac trial failure, Opioid overdose emergency, Cystic fibrosis management after generic tobramycin inhalation solution failure or intolerance, Cystic fibrosis management after tobramycin inhalation solution failure including brand solutions, Major Depressive Disorder, OCD, Bulimia Nervosa, or Panic Disorder with non-adherence to generic fluoxetine 20mg, Type 2 Diabetes Mellitus, Type 2 Diabetes Mellitus after generic metformin IR and ER trial failure, Type 2 Diabetes Mellitus after trial failure of specific generic metformin IR forms, Type 2 Diabetes Mellitus where unable to swallow or absorb metformin tablets, Symptomatic relief of non-infectious diarrhea with HIV/AIDS on ART after other agent trial failure, Hypocalcemia with hypoparathyroidism meeting specific criteria, Symptomatic neurogenic orthostatic hypotension meeting specific criteria, Any condition where Kit is required due to inability to use ingredients separately after trial, Kit use solely for convenience, Onychomycosis confirmed by KOH/culture after specific topical and oral antifungal trial failure (Jublia/Kerydin criteria), Onychomycosis confirmed by KOH/culture after ciclopirox and terbinafine or itraconazole trial failure (Generic Tavaborole criteria), Pain requiring miscellaneous branded topical lidocaine products after generic cream and ointment trial failure, Pain requiring specific lidocaine patches (Lidoderm, Synera, ZTlido) after generic patch, cream, and ointment trial failure, Pain requiring Paingo KFT after generic lidocaine/prilocaine cream, lidocaine cream, and ointment trial failure, Condition treated by steroids after generic prednisone and methylprednisolone trial failure, Recurrent herpes labialis in immunocompetent adults after topical and oral antiviral trial failure, Condition treated by Zileuton products after generic montelukast trial failure, All other uses of the listed drugs]
5.01.561: Repository Corticotropin Injection Treatments: [Repository Corticotropin Injection]; Indications: [Infantile Spasms (West Syndrome), Corticosteroid-Responsive Conditions (Treatment Use), Use for Diagnostic Testing of Adrenocortical Function, Conditions Not Generally Responsive to Corticosteroid Therapy (Treatment Use), All Other Indications Not Explicitly Listed, General Contraindications]
5.01.562: Imlygic (talimogene laherparepvec) Treatments: [Imlygic (talimogene laherparepvec)]; Indications: [Melanoma: Unresectable cutaneous, subcutaneous, and nodal lesions recurrent after initial surgery, All other indications/uses for Imlygic, Transcutaneous intrahepatic route of administration]
5.01.563_2025-07-01: Pharmacotherapy of Inflammatory Bowel Disorder Treatments: [Avsola (infliximab-axxq) IV, Entyvio (vedolizumab) IV, Inflectra (infliximab-dyyb) IV, Infliximab (Janssen – unbranded) IV, Remicade (infliximab) IV, Renflexis (infliximab-abda) IV, Tyruko (natalizumab-sztn) IV, Tysabri (natalizumab) IV, Zymfentra (infliximab-dyyb) SC, Adalimumab-adaz (Hyrimoz unbranded) SC, Adalimumab-adbm (Cyltezo unbranded) SC, Adalimumab-ryvk (Simlandi unbranded) SC, Cyltezo (adalimumab-adbm) SC, Simlandi (adalimumab-ryvk) SC, Stelara (ustekinumab) IV, Stelara (ustekinumab) SC, Skyrizi (risankizumab-rzaa) IV, Skyrizi (risankizumab-rzaa) SC on-body injector, Rinvoq (upadacitinib) oral, Abrilada (adalimumab-afzb) SC, Adalimumab-aacf (Idacio unbranded) SC, Adalimumab-aaty (Yuflyma unbranded) SC, Adalimumab-fkjp (Hulio unbranded) SC, Amjevita (adalimumab-atto) SC, Hadlima (adalimumab-bwwd) SC, Hulio (adalimumab-fkjp) SC, Humira (adalimumab) SC, Hyrimoz (adalimumab-adaz) SC, Idacio (adalimumab-aacf) SC, Yuflyma (adalimumab-aaty) SC, Yusimry (adalimumab-aqvh) SC, Cimzia (certolizumab pegol) SC, Entyvio (vedolizumab) SC, Omvoh (mirikizumab-mrkz) IV, Omvoh (mirikizumab-mrkz) SC, Tremfya (guselkumab) IV, Tremfya (guselkumab) SC, Xeljanz (tofacitinib) oral, Xeljanz XR (tofacitinib) oral, extended-release, Velsipity (etrasimod) oral, Zeposia (ozanimod) oral, Simponi (golimumab) SC, All listed IBD biologics and drugs]; Indications: [Crohn's Disease, Ulcerative Colitis, Subject to Site of Service Review, Preferred Site of Service Medically Necessary, Hospital Outpatient Site of Service Medically Necessary, Hospital Outpatient Site of Service Not Medically Necessary (Criteria Not Met), All other uses considered Investigational]
5.01.563: Pharmacotherapy of Inflammatory Bowel Disorder Treatments: [Remicade (infliximab) IV, Inflectra (infliximab-dyyb) IV, Infliximab (Janssen – unbranded) IV, Avsola (infliximab-axxq) IV, Renflexis (infliximab-abda) IV, Zymfentra (infliximab-dyyb) SC, Humira (adalimumab) (AbbVie) SC, Cyltezo (adalimumab-adbm) SC, Simlandi (adalimumab-ryvk) SC, Adalimumab-adaz (Hyrimoz unbranded) SC, Adalimumab-adbm (Cyltezo unbranded) SC, Adalimumab-ryvk (Simlandi unbranded) SC, Abrilada (adalimumab-afzb) SC, Adalimumab-aacf (Idacio unbranded) SC, Adalimumab-aaty (Yuflyma unbranded) SC, Adalimumab-fkjp (Hulio unbranded) SC, Amjevita (adalimumab-atto) SC, Hadlima (adalimumab-bwwd) SC, Hulio (adalimumab-fkjp) SC, Humira (adalimumab) (Cordavis) SC, Hyrimoz (adalimumab-adaz) SC, Idacio (adalimumab-aacf) SC, Yuflyma (adalimumab-aaty) SC, Yusimry (adalimumab-aqvh) SC, Cimzia (certolizumab pegol) SC, Simponi (golimumab) SC, Entyvio (vedolizumab) IV, Entyvio (vedolizumab) SC, Tysabri (natalizumab) IV, Tyruko (natalizumab-sztn) IV, Stelara (ustekinumab) IV, Stelara (ustekinumab) SC, Skyrizi (risankizumab-rzaa) IV, Skyrizi (risankizumab-rzaa) SC, Omvoh (mirikizumab-mrkz) IV, Omvoh (mirikizumab-mrkz) SC, Tremfya (guselkumab) IV, Tremfya (guselkumab) SC, Rinvoq (upadacitinib) oral, Xeljanz (tofacitinib) oral, Xeljanz XR (tofacitinib) oral extended-release, Velsipity (etrasimod) oral, Zeposia (ozanimod) oral]; Indications: [Crohn's Disease, Ulcerative Colitis, Medically Necessary Sites of Service (Preferred), Hospital Site of Service (First 90 days or Re-initiation), Hospital Site of Service (Access Limitations), Hospital Site of Service (Increased Risk of Complications), Hospital Site of Service (Cytokine Release Syndrome), Hospital Site of Service (Criteria Not Met), Investigational (Other Uses), Not Medically Necessary (Other Uses for Approved Conditions)]
5.01.564_2025-05-06: PHARMACY / MEDICAL POLICY – 5.01.564 Pharmacotherapy of Miscellaneous Autoimmune Diseases Treatments: [Adalimumab (Cyltezo, Simlandi, Hyrimoz Unbranded, etc.), Humira (adalimumab) (AbbVie), Adalimumab (Abrilada, Amjevita, Hadlima, Hulio, Humira Cordavis, Idacio, Yuflyma, Yusimry, etc.), Cosentyx (secukinumab), Bimzelx (bimekizumab-bkzx), Enbrel (etanercept), Infliximab (Remicade, Janssen Unbranded), Inflectra (infliximab-dyyb), Avsola (infliximab-axxq), Renflexis (infliximab-abda), Actemra (tocilizumab) IV, Actemra (tocilizumab) SC, Tofidence (tocilizumab-bavi), Tyenne (tocilizumab-aazg) IV, Tyenne (tocilizumab-aazg) SC, Benlysta (belimumab) IV/SC, Lupkynis (voclosporin), Saphnelo (anifrolumab-fnia), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), Kineret (anakinra), Otezla (apremilast), Uplizna (inebilizumab-cdon), Enspryng (satralizumab-mwge), Arcalyst (rilonacept), Ilaris (canakinumab), Niktimvo (axatilimab-csfr), Orencia (abatacept), Rezurock (belumosudil), Ryoncil (remestemcel-L-rknd), Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab), Fabhalta (iptacopan), Filspari (sparsentan), Tarpeyo (budesonide), Rituxan (rituximab), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs), Specified IV/Injectable Drugs Subject to Site of Service Review, Any Agent Listed in this Policy]; Indications: [Medically Necessary Site of Service (Preferred: Physician's office, Infusion center, Home infusion), Medically Necessary Site of Service (Hospital-based outpatient criteria met), Not Medically Necessary Site of Service (Hospital-based outpatient criteria not met), Hidradenitis Suppurativa (HS), Systemic Lupus Erythematosus (SLE) (Active, autoantibody positive), Lupus Nephritis (LN) (Active, Class III, IV, V), Pyoderma Gangrenosum (PG), Uveitis (Non-infectious intermediate, posterior, or panuveitis), Giant Cell Arteritis (GCA), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Cytokine Release Syndrome (CRS) (Treatment-induced Grade 3 or 4), Behcet's Disease (Oral ulcers), Neuromyelitis Optica Spectrum Disorder (NMOSD) (Anti-AQP4 antibody positive), Deficiency of Interleukin-1 Receptor Antagonist (DIRA), Recurrent Pericarditis (RP), Cryopyrin-Associated Periodic Syndromes (CAPS), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS) / Mevalonate Kinase Deficiency (MKD), Familial Mediterranean Fever (FMF), Still's Disease (AOSD/SJIA), Chronic Graft Versus Host Disease (cGVHD), Acute Graft Versus Host Disease (aGvHD) (Pediatric, steroid-refractory), Acute Graft Versus Host Disease (aGvHD) Prevention, Myasthenia Gravis (AChR or MuSK antibody positive), Myasthenia Gravis (AChR antibody positive), Primary Immunoglobulin A Nephropathy (IgAN), Sarcoidosis, Investigational Use or Condition]
5.01.565: Pharmacotherapy of Multiple Sclerosis Treatments: [Interferon-β 1a, Interferon-β 1b (Betaseron), Glatiramer (Generic or Glatopa), Copaxone (Glatiramer), Teriflunomide (Generic), Aubagio (Teriflunomide), Bafiertam (Monomethyl fumarate), Dimethyl fumarate (Generic), Tecfidera (Dimethyl fumarate), Vumerity (Diroximel fumarate), Fingolimod (Generic), Gilenya / Tascenso ODT (Fingolimod), Kesimpta (Ofatumumab), Mavenclad (Cladribine), Mayzent (Siponimod), Ponvory (Ponesimod), Zeposia (Ozanimod), Any medication listed in this policy]; Indications: [Relapsing Multiple Sclerosis (including CIS, RRMS, Active SPMS), Contraindication: CYP2C9*3/*3 Genotype, Mavenclad use following administration of two treatment courses, All other uses of medications listed in this policy]
5.01.566: Pharmacotherapy of Thrombocytopenia Treatments: [Alvaiz (eltrombopag choline) oral, Promacta (eltrombopag olamine) oral, Nplate (romiplostim) SC, Doptelet (avatrombopag) oral, Tavalisse (fostamatinib disodium hexahydrate) oral, Mulpleta (lusutrombopag) oral, Adzynma (ADAMTS13, recombinant-krhn), Rituximab (Rituxan, Ruxience, Truxima)]; Indications: [Hepatitis C-associated Thrombocytopenia, Chronic Immune Thrombocytopenia (ITP), Chronic Liver Disease (scheduled for invasive procedure), Severe Aplastic Anemia, Individuals with Hematopoietic Syndrome of Acute Radiation Syndrome, Chemotherapy-Induced Thrombocytopenia, Congenital Thrombotic Thrombocytopenic Purpura, Other Indications Not Explicitly Listed, Nplate - All Other Uses]
5.01.568: Venclexta (venetoclax) BCL-2 Inhibitor Treatments: [Venclexta (venetoclax)]; Indications: [Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Acute Myeloid Leukemia (AML), Any Other Indication or Use Not Explicitly Addressed]
5.01.569: Pharmacotherapy of Type 1 and Type 2 Diabetes Mellitus Treatments: [Metformin, GLP-1 Receptor Agonists, GIP-GLP-1 Receptor Agonists, Insulin-GLP-1 Combinations, DPP-4 Inhibitors, DPP-4 and Biguanide Combinations, DPP-4 and SGLT-2 Combinations, Tzield (teplizumab-mzwv), Amylin Mimetics, Any Drug Listed in this Policy]; Indications: [Type 1 Diabetes Mellitus, Stage 2 Type 1 Diabetes Mellitus, Stage 3 Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Weight Management, Re-authorization of Tzield beyond 14 days, Uses for conditions not listed in this policy or Policy 5.01.605, Uses for FDA-approved conditions listed in this policy or 5.01.605, but not explicitly listed as MN]
5.01.570: Pharmacologic Treatment of Duchenne Muscular Dystrophy Treatments: [Amondys 45 (casimersen), Exondys 51 (eteplirsen), Viltepso (vitolarsen), Vyondys 53 (golodirsen), Elevidys (delandistrogene moxeparvovec-rokl), Agamree (vamorolone), Emflaza (deflazacort), Generic deflazacort, Prednisone, Duvyzat (givinostat)]; Indications: [Duchenne Muscular Dystrophy (DMD), DMD w/ Exon 45 skipping mutation, DMD w/ Exon 51 skipping mutation, DMD w/ Exon 53 skipping mutation, Administered in Physician's Office, Administered in Infusion Center, Administered via Home Infusion, Administered in Hospital Outpatient Setting (Criteria Met), Administered in Hospital Outpatient Setting (Criteria Not Met), Mutation in DMD gene exon 1-17, Requires Ventilator Support, Active Heart Failure (EF < 40%), High Anti-AAVrh74 Antibody Titer, Uses for Conditions Not Outlined in Policy, Use of Exon Skipping Treatment After Elevidys Infusion, Elevidys Use in Non-Ambulatory Individuals, Repeat Treatment with Elevidys, Subject to Site of Service Review (Age 13+)]
5.01.571: PHARMACY / MEDICAL POLICY – C3 and C5 Complement Inhibitors Treatments: [Empaveli (pegcetacoplan), Fabhalta (iptacopan), Soliris (eculizumab) IV, Ultomiris (ravulizumab-cwvz) IV, Tavneos (avacopan), Syfovre (pegcetacoplan) intravitreal, Izervay (avacincaptad pegol) intravitreal, Piasky (crovalimab-akkz), Veopoz (pozelimab-bbfg), Zilbrysq (zilucoplan) SC]; Indications: [Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD), ANCA-Associated Vasculitis, Geographic Atrophy secondary to Dry Age-Related Macular Degeneration (AMD), CD55-deficient protein-losing enteropathy (CHAPLE disease), Physician's Office Site of Service, Infusion Center Site of Service, Home Infusion Site of Service, Hospital-Based Outpatient Site of Service, Hospital Site of Service Not Medically Necessary When Criteria Not Met, All Other Uses are Investigational, Short-Term Concomitant Therapy (Max 4 weeks) when Switching FROM Soliris or Ultomiris FOR PNH, Long-Term Concomitant Therapy (Beyond 4 weeks) when Switching PNH Drugs, Contraindication: Shiga toxin E. coli-related Hemolytic Uremic Syndrome (STEC-HUS), Contraindication: Ocular or Periocular Infections (Izervay), Contraindication: Active Intraocular Inflammation (Izervay), Contraindication: Choroidal Neovascularization (CNV) in the same eye (GA Treatments), Contraindication: Diabetic Retinopathy in the same eye (Izervay), Contraindication: Concurrent use of Syfovre and Izervay (GA Treatments), Contraindication: Unresolved Neisseria meningitidis infection (Veopoz)]
5.01.572: Coverage Criteria for Excluded and Non-Formulary Drugs Treatments: [Excluded or Non-Formulary Drug or Biologic Agent]; Indications: [Use of Excluded/Non-Formulary Drug with Formulary Alternatives, Criteria Met, Use of Excluded/Non-Formulary Drug with No Formulary Alternatives, Criteria Met, Use of Excluded/Non-Formulary Brand Name Drug with Generic Equivalent, Criteria Met, Investigational or Experimental Use]
5.01.573: Pharmacotherapy of Perinatal/Infantile and Juvenile-Onset Hypophosphatasia (HPP) Treatments: [Strensiq (asfotase alfa)]; Indications: [Perinatal/Infantile and Juvenile-Onset Hypophosphatasia (HPP), Adult-Onset Hypophosphatasia (HPP), All other uses]
5.01.574: Pharmacotherapy of Spinal Muscular Atrophy (SMA) Treatments: [Evrysdi (risdiplam), Spinraza (nusinersen), Zolgensma (onasemnogene abeparvovec-xioi)]; Indications: [SMA Types 1, 2, or 3 with bi-allelic SMN1 mutation, SMA with bi-allelic SMN1 mutation, SMA patients aged less than 2 years, SMA patients with 4 or fewer SMN2 copies, SMA patients without advanced SMA, SMA patients with baseline anti-AAV9 antibody levels ≤ 1:50, SMA without bi-allelic SMN1 mutation, SMA Type 4 (Adult Onset), SMA patients with 5 or more SMN2 copies, Advanced SMA, SMA patients with baseline anti-AAV9 antibody levels > 1:50, No prior Zolgensma treatment received, Not used in combination with Evrysdi or Spinraza, Repeat Zolgensma infusion, Any other SMA type or condition not explicitly listed as Medically Necessary]
5.01.575: Dupixent (dupilumab) Treatments: [Dupixent (dupilumab)]; Indications: [Atopic dermatitis, Moderate-to-severe asthma, Chronic obstructive pulmonary Disease, Chronic rhinosinusitis with nasal polyposis, Eosinophilic esophagitis, Prurigo nodularis, Use in individuals aged less than 6 months, All other uses not listed as medically necessary, Not used in combination with certain asthma biologics, Not used in combination with certain CRSwNP biologics]
5.01.576: Drugs for Rare Diseases Treatments: [Aldurazyme (laronidase) IV, Cerezyme (imiglucerase) IV, Crysvita (burosumab) SC, Elaprase (idursulfase) IV, Elelyso (taliglucerase alfa) IV, Fabrazyme (agalsidase beta) IV, Kanuma (sebelipase alfa) IV, Lumizyme (alglucosidase alfa) IV, Mepsevii (vestronidase alfa-vjbk) IV, Naglazyme (galsulfase) IV, Nexviazyme (avalglucosidase alfa-ngpt) IV, Vimizim (elosulfase alfa) IV, Vpriv (velaglucerase alfa) IV, Elfabrio (pegunigalsidase alfa-iwxj) IV, Galafold (migalastat) oral, Pombiliti (cipaglucosidase alfa-atga) IV, Opfolda (miglustat) oral, Cerdelga (eliglustat) oral, Generic miglustat oral, Zavesca (miglustat) oral, Xuriden (uridine triacetate) oral, Generic betaine anhydrous oral, Cystadane (betaine anhydrous) oral, Yorvipath (palopegteriparatide) SC, Revcovi (elapegademase-lvlr) IM, Firdapse (amifampridine) oral, Dojolvi (triheptanoin) oral, Cablivi (caplacizumab-yhdp) IV/SC, Tepezza (teprotumumab-trbw) IV, Givlaari (givosiran) SC, Gattex (teduglutide) SC, Keveyis (dichlorphenamide) oral, Generic dichlorphenamide oral, Sucraid (sacrosidase) oral, Zokinvy (lonafarnib) oral, Hemangeol (propranolol) oral, Oxlumo (lumasiran) SC, Rivfloza (nedosiran) SC, Imcivree (setmelanotide) SC, Gamifant (emapalumab-lzsg) IV, Brineura (cerliponase alfa) intraventricular, Sylvant (siltuximab) IV, Pyrukynd (mitapivat) oral, Xenpozyme (olipudase alfa-rpcp) IV, Skyclarys (omaveloxolone) oral, Lamzede (velmanase alfa-tycv) IV, Daybue (trofinetide) oral solution, Cholbam (cholic acid) capsule, Sohonos (palovarotene) capsule, Xolremdi (mavorixafor) oral, Besremi (ropeginterferon alfa-2b-njft) SC, Voxzogo (vosoritide) SC]; Indications: [Fabry Disease, Pompe Disease, Late-onset Pompe Disease, Gaucher’s Disease Type 1, Hereditary Orotic Aciduria, Homocystinuria, Hypoparathyroidism, Mucopolysaccharidosis Type I (MPS I), Mucopolysaccharidosis Type II (MPS II), X-Linked Hypophosphatemia (XLH), FGF23-related hypophosphatemia in Tumor Induced Osteomalacia (TIO), Mucopolysaccharidosis Type IVA (MPS IVA), Mucopolysaccharidosis Type VI (MPS VI), Mucopolysaccharidosis Type VII (MPS VII), Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID), Lambert-Eaton Myasthenic Syndrome (LEMS), Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD), Acquired Thrombotic Thrombocytopenic Purpura (aTTP), Thyroid Eye Disease, Acute Hepatic Porphyria (AHP), Short Bowel Syndrome (SBS), Primary Periodic Paralysis, Sucrase Deficiency, Progeroid Syndromes, Proliferating Infantile Hemangioma, Primary Hyperoxaluria Type 1 (PH1), Obesity due to POMC, PCSK1, or LEPR Deficiency, Bardet-Biedl Syndrome (BBS), Primary Hemophagocytic Lymphohistiocytosis (HLH), Neuronal Ceroid Lipofuscinosis Type 2 (CLN2), Multicentric Castleman's Disease (MCD), Lysosomal Acid Lipase (LAL) Deficiency, Molybdenum Cofactor Deficiency (MoCD) Type A, Paroxysmal Nocturnal Hemoglobinuria (PNH), Plasminogen Deficiency (PLGD) Type 1 (Hypoplasminogenemia), Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), Polycythemia Vera, Achondroplasia (ACH), Cold Agglutinin Disease (CAD), Pyruvate Kinase Deficiency (PKD), Acid Sphingomyelinase Deficiency (ASMD), Friedreich’s Ataxia, Alpha-Mannosidosis, Rett Syndrome, Bile Acid Synthesis Disorders due to single enzyme defects (SED), Peroxisomal disorders (PDs) including Zellweger spectrum disorders, Fibrodysplasia Ossificans Progressiva (FOP), WHIM Syndrome, Niemann-Pick Disease Type C (NPC), Subject to Site of Service Review, Site of Service Review Age Criteria (>= 13 years), Combination use of Elfabrio, Fabrazyme, and Galafold, Combination use of Lumizyme and Nexviazyme, Pompe: Pombiliti and Opfolda used concurrently, Gaucher: ERT not a therapeutic option, Gaucher: Failed preferred products for Zavesca, Gaucher: Zavesca due to formulation difference, Homocystinuria: Adjunctive vitamin therapy required or concurrent, Homocystinuria: Failed generic betaine anhydrous, Hypoparathyroidism: Adjunctive Calcium/Vitamin D required or concurrent, TIO: Tumor is resectable or localizable, aTTP: Cablivi continuous use beyond 90 days, aTTP: Adjunctive Plasma Exchange and Immunosuppression required, Thyroid Eye Disease: Tepezza in combination with other biologics, Short Bowel Syndrome: Parenteral Nutrition Dependency required, Periodic Paralysis: Failed/Intolerant to Acetazolamide required, Periodic Paralysis: Failed generic dichlorphenamide, Sucrase Deficiency: Low Sucrose, Low Starch Diet required, Progeroid Syndromes: Zokinvy with BSA < 0.39 m², Infantile Hemangioma: Requires Systemic Therapy, PH1: Liver or Kidney Transplant, Obesity (POMC/PCSK1/LEPR): Imcivree for benign/likely benign variants, HLH: Failed/Intolerant to Conventional Therapy required, HLH: HSCT Performed, Alpha-Mannosidosis: Presence of neurological symptoms, Alpha-Mannosidosis: Received HSCT/BMT, Achondroplasia: Planned/Expected Limb-Lengthening Surgery, CAD: Presence of Cold Agglutinin Syndrome, CAD: Enjaymo in combination with Rituximab, PKD: Pyrukynd Exclusions (Genetics, Splenectomy, Transplant), PNH: Required Vaccinations, NPC: Miplyffa used with Miglustat, NPC: Miplyffa in combination with Aqneursa, NPC: Aqneursa in combination with Miplyffa, NPC: Failed generic miglustat for Zavesca, NPC: Zavesca due to formulation difference]
5.01.578: Amyotrophic Lateral Sclerosis (ALS) Medications Treatments: [Generic edaravone IV, Radicava (edaravone) IV, Radicava ORS (edaravone) Oral suspension, Qalsody (tofersen) Intrathecal, Teglutik (riluzole) Oral suspension, Tiglutik (riluzole), Generic riluzole tablets]; Indications: [Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis (ALS) with SOD1 mutation, Any other indication or use not explicitly listed as medically necessary]
5.01.581: Pharmacologic Treatment of Hemophilia Treatments: [Beqvez (fidanacogene elaparvovec-dzkt), Hemgenix (etranacogene dezaparvovec-drlb), Hemlibra (emicizumab-kxwh), Hympavzi (marstacimab-hncq), Roctavian (valoctocogene roxaparvovec-rvox)]; Indications: [Hemophilia A (congenital factor VIII deficiency), Hemophilia B (congenital factor IX deficiency), Severe Hemophilia A (factor VIII activity < 1%), Severe or Moderately Severe Hemophilia B (factor IX activity <= 2%), Hemophilia A with or without factor VIII inhibitors, Hemophilia A or B with no factor VIII or IX inhibitors, History of FIX inhibitors or positive screen >= 0.6 BU, History of receiving gene therapy or being considered for another gene therapy for hemophilia B, HIV positive with uncontrolled infection, Active Hepatitis B infection, Active Hepatitis C infection, Neutralizing antibodies to AAVRh74var capsid, Pre-existing antibodies to AAV5 detected by FDA-approved test, Concurrent use with high dose aPCC, History or presence of factor VIII or IX inhibitors, Repeat Treatment, Any other condition or use not listed as medically necessary]
5.01.582: Antibody-Drug Conjugates Treatments: [Besponsa (inotuzumab ozogamicin), Elahere (mirvetuximab soravtansine-gynx), Mylotarg (gemtuzumab ozogamicin), Padcev (enfortumab vedotin-ejfv), Tivdak (tisotumab vedotin-tftv), Zynlonta (loncastuximab tesirine-lpyl)]; Indications: [Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL), Folate receptor alpha (FRa) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, Newly-diagnosed CD33+ Acute Myeloid Leukemia (AML), Relapsed or refractory CD33+ AML, Locally advanced or metastatic urothelial cancer (mUC), Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, Relapsed or refractory large B-cell lymphoma (LBCL), All other uses/indications]
5.01.584: CGRP Inhibitors for Migraine Prophylaxis Treatments: [Aimovig (erenumab-aooe), Ajovy (fremanezumab-vfrm), Emgality (galcanezumab-gnlm), Vyepti (eptinezumab-jjmr), Nurtec ODT (rimegepant), Qulipta (atogepant), Any CGRP Inhibitor listed in policy]; Indications: [Preventive Treatment of Migraine (Episodic or Chronic), Episodic Cluster Headache, Hemiplegic Migraine, Vestibular Migraine, Use in combination with other listed CGRP inhibitors, Other conditions or uses not specified in this policy or Policy 5.01.503]
5.01.585: Pharmacologic Treatment of Phenylketonuria Treatments: [Generic sapropterin oral, Javygtor (sapropterin) oral, Kuvan (sapropterin) oral, Palynziq (pegvaliase-pqpz) SC, Any listed drug (Generic Sapropterin, Javygtor, Kuvan, Palynziq)]; Indications: [Phenylketonuria, Use in combination with other listed drugs, All other uses]
5.01.586: Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders Treatments: [Intravenous Ketamine Infusion, Intravenous Lidocaine Infusion, Ketamine-Assisted Therapy]; Indications: [Chronic Pain (General), Chronic Neuropathic Pain, Chronic Daily Headache, Fibromyalgia, Depression, Anxiety, Other Psychiatric Disorders/Symptoms, Substance Use Disorders]
5.01.587: Hereditary Angioedema Treatments: [Berinert (pdC1-INH) IV, Cinryze (pdC1-INH) IV, Icatibant (Generic and Sajazir) SC, Firazyr (icatibant) SC, Haegarda (pdC1-INH) SC, Kalbitor (ecallantide) SC, Orladeyo (berotralstat) oral, Ruconest (rhC1-INH) IV, Takhzyro (lanadelumab-flyo) SC, Any targeted HAE-specific therapy]; Indications: [Hereditary Angioedema Type I or II, Acquired Angioedema, Treatment of Acute Angioedema Attacks, Long-term Prophylaxis of Acute Angioedema Attacks, Site of Service Review (Patients Age 13+), Site of Service: Medically Necessary Preferred Sites, Site of Service: Hospital Outpatient Medically Necessary Exceptions, Site of Service: Not Medically Necessary when Criteria Not Met, Not Used Concomitantly with Other Targeted HAE Therapies, Prior Trial or Intolerance to Generic Icatibant or Sajazir, Administered by Healthcare Professional with Anaphylaxis Support]
5.01.588: Pharmacologic Prevention and Treatment of HIV/AIDS Treatments: [Apretude (cabotegravir extended-release injectable suspension) IM, Descovy (emtricitabine and tenofovir alafenamide) oral, Rukobia (fostemsavir) oral, Sunlenca (lenacapavir) oral, SC, Trogarzo (ibalizumab) IV, Truvada (emtricitabine and tenofovir disoproxil fumarate) oral, Generic emtricitabine and tenofovir disoproxil fumarate oral, Any drug listed in this policy]; Indications: [Pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection, Treatment of HIV-1 infection, Treatment of multidrug resistant HIV-1, Requires trial of generic emtricitabine and tenofovir disoproxil fumarate first, Use in combination with other antiretrovirals, Any other use or condition not specifically outlined as Medically Necessary in this policy]
5.01.589: BRAF and MEK Inhibitors Treatments: [Encorafenib (Braftovi), Binimetinib (Mektovi), Dabrafenib (Tafinlar), Trametinib (Mekinist), Vemurafenib (Zelboraf), Cobimetinib (Cotellic), Cetuximab (Erbitux), Selumetinib (Koselugo), Tovorafenib (Ojemda), Braftovi (Encorafenib) and Mektovi (Binimetinib) Combination, Tafinlar (Dabrafenib) and Mekinist (Trametinib) Combination, Zelboraf (Vemurafenib) and Cotellic (Cobimetinib) Combination, Braftovi (Encorafenib) and Erbitux (Cetuximab) Combination, Any Listed BRAF or MEK Inhibitor (Monotherapy or Combination)]; Indications: [Unresectable or Metastatic Melanoma with BRAF V600E or V600K Mutation, Metastatic Colorectal Cancer (CRC) with BRAF V600E Mutation, after prior therapy, Metastatic Non-Small Cell Lung Cancer (NSCLC) with BRAF V600E Mutation, Adjuvant treatment of Melanoma with BRAF V600E or V600K Mutations and lymph node involvement, following complete resection, Locally Advanced or Metastatic Anaplastic Thyroid Cancer (ATC) with BRAF V600E Mutation and with no satisfactory locoregional treatment options, Unresectable or Metastatic Solid Tumors with BRAF V600E Mutation who have progressed following prior treatment and have no satisfactory alternative treatment options (adult and pediatric ≥1 year), Pediatric Low Grade Glioma (LGG) with BRAF V600E Mutation who require systemic therapy (pediatric ≥1 year and <18 years), Histiocytic Neoplasms (adult individuals), Erdheim-Chester Disease (ECD) with BRAF V600 Mutation, Unresectable or Metastatic Melanoma with BRAF V600E or V600K Mutations, BRAF-inhibitor treatment-naïve, Symptomatic, Inoperable Plexiform Neurofibromas associated with Neurofibromatosis type 1 (NF1) (pediatric ≥2 years and <18 years), Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 Mutation (pediatric ≥6 months and <18 years), Wild-type BRAF, All other uses of listed medications]
5.01.590: PHARMACY POLICY – 5.01.590 Bruton's Kinase Inhibitors Treatments: [Brukinsa (zanubrutinib), Calquence (acalabrutinib), Imbruvica (ibrutinib), Jaypirca (pirtobrutinib), Any Bruton's Kinase Inhibitor Listed]; Indications: [Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma, Follicular Lymphoma, Chronic Graft Versus Host Disease, Any Other Indication Not Listed]
5.01.592: Phosphoinositide 3-kinase (PI3K) Inhibitors Treatments: [Aliqopa (copanlisib), Copiktra (duvelisib), Itovebi (inavolisib), Joenja (leniolisib), Piqray (alpelisib), Truqap (capivasertib), Vijoice (alpelisib), Zydelig (idelalisib), Any PI3K Inhibitor covered by this policy]; Indications: [Relapsed follicular lymphoma (FL), Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Endocrine-resistant PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, Activated phosphoinositide 3-kinase delta syndrome (APDS), HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer (for Piqray), PIK3CA-Related Overgrowth Spectrum (PROS), HR-positive, HER2-negative breast cancer (for Truqap), Relapsed chronic lymphocytic leukemia (CLL) (for Zydelig), All other uses (Investigational)]
5.01.593_2025-05-06: Pharmacologic Treatment of Transthyretin-Mediated Amyloidosis Treatments: [Amvuttra (vutrisiran) SC, Attruby (acoramidis) oral, Onpattro (patisiran) IV, Vyndamax (tafamidis), Vyndaqel (tafamidis meglumine) oral, Wainua (eplontersen) SC]; Indications: [Polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR), Cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), Severe Heart Failure (NYHA III/IV) - Contraindication for Polyneuropathy Treatments, Neuropathy Not Related to hATTR, Prior Liver Transplantation - Contraindication for Polyneuropathy Treatments, Light-Chain Amyloidosis - Contraindication for ATTR-CM Treatments, History of Heart Transplantation - Contraindication for ATTR-CM Treatments, Implanted Cardiac Device - Contraindication for ATTR-CM Treatments, Not Used in Combination with Other Listed hATTR/ATTR Treatments, Any Other Condition Not Explicitly Addressed]
5.01.593: Pharmacologic Treatment of Transthyretin-Mediated Amyloidosis Treatments: [Amvuttra (vutrisiran) SC, Attruby (acoramidis) oral, Onpattro (patisiran) IV, Vyndamax (tafamidis) oral, Vyndaqel (tafamidis meglumine) oral, Wainua (eplontersen) SC]; Indications: [Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis (hATTR), Cardiomyopathy of Wild Type or Hereditary Transthyretin-Mediated Amyloidosis (ATTR-CM), Amvuttra Combination with TTR Stabilizers, Onpattro, Tegsedi, or Wainua, Onpattro Combination with TTR Stabilizers, Amvuttra, Tegsedi, or Wainua, Wainua Combination with TTR Stabilizers, Amvuttra, Onpattro, or Tegsedi, Attruby Combination with Amvuttra, Onpattro, Vyndamax, Vyndaqel, or Wainua, Tafamidis Combination with Attruby, Amvuttra, Onpattro, or Wainua, NYHA Class III or IV Heart Failure, Neuropathy Not Related to hATTR Amyloidosis, Prior Liver Transplantation, Presence of Light-Chain Amyloidosis, History of Liver or Heart Transplantation, Implanted Cardiac Device, All Other Uses/Indications Not Explicitly Listed]
5.01.595: Injectable Clostridial Collagenase for Fibroproliferative Disorders Treatments: [Injectable Clostridial Collagenase (Xiaflex)]; Indications: [Dupuytren's contracture, Peyronie's disease, Adhesive capsulitis, All other indications, Re-authorization for Dupuytren's contracture (same cord), Re-authorization for Peyronie's disease]
5.01.596: Pharmacologic Treatment of Osteoporosis Treatments: [Bonsity, Forteo, and Brand Teriparatide, Generic Teriparatide, Evenity (romosozumab-aqqg), Prolia (denosumab), Tymlos (abaloparatide), Any drug listed in this policy]; Indications: [Osteoporosis (Treatment), Increase bone mass in men on ADT for nonmetastatic prostate cancer, Increase bone mass in women on AI therapy for breast cancer, Evenity use beyond 12 months duration, All other uses/conditions not explicitly listed]
5.01.598: Pharmacologic Treatment to Reduce Serum Phosphorus Treatments: [Fosrenol (lanthanum carbonate), Renagel (sevelamer HCl), Renvela (sevelamer carbonate), Velphoro (sucroferric oxyhydroxide), Auryxia (ferric citrate), Xphozah (tenapanor), Any Sevelamer Product (HCl or Carbonate), Any Phosphate Binder Therapy, Any Oral Iron Product, Any IV Iron Product]; Indications: [Hyperphosphatemia, Iron Deficiency Anemia, Any other use/condition not specified in policy]
5.01.599: Pharmacologic Treatment of Sleep Disorders Treatments: [Brand Sodium Oxybate / Xyrem (Sodium Oxybate), Lumryz (Sodium Oxybate), Xywav (Calcium Magnesium, Potassium, and Sodium Oxybates), Sunosi (Solriamfetol), Wakix (Pitolisant), Any Covered Sleep Medication (Brand/Xyrem, Lumryz, Xywav, Sunosi, Wakix)]; Indications: [Excessive Daytime Sleepiness in Narcolepsy, Cataplexy in Narcolepsy, Idiopathic Hypersomnia, Excessive Daytime Sleepiness in Obstructive Sleep Apnea (OSA), Severe Hepatic Impairment (Child-Pugh C), Used in Combination with Other Covered Sleep Medications, Dose Exceeding Policy Maximum, Use for Conditions Not Explicitly Outlined]
5.01.603: Epidermal Growth Factor Receptor (EGFR) Inhibitors Treatments: [Generic erlotinib, Generic gefitinib, Gilotrif (afatinib), Iressa (gefitinib), Lazcluze (lazertinib), Tagrisso (osimertinib), Tarceva (erlotinib), Vizimpro (dacomitinib), Erbitux (cetuximab), Rybrevant (amivantamab-vmjw), Vectibix (panitumumab)]; Indications: [Metastatic Non-Small Cell Lung Cancer (NSCLC), NSCLC with EGFR Exon 19 deletions or Exon 21 L858R mutations, NSCLC Treatment Setting/Line of Therapy, In combination with platinum-based chemotherapy, Locally Advanced, Unresectable or Metastatic Pancreatic Cancer, In combination with gemcitabine, NSCLC with Other EGFR Mutations, Tumors with Resistant EGFR Mutations, Metastatic Squamous NSCLC progressing after platinum-based chemotherapy, Prior trial and failure of generic gefitinib, Age 18 years or older, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), In combination with Rybrevant (amivantamab-vmjw), Quantity/Dose Limit Applies, Adjuvant therapy for NSCLC (post-resection) with EGFR Exon 19 deletions or Exon 21 L858R mutations, Locally Advanced Unresectable (Stage III) NSCLC post-chemoradiation with EGFR Exon 19 deletions or Exon 21 L858R mutations, Metastatic EGFR T790M mutation-positive NSCLC post-TKI therapy, Initial treatment for Locally Advanced or Metastatic NSCLC with EGFR Exon 19/21 mutations in combination with pemetrexed and platinum-based chemotherapy, Prior trial and failure of generic erlotinib, Metastatic Colorectal Cancer (mCRC), KRAS and NRAS wild-type, As a single agent therapy, CRC Treatment Setting/Line of Therapy, In combination with the FOLFIRI or FOLFOX regimen, In combination with irinotecan for individuals refractory to irinotecan-based chemotherapy, BRAF V600E mutation, In combination with Braftovi (encorafenib) for metastatic CRC with BRAF V600E mutation after prior therapy, In combination with Braftovi (encorafenib) and mFOLFOX6 for metastatic CRC with BRAF V600E mutation, Locally Advanced or Metastatic Colorectal Cancer, KRAS G12C mutation, In combination with Krazati (adagrasib) for KRAS G12C-mutated CRC post-prior chemotherapy, Locally or Regionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN), In combination with radiation therapy, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN), SCCHN as single agent post-radiation with recurrence or metastases, Recurrent, second primary, or metastatic SCCHN (single agent or combo platinum), Squamous Cell Carcinoma of the Skin, Recurrent or distant metastatic Squamous Cell Carcinoma of the Skin, NSCLC with EGFR Exon 20 insertion mutations, NSCLC progressed on or after platinum-based chemotherapy, In combination with carboplatin and pemetrexed, Rybrevant Dose Limits, NSCLC progressed on or after EGFR TKI therapy, In combination with Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib), No prior Vectibix (panitumumab) therapy, No prior Erbitux (cetuximab) therapy, In combination with Lumakras (sotorasib) for KRAS G12C-mutated mCRC post-prior chemotherapy, All other uses not specifically listed, Other/Unspecified Tumor Types (Solid Tumors or Hematological Malignancies)]
5.01.606: Hepatitis C Antiviral Therapy Treatments: [Any Hepatitis C Antiviral Therapy, Any Direct-Acting Antiviral (DAA), Epclusa (sofosbuvir-velpatasvir), Harvoni (ledipasvir-sofosbuvir), Mavyret (glecaprevir-pibrentasvir), Sovaldi (sofosbuvir), Vosevi (sofosbuvir-velpatasvir-voxilaprevir), Zepatier (elbasvir-grazoprevir), Any Pegylated Interferon, Ribavirin]; Indications: [Any Hepatitis C Condition/Context, Chronic Hepatitis C, Any Hepatitis C Genotype, Hepatitis C Genotype 1, Hepatitis C Genotype 1a, Hepatitis C Genotype 1b, Hepatitis C Genotype 2, Hepatitis C Genotype 3, Hepatitis C Genotype 4, Hepatitis C Genotype 5, Hepatitis C Genotype 6, Any Cirrhosis Status, Without Cirrhosis, Compensated Cirrhosis (Child-Pugh A), Decompensated Cirrhosis (Child-Pugh B or C), Treatment-Naïve, Any Treatment-Experienced, Any DAA Treatment Experienced, Experienced with NS3/4A PI, No Prior NS5A Inhibitor, Experienced with NS5A, No Prior NS3/4A PI, Experienced with Pegylated Interferon, Ribavirin, and/or Sofosbuvir, Experienced with HCV Regimen Containing NS5A Inhibitor, Experienced with HCV Regimen Containing Sofosbuvir Without NS5A Inhibitor, Liver Transplant Recipient, According to AASLD/IDSA Guidelines, Deviations from AASLD/IDSA Guideline Length of Therapy, Resistance-Associated Substitutions (RAS) Analysis Context, Equally or More Effective Alternative Treatment Available at Lower Cost, Special Circumstances Not Meeting Standard Criteria, Requires Prior Authorization, Non-Metallic Formulary Plans, Individual/Small Group/Student ISHIP Metallic Formulary Plans, Individuals Aged 3 Years and Older, Individuals Aged 12 Years and Older, With Baseline NS5A Polymorphisms, Without Baseline NS5A Polymorphisms]
5.01.607: Continuity of Coverage for Maintenance Medications Treatments: [Continuation of Maintenance Medication]; Indications: [New Member, Drug Has Preferred Generic/Biosimilar Alternative Context, New Member, Drug Has NO Preferred Generic/Biosimilar Alternative Context, Current Member, Drug Has Preferred Generic/Biosimilar Alternative Context, Current Member, Drug Has NO Preferred Generic/Biosimilar Alternative Context, Contraindication: Experimental or Investigational Use, Policy Rule: Coverage Excluded by Member Contract, Contraindication: Received via Manufacturer Samples/Coupons, Policy Rule: Current Member Received Notification of New Restrictions]
5.01.608: Pharmacologic Treatment of Postpartum Depression Treatments: [Zulresso (brexanolone) IV, Zurzuvae (zuranolone) oral, Medications listed in this policy (Zulresso and Zurzuvae)]; Indications: [Major Depressive Disorder with Peripartum Onset, Other conditions not outlined in policy, Future re-authorization of Zulresso, Future re-authorization of Zurzuvae]
5.01.609: Spravato (esketamine) Nasal Spray Treatments: [Spravato (esketamine) Nasal Spray, Esketamine or Ketamine (Other Formulations)]; Indications: [Major Depressive Disorder (Unipolar, without Psychotic Features), Major Depressive Disorder (MDD) with Acute Suicidal Ideation or Behavior, Chronic Pain, Bipolar Depression, All other indications (Investigational uses), Any Indication, Age less than 18 years, Current or Past Psychosis, Current Substance Use Disorder (unless in remission/confined), Aneurysmal Vascular Disease, Arteriovenous Malformation, History of Intracerebral Hemorrhage, Hypersensitivity to Esketamine, Ketamine, or Excipients, Concurrent use of any hallucinogens/psychedelics, Concurrent use of any illicit drugs, Concurrent use of illicit/non-prescribed stimulants or prescribed stimulants in excess of dose, Alcohol or Marijuana use within 24 hours pre/post treatment without agreement, Use that meets age/diagnosis but not other Medical Necessity criteria, Use with more than one provider/group/clinic concurrently, Use in conjunction with any modality of neuromodulation, Use in conjunction with any other formulation of ketamine or any psychedelic drug]
5.01.610: Pharmacologic Treatment in Assisted Reproduction Treatments: [Brand Chorionic Gonadotropin, Pregnyl (chorionic gonadotropin), Novarel (chorionic gonadotropin), Ovidrel (choriogonadotropin alfa), Follistim AQ (follitropin beta), Gonal-f (follitropin alfa), Brand Ganirelix, Generic ganirelix and Fyremadel (ganirelix), Generic cetrorelix or Cetrotide (cetrorelix), Any drug listed in this policy]; Indications: [Assisted Reproduction, Non-assisted reproduction related conditions, All other uses for assisted reproduction]
5.01.611: Pharmacologic Treatment of Urea Cycle Disorders Treatments: [Carbaglu (carglumic acid), Generic carglumic acid, Ravicti (glycerol phenylbutyrate), Buphenyl and Olpruva (sodium phenylbutyrate), Pheburane (sodium phenylbutyrate), Generic sodium phenylbutyrate, Any listed Urea Cycle Disorder medication]; Indications: [Acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency, Chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency, Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA), Chronic management of individuals with urea cycle disorders, Chronic management of urea cycle disorders with documented deficiency of CPS, OTC, or AS, All other uses or conditions not outlined in policy]
5.01.612: Pharmacologic Treatment of Cystinosis Treatments: [Cystagon (cysteamine bitartrate) capsules, Procysbi (cysteamine bitartrate) delayed-release capsules/granules, Cystadrops (cysteamine ophthalmic solution), Cystaran (cysteamine ophthalmic solution)]; Indications: [Nephropathic Cystinosis, Corneal Cystine Crystal Accumulation, All Other Uses/Indications]
5.01.613: Oral Iron Chelating Agents Treatments: [Any Oral Iron Chelating Agent Listed in Policy, Deferasirox (Generic), Deferasirox (Branded: Exjade, Jadenu, Jadenu Sprinkle), Deferiprone (Generic), Deferiprone (Branded: Ferriprox)]; Indications: [Chronic iron overload due to blood transfusions (transfusional hemosiderosis), Chronic iron overload in non-transfusion dependent thalassemia syndromes, Transfusional iron overload due to thalassemia syndromes, Chronic iron overload in transfusions related to sickle cell disease, All other uses or conditions not specified in policy]
5.01.614: PHARMACY / MEDICAL POLICY – Erythroid Maturation Agents Treatments: [Reblozyl (luspatercept-aamt)]; Indications: [Anemia in adult individuals with beta thalassemia, Anemia in adult MDS-RS or MDS/MPN-RS-T failing ESA, Anemia in adult MDS (ESA-naïve), All other uses/indications not explicitly listed as Medically Necessary]
5.01.615: Pharmacologic Treatment of Chronic Non-Infectious Liver Diseases Treatments: [Iqirvo (elafibranor), Livdelzi (seladelpar), Ocaliva (obeticholic acid), Rezdiffra (resmetirom), Ursodeoxycholic acid (UDCA)]; Indications: [Primary Biliary Cholangitis (PBC), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Excluded Drug Combinations, Significant Alcohol Consumption, Active Hepatitis C Infection, Hemochromatosis, Wilson's Disease, Cirrhosis (F4 Fibrosis) due to MASH, Advanced PBC (Ocaliva Specific), Other Indications Not Specified]
5.01.616: Pharmacologic Treatment of Gout Treatments: [Select Oral Gout Medications (Colchicine, Allopurinol, Febuxostat), Ilaris (canakinumab) SC, Krystexxa (pegloticase) IV, Any Listed Gout Drug in this Policy]; Indications: [Gout (General), Acute Gout Flares, Chronic Gout, Contraindication: Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency, Contraindication: Positive for HLA-B*5801 Allele (relevant for allopurinol use), All other uses/conditions for listed drugs]
5.01.617: Folate Antimetabolites Treatments: [Alimta (pemetrexed) IV, Pemrydi RTU (pemetrexed) IV, Axtle (pemetrexed) IV, Brand pemetrexed (Avyxa- unbranded) IV, Brand pemetrexed (Hospira- unbranded) IV, Brand pemetrexed (Novaplus- unbranded) IV, Folotyn (pralatrexate) IV, Jylamvo (methotrexate) oral solution, Otrexup (methotrexate) SC, Rasuvo (methotrexate) SC, Brand pemetrexed (Accord- unbranded) IV, Brand pemetrexed (BluePoint Laboratories- unbranded) IV, Brand pemetrexed (Sandoz- unbranded) IV, Brand pemetrexed (Teva- unbranded) IV, Brand pemetrexed ditromethamine IV, Pemfexy (pemetrexed) IV, Trexall (methotrexate) oral, Xatmep (methotrexate) oral solution, Generic methotrexate tablets, Generic injectable methotrexate]; Indications: [Metastatic non-squamous NSCLC (initial, no EGFR/ALK/ROS1 aberrations), Metastatic non-squamous NSCLC (EGFR/ALK/ROS1 mutations, post target therapy progression), Locally advanced or metastatic non-squamous NSCLC (initial chemotherapy), Locally advanced or metastatic non-squamous NSCLC (maintenance post-platinum chemo), Recurrent, metastatic non-squamous NSCLC (after prior chemotherapy), Malignant pleural mesothelioma (unresectable or not surgical candidate), Relapsed or refractory peripheral T-cell lymphoma (PTCL), Rheumatoid arthritis (RA), Polyarticular juvenile idiopathic arthritis (pJIA), Psoriasis (adults), Acute lymphoblastic leukemia (ALL) (< 18 years), Use in combination with another methotrexate product, Any other use not specifically listed as Medically Necessary]
5.01.618: Selective Estrogen Receptor Modulators and Down Regulators Treatments: [Arimidex (anastrozole), Aromasin (exemestane), Evista (raloxifene), Fareston (toremifene), Faslodex (fulvestrant), Femara (letrozole), Orserdu (elacestrant)]; Indications: [Adjuvant treatment of hormone receptor-positive early breast cancer (postmenopausal), Locally advanced or metastatic breast cancer (HR-positive or unknown, postmenopausal), Advanced breast cancer with progression following tamoxifen therapy (postmenopausal), Recurrent or metastatic endometrial or uterine cancer, Recurrent ovarian cancer, Risk reduction for breast cancer (postmenopausal), Extended adjuvant treatment of hormone receptor-positive early breast cancer after tamoxifen (postmenopausal), Risk reduction for invasive breast cancer (postmenopausal), Treatment and prevention of osteoporosis (postmenopausal), Risk reduction for invasive breast cancer in women with osteoporosis (postmenopausal), Risk reduction for invasive breast cancer in high-risk women (postmenopausal), Metastatic breast cancer (HR-positive or unknown, postmenopausal), Advanced breast cancer (HR+, HER2-, postmenopausal, endocrine naive), Advanced breast cancer with progression following endocrine therapy (HR+, postmenopausal), Combination with ribociclib for advanced/metastatic breast cancer (HR+, HER2-, postmenopausal), Combination with palbociclib or abemaciclib for advanced/metastatic breast cancer (HR+, HER2-, postmenopausal), after endocrine progression, Combination with Truqap (capivasertib) for advanced/metastatic breast cancer (HR+, HER2-, PIK3CA/AKT1/PTEN-altered), after progression/recurrence (adults), Advanced breast cancer (HR-positive or unknown, postmenopausal), Advanced or metastatic breast cancer (ER+, HER2-, ESR1-mutated, postmenopausal women or adult men)]
5.01.619: Intravitreal and Suprachoroidal Corticosteroids Treatments: [Ozurdex (dexamethasone intravitreal implant), Iluvien (fluocinolone acetonide intravitreal implant), Retisert (fluocinolone acetonide intravitreal implant), Xipere (triamcinolone acetonide injectable suspension), Yutiq (fluocinolone acetonide intravitreal implant)]; Indications: [Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO), Non-infectious Uveitis of the Posterior Segment, Diabetic Macular Edema (DME), Chronic Non-infectious Uveitis Affecting the Posterior Segment, Macular Edema Associated with Uveitis, Active or suspected ocular or periocular infection, Glaucoma with a cup to disc ratio of greater than 0.8, Torn or ruptured posterior lens capsule, All other uses/conditions not specified in policy]
5.01.620: Vascular Endothelial Growth Factor (VEGF) Receptor Inhibitors for Ocular Disorders Treatments: [Beovu (brolucizumab-dbll), Byooviz (ranibizumab-nuna), Cimerli (ranibizumab-eqrn), Eylea (aflibercept), Eylea HD (aflibercept), Lucentis (ranibizumab), Macugen (pegaptanib), Pavblu (aflibercept-ayyh), Susvimo (ranibizumab intravitreal implant), Vabysmo (faricimab-svoa)]; Indications: [Neovascular (Wet) Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Macular Edema Following Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), Diabetic Retinopathy (DR), Retinopathy of Prematurity (ROP), Not used in combination with other listed drugs (Per eye treated), All other uses of the drugs listed for conditions not outlined]
5.01.621: Drugs for Weight Management Treatments: [Contrave (naltrexone/bupropion), Qsymia (phentermine/topiramate extended-release), Saxenda (liraglutide), Wegovy (semaglutide), Xenical (orlistat) or brand orlistat, Zepbound (tirzepatide)]; Indications: [Chronic Weight Management (Adults), Chronic Weight Management (Pediatric, 12-17 years), Major Adverse Cardiovascular Events (MACE) Risk Reduction in Adults with Established CVD, Asthma (as weight-related comorbidity), Cardiovascular Disease (as weight-related comorbidity), Chronic Obstructive Pulmonary Disease (COPD) (as weight-related comorbidity), Coronary Artery Disease (CAD) (as weight-related comorbidity), Dyslipidemia (as weight-related comorbidity), Hypertension (as weight-related comorbidity), Knee Osteoarthritis (as weight-related comorbidity), Metabolic-dysfunction associated steatotic liver disease / Non-alcoholic fatty liver disease (as weight-related comorbidity), Obstructive Sleep Apnea (OSA) (as weight-related comorbidity), Polycystic Ovarian Syndrome (PCOS) (as weight-related comorbidity), Type 2 Diabetes Mellitus (as weight-related comorbidity), Not Used Concurrently with Other Weight Loss Drugs, Any Other Indication]
5.01.622: Pharmacy Benefit Coverage Guideline – Exception Request to Utilization Management Restrictions for Washington State Fully-Insured Members Treatments: [Request for substitute drug, Request to continue with current drug, Request for a higher drug dosage, Request for off-label use, Drug As listed (Exception Request Type)]; Indications: [Contraindication to the formulary drug, Adverse event with previously tried drug, Drug not therapeutically effective, Adverse event with interchangeable generic equivalent, Adverse event with interchangeable biological product, Predictable adverse clinical outcome from switching, Physical or mental harm from switching, Barrier to adherence or compliance, Negative impact on comorbid condition, Clinically predictable negative drug interaction, Decrease in functional ability, Successful clinical treatment requires higher dosage, Medical reason for higher dose, Less frequent dosing with higher strength not an option, Context of off-label use request, Applies ONLY to Washington State fully-insured members, Does NOT apply to non-Washington state fully-insured or self-insured members, Pharmacy Exception Request Form required, Documentation required in chart notes, Subject to FDA dosage and administration prescribing information]
5.01.623: Topical Drugs for Actinic Keratosis and Other Dermatologic Conditions Treatments: [Carac (fluorouracil 0.5%), Brand fluorouracil, Generic imiquimod 3.75%, Klisyri (tirbanibulin), Tolak (fluorouracil 4%), Zyclara (imiquimod 2.5% and 3.75%), Generic imiquimod 5%, Generic topical fluorouracil product, Any drug covered by this policy]; Indications: [Actinic Keratosis, External genital and perianal warts (EGW), All other uses/conditions not outlined in this policy]
5.01.624: Alpha-1 Proteinase Inhibitors Treatments: [Aralast NP, Prolastin-C, Zemaira, Glassia, Any Alpha-1 Proteinase Inhibitor]; Indications: [Clinically evident emphysema due to severe hereditary deficiency of alpha₁-PI (alpha₁-antitrypsin deficiency), All other uses/conditions not outlined in this policy, Site of Service: Physician's office, Infusion center, or Home infusion, Site of Service: Hospital-based outpatient setting - Criteria met, Site of Service: Hospital-based outpatient setting - Criteria not met]
5.01.625: Gonadotropin Releasing Hormone (GnRH) Analogs Treatments: [Lupron Depot (leuprolide acetate), Trelstar (triptorelin pamoate), Zoladex (goserelin), Fensolvi (leuprolide acetate), Generic leuprolide, Lupron Depot PED (leuprolide acetate), Supprelin LA (histrelin implant), Synarel (nafarelin), Triptodur (triptorelin), Vantas (histrelin implant), Myfembree (relugolix/estradiol/norethindrone acetate), Orilissa (elagolix), Eligard (leuprolide acetate), Firmagon (degarelix), Orgovyx (relugolix), Camcevi (leuprolide mesylate), Lupaneta Pack (leuprolide/norethindrone), Oriahnn (elagolix/estradiol/norethindrone acetate), Verzenio (abemaciclib), Brand leuprolide depot (other), Any GnRH Analog or Related Product Listed]; Indications: [Advanced Breast Cancer (Palliative), Early Breast Cancer (Adjuvant), Early Breast Cancer (Adjuvant, High Risk), Central Precocious Puberty, Endometriosis, Endometriosis (Moderate to Severe Pain), Gender Dysphoria, Ovulation Suppression for Frozen Embryo Transfer, Advanced Prostate Cancer, Locally Confined Prostate Cancer (Stage T2b-T4) with Flutamide, Uterine Fibroids (Anemia), Uterine Fibroids (Presurgery), Uterine Fibroids (Heavy Menstrual Bleeding), Uterine Fibroids (Endometrial Thinning), Any Indication, All Other Uses Not Listed, Gender Dysphoria (Criteria Not Met for MN), Gender Dysphoria (Use of Unlisted Products), Listed Indications (Other Medical Necessity Criteria Not Met), Zoladex for Endometriosis (Beyond 6 Months), Zoladex for Endometrial Thinning (Beyond 6 Months), Leuprolide for Uterine Fibroids (Beyond 3 Months), Myfembree for Endometriosis (Beyond 24 Months), Orilissa 150mg for Endometriosis (Beyond 24 Months), Orilissa 200mg for Endometriosis (Beyond 6 Months), Myfembree for Uterine Fibroids (Beyond 24 Months), Oriahnn for Uterine Fibroids (Beyond 24 Months), Leuprolide/Synarel for Endometriosis (Beyond 12 Months), Contraindication: Osteoporosis, Contraindication: Severe Hepatic Impairment (Child-Pugh C), Contraindication: History of Gonadectomy, Contraindication: Interfering Psychiatric Disorder (Gender Dysphoria)]
5.01.626: PHARMACY / MEDICAL POLICY – 5.01.626 Amyloid Antibodies for the Treatment of Alzheimer's Disease Treatments: [Kisunla (donanemab-azbt), Leqembi (lecanemab-irmb), Aduhelm (aducanumab-avwa)]; Indications: [Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia due to Alzheimer's Disease (documented amyloid), Any condition other than Mild Cognitive Impairment or Mild AD Dementia due to documented amyloid, Use in combination with other monoclonal antibodies for Alzheimer's disease]
5.01.627: Thymic Stromal Lymphopoietin (TSLP) Inhibitors Treatments: [Tezspire (tezepelumab-ekko)]; Indications: [Severe Asthma, Exclusion: Combination with other Biologics for Asthma, Any other indication or use not specified]
5.01.628: Pharmacologic Treatment of Atopic Dermatitis Treatments: [Vtama (tapinarof) topical, Elidel (pimecrolimus) topical, Protopic (tacrolimus) topical, Topical Calcineurin Inhibitors (Class), Dupixent (dupilumab) SC, Adbry (tralokinumab-Idrm) SC, Ebglyss (lebrikizumab-Ibkz) SC, Cibinqo (abrocitinib) oral, Opzelura (ruxolitinib) topical, Rinvoq (upadacitinib) oral, Eucrisa (crisaborole) topical, Zoryve (roflumilast) 0.15% cream topical, Topical Corticosteroids (Class)]; Indications: [Atopic Dermatitis (AD), Atopic Dermatitis (Mild to Moderate), Atopic Dermatitis (Moderate to Severe), Vitiligo, Other Conditions Not Outlined in This Policy, Age 2 years or Older, Age 12 years or Older, Age 3 Months or Older, Not Immunocompromised, Inadequate Response or Intolerance to Topical Corticosteroid, Inadequate Response or Intolerance to High Potency Topical Corticosteroid, Inadequate Response or Intolerance to Topical Calcineurin Inhibitor, Prior Trial of Generic Pimecrolimus and Tacrolimus, Inadequate Response or Intolerance to Traditional Systemic Therapy, Prescribed by or in Consultation with Specialist]
5.01.629_2025-07-01: Pharmacologic Treatment of Psoriasis Treatments: [Enbrel (etanercept) SC, Cyltezo (adalimumab-adbm) SC, Simlandi (adalimumab-ryvk) SC, Adalimumab-adaz (Hyrimoz unbranded) SC, Adalimumab-adbm (Cyltezo unbranded) SC, Adalimumab-ryvk (Simlandi unbranded) SC, Inflectra (infliximab-dyyb) IV, Infliximab (Janssen – unbranded) IV, Remicade (infliximab) IV, Taltz (ixekizumab) SC, Stelara (ustekinumab) SC, Skyrizi (risankizumab-rzaa) SC, Tremfya (guselkumab) SC, Otezla (apremilast) oral, Sotyktu (deucravacitinib) oral, Ilumya (tildrakizumab-asmn) SC, Cimzia (certolizumab pegol) SC, Abrilada (adalimumab-afzb) SC, Adalimumab-aacf (Idacio unbranded) SC, Adalimumab-aaty (Yuflyma unbranded) SC, Adalimumab-fkjp (Hulio unbranded) SC, Amjevita (adalimumab-atto) SC, Hadlima (adalimumab-bwwd) SC, Hulio (adalimumab-fkjp) SC, Humira (adalimumab) SC, Hyrimoz (adalimumab-adaz) SC, Idacio (adalimumab-aacf) SC, Yuflyma (adalimumab-aaty) SC, Yusimry (adalimumab-aqvh) SC, Bimzelx (bimekizumab-bkzx) SC, Cosentyx (secukinumab) SC, Siliq (brodalumab) SC, Avsola (infliximab-axxq) IV, Renflexis (infliximab-abda) IV, Vtama (tapinarof) cream, Zoryve (roflumilast) 0.3% cream, Duobrii (halobetasol and tazarotene) lotion, Enstilar (betamethasone and calcipotriene) foam, Taclonex (betamethasone and calcipotriene) ointment/suspension, Wynzora (betamethasone and calcipotriene) cream, Brand calcipotriene foam, Dovonex (calcipotriene) cream, Sorilux (calcipotriene) foam, Vectical (calcitriol) ointment, Soriatane (acitretin) oral, Spevigo (spesolimab-sbzo) SC/IV]; Indications: [Plaque Psoriasis, Moderate to severe plaque psoriasis (>= 10% BSA or exceptions), Generalized Pustular Psoriasis (GPP), Generalized Pustular Psoriasis (GPP) flare, Severe pustular, exfoliative or inflammatory psoriasis (Emergent Treatment), Plaque Psoriasis (BSA >= 3%), Plaque Psoriasis (BSA >= 2%), Site of service for IV/injectable administration, Unspecified Uses or Failure to Meet Specific Criteria, All Other Indications or Uses (Investigational)]
5.01.629: PHARMACY / MEDICAL POLICY – 5.01.629 Pharmacologic Treatment of Psoriasis Treatments: [Abrilada (adalimumab-afzb) SC, Adalimumab-aacf (Idacio unbranded) SC, Adalimumab-aaty (Yuflyma unbranded) SC, Adalimumab-fkjp (Hulio unbranded) SC, Amjevita (adalimumab-atto) SC, Hadlima (adalimumab-bwwd) SC, Hulio (adalimumab-fkjp) SC, Humira (adalimumab) (AbbVie) SC, Humira (adalimumab) (Cordavis) SC, Hyrimoz (adalimumab-adaz) SC, Idacio (adalimumab-aacf) SC, Yuflyma (adalimumab-aaty) SC, Yusimry (adalimumab-aqvh) SC, Adalimumab-adaz (Hyrimoz unbranded) SC, Cyltezo (adalimumab-adbm) SC, Adalimumab-adbm (Cyltezo unbranded) SC, Simlandi (adalimumab-ryvk) SC, Adalimumab-ryvk (Simlandi unbranded) SC, Soriatane (acitretin) oral, Otezla (apremilast) oral, Enstilar (betamethasone and calcipotriene) topical foam, Taclonex (betamethasone and calcipotriene) topical, Wynzora (betamethasone and calcipotriene) topical cream, Bimzelx (bimekizumab-bkzx) SC, Siliq (brodalumab) SC, Brand calcipotriene foam topical, Dovonex (calcipotriene) topical cream, Sorilux (calcipotriene) topical foam, Vectical (calcitriol) topical ointment, Cimzia (certolizumab pegol) SC, Sotyktu (deucravacitinib) oral, Enbrel (etanercept) SC, Tremfya (guselkumab) SC, Duobrii (halobetasol and tazarotene) topical lotion, Avsola (infliximab-axxq) IV, Inflectra (infliximab-dyyb) IV, Infliximab (Janssen – unbranded) IV, Remicade (infliximab) IV, Renflexis (infliximab-abda) IV, Taltz (ixekizumab) SC, Skyrizi (risankizumab-rzaa) SC, Cosentyx (secukinumab) SC, Spevigo (spesolimab-sbzo) SC/IV, Vtama (tapinarof) topical cream, Ilumya (tildrakizumab-asmn) SC, Stelara (ustekinumab) SC, Zoryve (roflumilast) 0.3% topical cream]; Indications: [Plaque Psoriasis, Moderate to severe plaque psoriasis, Generalized Pustular Psoriasis (GPP), Generalized Pustular Psoriasis flare, Severe pustular, exfoliative or inflammatory psoriasis (emergent treatment), Site of Service Administration (for reviewed IV/Injectable drugs), Site of Service - Preferred Locations, Site of Service - Hospital Outpatient (Initial/Re-initiation), Site of Service - Hospital Outpatient (Geographic Exception), Site of Service - Hospital Outpatient (Clinical Risk Exception), Site of Service - Hospital Outpatient (Cytokine Release Syndrome), Site of Service - Hospital Outpatient (Not Medically Necessary), All other uses of listed drugs for approved conditions, Uses subject to FDA dosage/administration info, Combination uses or conditions not outlined in policy]
5.01.630: Intravenous Iron Replacement Products Treatments: [Any Intravenous Iron Replacement Product, Preferred Intravenous Iron Replacement Products, Ferumoxytol (Feraheme / Generic), Ferric Carboxymaltose (Injectafer), Ferric Derisomaltose (Monoferric)]; Indications: [Iron Deficiency Anemia (IDA), Chronic Kidney Disease (CKD), Non-Dialysis Dependent Chronic Kidney Disease, Chronic Heart Failure (CHF) NYHA Class II or III, Use in combination with other listed IV iron products, Use for conditions not FDA approved]
5.01.631: Pharmacologic Treatment of Clostridioides Difficile Treatments: [Rebyota (fecal microbiota, live-jslm) rectal suspension, Vowst (fecal microbiota spores, live-brpk) capsules, for oral administration, Zinplava (bezlotoxumab) IV]; Indications: [Clostridioides Difficile Infection (CDI), Two or more recurrent Clostridioides difficile infection (CDI) episodes, Clostridioides difficile infection (CDI) at high risk for recurrence, Positive stool test for toxigenic Clostridioides difficile within last 30 days, Current episode of CDI is controlled, Administration within 72 hours following completion of antibacterial treatment for CDI, Limited to a single treatment course/dose, Currently receiving standard of care antibacterial therapy for CDI, All other uses/conditions not explicitly outlined, Future re-authorization after initial course/dose]
5.01.632: Pharmacologic Treatment of Bladder Cancer Treatments: [Adstiladrin (nadofaragene firadenovec-vncg) Intravesical, Anktiva (nogapendekin alfa inbakicept-pmln) Intravesical]; Indications: [Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ (CIS), BCG-Unresponsive, Any Other Indication or Use]
5.01.633: Intraarticular Corticosteroids Treatments: [Zilretta (triamcinolone acetonide extended-release injectable suspension)]; Indications: [Moderate to Severe Osteoarthritis of Knee, Mild Osteoarthritis of Knee, Re-authorization following initial injection, Any other indication not specified]
5.01.634: Gene Therapies for Cerebral Adrenoleukodystrophy Treatments: [Skysona (elivaldogene autotemcel)]; Indications: [Childhood Cerebral Adrenoleukodystrophy (CALD) with Early, Active Disease, Eligible for Allogeneic HSCT but Unable to Receive Due to No Matched Sibling Donor, Prior Allogeneic HSCT Received, Prior Gene Therapy Received, Specific Age (4-17) and Sex (Male) Limits Apply, Prescribed by Hematologist or Neurologist, Limited to One-Time Infusion, Repeat Treatment with Skysona, All Other Uses Not Explicitly Addressed]
5.01.635: Pharmacologic Treatment of Epidermolysis Bullosa Treatments: [Filsuvez (birch triterpenes), Vyjuvek (beremagene geperpavec-svdt)]; Indications: [Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, Contraindication: Pregnancy, Contraindication: Squamous Cell Carcinoma in Wound, Concurrent Use of Filsuvez and Vyjuvek, Any Other Indication Not Specified]
5.01.636: Chronic Hepatitis B Antiviral Therapy Treatments: [Baraclude (entecavir) oral, Epivir-HBV (lamivudine) oral solution, Epivir-HBV (lamivudine) oral tablet, Pegasys (peginterferon alfa-2a) SC, Vemlidy (tenofovir alafenamide) oral, Viread (tenofovir disoproxil fumarate) oral, Any listed Hepatitis B Antiviral (Baraclude, Epivir-HBV, Pegasys, Vemlidy, Viread)]; Indications: [Chronic Hepatitis B Virus (HBV) Infection, HIV-1 Infection, HBV/HIV Coinfection and Receiving HAART, Inadequate Response or Intolerance to Generic Equivalent, Medical Necessity for Specific Formulation (e.g., Oral Solution), Uses Not Outlined in This Policy or Related HCV Policy]
5.01.637: Pharmacologic Treatment of Alopecia Treatments: [Leqselvi (deuruxolitinib) oral, Litfulo (ritlecitinib) oral, Olumiant (baricitinib) oral]; Indications: [Severe Alopecia Areata, Combination Use with Certain Immunosuppressants/JAK Inhibitors, Other/Unspecified Conditions]
5.01.638: Omisirge (omidubicel) Treatments: [Omisirge (omidubicel-onlv)]; Indications: [Hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning, Individual is aged 12 years or older, Candidate for myeloablative allogeneic HSCT, Prescribed by or in consultation with hematologist/oncologist, Availability of alternative HLA-matched/mismatched donor, History of prior allogeneic hematopoietic stem cell transplant, Other malignancy or significant immunodeficiency disorder, Active, uncontrolled Hepatitis C or B infection, Known sensitivity to Omisirge components, Repeat treatment, All other uses not outlined in policy]
5.01.640: Pharmacologic Treatment of Sickle Cell Disease Treatments: [Adakveo (crizanlizumab-tmca), Casgevy (exagamglogene autotemcel), Endari (L-glutamine), Lyfgenia (lovotibeglogene autotemcel), Various Intravenous and Injectable Drugs]; Indications: [Sickle Cell Disease (SCD), Contraindication: Moyamoya disease (Casgevy), Contraindication: Advanced liver disease (Casgevy), Contraindication: HIV, HBV, or HCV infection (Casgevy), Contraindication: Prior or current malignancy (Casgevy), Contraindication: Familial Cancer Syndrome (Casgevy), Contraindication: Immunodeficiency disorder (Casgevy), Contraindication: Prior gene therapy or allogeneic transplant (Casgevy), Contraindication: Hypersensitivity to conditioning agents (Casgevy), Contraindication: Low neutrophil or platelet count (Lyfgenia), Contraindication: Severe cerebral vasculopathy (Lyfgenia), Contraindication: Advanced liver disease (Lyfgenia), Contraindication: Chronic kidney disease (Lyfgenia), Contraindication: Low cardiac T2* (Lyfgenia), Contraindication: Pulmonary hypertension (Lyfgenia), Contraindication: Unable to receive red blood cell transfusions (Lyfgenia), Contraindication: HIV, HBV, or HCV infection (Lyfgenia), Contraindication: Prior or current malignancy (Lyfgenia), Contraindication: Familial Cancer Syndrome (Lyfgenia), Contraindication: Immunodeficiency disorder (Lyfgenia), Contraindication: Prior gene therapy or allogeneic transplant (Lyfgenia), Contraindication: Hypersensitivity to conditioning agents (Lyfgenia), Site of service criteria not met (Age 13+ only), Repeat treatment, Other indications not specified in policy]
5.01.641: Pharmacologic Treatment of Vitiligo Treatments: [Opzelura (ruxolitinib)]; Indications: [Nonsegmental Vitiligo, All Other Conditions or Uses Not Explicitly Outlined, Uses for Approved Conditions Not Meeting Medical Necessity Criteria]
5.01.642: Gene Therapies for Rare Diseases Treatments: [Kebilidi (eladocagene exuparvovec-tneq), Lenmeldy (atidarsagene autotemcel)]; Indications: [Aromatic L-amino acid decarboxylase (AADC) deficiency, Metachromatic Leukodystrophy (MLD), Neutralizing Antibodies to Adeno-Associated Virus Serotype 2 (AAV2), Previous Hematopoietic Stem Cell Transplant (HSCT), Previous Treatment with Any Gene Therapy, Repeat Treatment, All Other Uses/Conditions Not Listed]
5.01.643: Prescription Digital Therapeutics for Substance Use Disorders Treatments: [Prescription Digital Therapeutics]; Indications: [Substance use disorders (including Opioid Use Disorder), Adjunct to outpatient treatment]
5.01.644: Medical Pharmacologic Treatment of Multiple Sclerosis Treatments: [Any IV or Injectable MS Drug Listed in Policy, Lemtrada (alemtuzumab) IV, Tyruko (natalizumab-sztn) IV, Tysabri (natalizumab) IV, Briumvi (ublituximab-xiiy) IV, Ocrevus (ocrelizumab) IV, Ocrevus Zunovo (ocrelizumab-hyaluronidase-ocsq) SC]; Indications: [Multiple Sclerosis (Any Type), Relapsing Forms of Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Site of Service: Physician's Office, Site of Service: Infusion Center, Site of Service: Home Infusion, Site of Service: Hospital-Based Outpatient Setting (General), Site of Service: Hospital-Based Outpatient Clinical Level of Care, Concurrent use with other MS disease modifying drugs, All other uses of listed medications, Hospital-based Outpatient Site when Criteria Not Met, Any Indication or Use]
5.01.646: PHARMACY POLICY – SGLT2 Inhibitors Treatments: [Farxiga (dapagliflozin), Jardiance (empagliflozin), Synjardy (empagliflozin-metformin), Synjardy XR (empagliflozin-metformin extended-release), Xigduo XR (dapagliflozin-metformin extended-release), Brand bexagliflozin, Brenzavvy (bexagliflozin), Brand dapagliflozin-metformin, Invokana (canagliflozin), Invokamet (canagliflozin-metformin), Invokamet XR (canagliflozin-metformin extended-release), Steglatro (ertugliflozin), Segluromet (ertugliflozin-metformin), Brand dapagliflozin, Inpefa (sotagliflozin), Any SGLT2 inhibitor listed in this policy]; Indications: [Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD), Chronic Heart Failure (NYHA Class II to IV), Chronic Kidney Disease AND Type 2 Diabetes with Cardiovascular Risk Factors, Investigational: All other uses for conditions not listed in this policy, Not Medically Necessary: All other uses for approved conditions listed in this policy]
5.01.647: MEDICAL POLICY – 5.01.647 Medical Necessity Criteria for Custom Incentive and Open Formularies Treatments: [First-line TNF-alpha Inhibitors (Adalimumab Agents), Second-line TNF-alpha Inhibitors (Adalimumab Agents), Any Listed Adalimumab Agent]; Indications: [Ankylosing spondylitis, Crohn's disease, Hidradenitis suppurativa, Plaque psoriasis, Polyarticular juvenile idiopathic arthritis, Active psoriatic arthritis, Pyoderma gangrenosum, Moderate to severe rheumatoid arthritis, Sarcoidosis, Ulcerative colitis, Non-infectious intermediate, posterior, or panuveitis, Use for conditions not outlined in this policy, Use in combination with other listed agents, Uses for approved conditions that do not meet specific criteria]
5.01.648: Insulin Therapy Treatments: [Any Insulin Therapy, Rapid-Acting Insulin, Regular/Short-Acting Insulin, Intermediate-Acting NPH Insulin, Mix of Intermediate-Acting NPH and Regular Insulin, Mix of Intermediate Insulin Lispro Protamine + Rapid-Acting Insulin Lispro and Mix of Intermediate-Acting Insulin Aspart Protamine + Rapid-Acting Insulin Aspart, Long-Acting Insulin]; Indications: [Any Type of Diabetes (Type 1 or Type 2), Other Conditions (Not Type 1 or 2 Diabetes), Other Uses for Listed Conditions (Not Medically Necessary)]
5.01.649: Pharmacologic Treatment of Seizures Treatments: [Aptiom (eslicarbazepine), Banzel (rufinamide), Generic rufinamide, Briviact (brivaracetam), Diacomit (stiripentol), Epidiolex (cannabidiol), Fintepla (fenfluramine), Fycompa (perampanel), Libervant (diazepam), Motpoly XR (lacosamide extended-release), Generic oxcarbazepine extended-release, Oxtellar XR (oxcarbazepine extended-release), Qudexy XR (topiramate extended-release capsules), Brand topiramate extended-release capsules, Generic vigabatrin / Vigadrone / Vigpoder, Sabril (vigabatrin), Spritam (levetiracetam tablets for oral suspension), Sympazan (clobazam oral film), Trokendi XR (topiramate extended-release capsules), Vigafyde (vigabatrin), Vimpat (lacosamide), Xcopri (cenobamate), Zonisade (zonisamide oral suspension), Ztalmy (ganaxolone)]; Indications: [Partial-onset seizures, Seizures associated with Lennox-Gastaut syndrome, Seizures associated with Dravet syndrome, Seizures associated with tuberous sclerosis complex, Generalized tonic-clonic seizures, Acute treatment of intermittent episodes of frequent seizure activity, Myoclonic seizures, Infantile spasms, Refractory complex partial seizures (Adjunctive Therapy), Migraine prevention, Seizures associated with CDKL5 deficiency disorder (CDD), Any condition not explicitly listed as medically necessary]
5.01.651: Pharmacologic Treatment of Parkinson's Disease Treatments: [Generic apomorphine, Apokyn (apomorphine), Branded Carbidopa-Levodopa Combinations, Gocovri (amantadine), Inbrija (levodopa inhalation powder), Lodosyn (carbidopa), Nourianz (istradefylline), Ongentys (opicapone), Osmolex ER (amantadine), Stalevo (carbidopa-levodopa-entacapone), Vyalev (foscarbidopa and foslevodopa), Xadago (safinamide), Zelapar (selegiline), Any drug listed in this policy]; Indications: [Parkinson's disease, Parkinson's disease experiencing OFF episodes, Dyskinesia in Parkinson's disease, Motor fluctuations in advanced Parkinson's disease, Drug-induced extrapyramidal reactions, Use for conditions not listed in policy, Concomitant use with nonselective MAO inhibitor]
6.01.25: Minimally Invasive Approaches to Vertebral Fractures and Osteolytic Lesions of the Spine Treatments: [Percutaneous Vertebroplasty, Percutaneous Sacroplasty, Percutaneous Balloon Kyphoplasty or Mechanical Vertebral Augmentation (FDA-Cleared Device), Percutaneous Radiofrequency Kyphoplasty, Percutaneous Mechanical Vertebral Augmentation (Non-FDA-Cleared Device)]; Indications: [Symptomatic osteoporotic vertebral fractures failed conservative >= 6 weeks, Symptomatic osteoporotic vertebral fractures acute (< 6 weeks), severe, Severe pain due to osteolytic lesions of the spine (multiple myeloma/metastatic), Acute vertebral fractures (osteoporosis/trauma) not severe (not hospitalized/preventing ambulation), Sacral insufficiency fractures due to osteoporosis, Sacral lesions due to multiple myeloma or metastatic malignancies, Percutaneous Vertebroplasty: Any indication other than Medically Necessary, Percutaneous Sacroplasty: Any indication, Balloon Kyphoplasty / Mech Aug (FDA-Cleared): Any indication other than Medically Necessary, Percutaneous Radiofrequency Kyphoplasty (Any Device), Percutaneous Mechanical Vertebral Augmentation (Non-FDA-Cleared Device)]
6.01.46: Dynamic Spinal Visualization and Vertebral Motion Analysis Treatments: [Dynamic Spinal Visualization and Vertebral Motion Analysis (All Techniques/Systems)]; Indications: [Evaluation of Spinal Disorders including Neck and Back Pain]
6.01.521: Bone Mineral Density Studies Treatments: [Bone Mineral Density Measurement (Any Method), Dual X-ray Absorptiometry (DXA) - Central (Hip/Spine), Dual X-ray Absorptiometry (DXA) - Peripheral, Single Energy X-ray Absorptiometry (SEXA) - Peripheral, Ultrasound Densitometry - Peripheral, Quantitative Computed Tomography (QCT) - Central, Total Body Calcium Measurement, Photon Absorptiometry (Single/Dual), Radiographic Absorptiometry]; Indications: [Any Adult Individual, At Risk for Osteoporosis, Women Aged 65 and Older, Men Aged 70 and Older, Women Younger than 65 with Elevated Risk, Men Aged 50 to 70 with Elevated Risk, Pathologic Condition Associated with Bone Loss, Taking Medication Associated with Bone Loss, History of Fracture, Osteopenia or Fragility Fractures on Imaging, Pediatric (Skeletally Immature), Repeat: Previous Normal BMD, Not on Treatment, Repeat: Previous Osteopenia, Not on Treatment, Repeat: Monitoring Pharmacologic Treatment, Being Considered for Pharmacologic Therapy, Evidence of Bone Loss Would Lead to Treatment, Monitoring Following Treatment Cessation, Monitoring Prior To/During Bisphosphonate Holiday, Results Will Influence Treatment Decisions, Central DXA Not Feasible, Hyperparathyroidism]
6.01.525: Therapeutic Radiopharmaceuticals in Oncology Treatments: [Lutathera (lutetium 177 Lu 177 dotatate), Pluvicto (lutetium Lu 177 vipivotide tetraxetan), Xofigo (radium Ra 223 dichloride)]; Indications: [Low or intermediate grade (Ki-67 <= 20%) locally advanced or metastatic gastroenteropancreatic neuroendocrine tumor, Pheochromocytoma or paraganglioma, Metastatic castration-resistant prostate cancer, Castration-resistant prostate cancer with symptomatic bone metastases, Severe renal impairment (creatinine clearance < 40 mL/min), Known visceral metastatic disease (lung, liver, lymph node > 3cm), Lutathera treatment greater than 4 doses, Pluvicto treatment greater than 6 doses, Xofigo treatment greater than 6 doses, Any indication not explicitly addressed in this policy]
6.01.528: Whole-Body Dual X-Ray Absorptiometry and Bioelectrical Impedance Analysis to Determine Body Composition Treatments: [Whole-Body Dual Energy X-Ray Absorptiometry for Body Composition, Bioelectrical Impedance Analysis for Body Composition, Any Whole-Body Dual Energy X-Ray Absorptiometry or Bioelectrical Impedance Analysis for Body Composition]; Indications: [Any Indication for Body Composition Assessment, Contraindication: Pregnancy]
6.01.54: Dopamine Transporter Single-Photon Emission Computed Tomography Treatments: [Dopamine Transporter Imaging with SPECT]; Indications: [Clinically Uncertain Parkinson Disease, Clinically Uncertain Dementia with Lewy Bodies, All Other Indications Not Explicitly Covered, Diagnosis, Management, or Surveillance of Alzheimer Disease]
6.01.68: Irreversible Electroporation of Tumors Located in the Liver, Pancreas, Kidney, or Lung Treatments: [Irreversible Electroporation (IRE)]; Indications: [Primary or metastatic solid tumors in the liver, pancreas, kidney, or lung, Exclusion: Pulsed field ablation for Atrial Fibrillation, Exclusion: Irreversible Electroporation for Prostate Cancer]
7.01.07: Electrical Bone Growth Stimulation of the Appendicular Skeleton Treatments: [Noninvasive Electrical Bone Growth Stimulator, Invasive Electrical Bone Growth Stimulator, Semi-invasive Electrical Bone Growth Stimulator, Any Electrical Bone Growth Stimulator Type]; Indications: [Fracture Nonunion, Congenital Pseudoarthrosis, Delayed Union, Fresh Fracture, Stress Fracture, Immediate Postsurgical Treatment, Arthrodesis, Failed Arthrodesis, Any Indication or Condition Not Otherwise Specified]
7.01.104: Subtalar Arthroereisis Treatments: [Subtalar Arthroereisis]; Indications: [Any Indication, Excessive Subtalar Joint Mobility, Mobile Flatfoot, Adult Acquired Flatfoot Deformity (AAFD) Stage IIB, Excludes Subtalar Arthrodesis]
7.01.107: Interspinous and Interlaminar Stabilization/Distraction Devices (Spacers) Treatments: [Interspinous or Interlaminar Distraction Device, Interlaminar Stabilization Device]; Indications: [Spinal Stenosis, As a stand-alone procedure, Following or with decompression surgery, Spondylolisthesis Grade 2 or Higher, Scoliosis or Coronal Instability, Dynamic Instability, Iatrogenic Instability, Allergy to Titanium, Titanium Alloy, or MR Contrast, Ankylosed Segment at Affected Level, Spinal Fracture or Compromised Vertebral Body at Affected Level, Cauda Equina Syndrome, Severe Osteoporosis, Active or Chronic Infection, Prior Fusion or Decompression at Index Level, Morbid Obesity (BMI > 40), Severe Facet Hypertrophy, Isthmic Spondylolisthesis or Spondylolysis, Back or Leg Pain of Unknown Etiology, Axial Back Pain Only (No Leg/Buttock/Groin Pain)]
7.01.108: Artificial Intervertebral Disc: Cervical Spine Treatments: [Artificial Cervical Intervertebral Disc Implantation (Any Level or Type), Artificial Cervical Intervertebral Disc Implantation (Single Level), Artificial Cervical Intervertebral Disc Implantation (Two Contiguous Levels), Subsequent Artificial Cervical Intervertebral Disc Implantation (Adjacent Level)]; Indications: [Intractable Cervical Radicular Pain or Myelopathy due to Degenerative Disc Disease (C3-C7), All Other Indications for Cervical Disc Implantation, Active Infection, Anatomical Deformity, Combined simultaneously with Cervical Spinal Fusion at another level, Disc Implantation at more than 2 levels, Malignancy, Metabolic Bone Disease, Presence of Facet Arthritis, Previous Fusion at another Cervical level (Adjacent Segment), Prior Surgery at the Treated Level, Rheumatoid Arthritis or other Autoimmune Disease, Translational Instability, Not Skeletally Mature, Initial Cervical Artificial Disc Implantation Not Fully Healed (for subsequent procedure)]
7.01.109: Magnetic Resonance Imaging-Guided Focused Ultrasound Treatments: [Magnetic Resonance-Guided Focused Ultrasound Ablation]; Indications: [Pain Control in Adults with Bone Metastases Refractory to Radiotherapy, Medicine-Refractory Essential Tremors, Uterine Fibroids, Other Tumors, Medication-Refractory Tremor Dominant Parkinson's Disease, All Other Situations]
7.01.113: Bioengineered Skin and Soft Tissue Substitutes Treatments: [AlloDerm, AlloMend, Cortiva, DermACELL, DermaMatrix, FlexHD, FlexHD Pliable, GraftJacket Regenerative Tissue Matrix, AlloPatch, Apligraf, Dermagraft, Integra Omnigraft Dermal Regeneration Matrix, Integra Matrix Wound Dressing, mVasc, TheraSkin, Oasis Wound Matrix, OrCel, Epicel, Integra Dermal Regeneration Template, ReCell, Any Bioengineered Skin/Soft Tissue Substitute, Other Bioengineered Skin/Soft Tissue Substitutes (Investigational)]; Indications: [Breast Reconstruction, Diabetic Lower-Extremity Ulcers, Lower-Extremity Ulcers due to Venous Insufficiency, Dystrophic Epidermolysis Bullosa, Second- and Third-Degree Burns, Infection, Tendon Repair, Hernia Repair, Any Other Indication for Listed Products, Any Indication Not Otherwise Specified]
7.01.120: Facet Arthroplasty Treatments: [Total Facet Arthroplasty]; Indications: [Lumbar Spinal Stenosis, Facet Arthrosis, Spondylolisthesis]
7.01.125: Occipital Nerve Stimulation Treatments: [Occipital Nerve Stimulation]; Indications: [All Indications, Refractory Migraine, Hemicrania Continua, Cluster Headache]
7.01.126: Image-Guided Minimally Invasive Decompression for Spinal Stenosis Treatments: [Image-Guided Minimally Invasive Spinal Decompression, Open/Conventional Spinal Decompression Surgery, Less Invasive Surgical Spinal Decompression (Open/Microendoscopic), Epidural Steroid Injection]; Indications: [Any Spinal Stenosis Type, Excludes Nerve Root Compression, Disc Herniation, or Lateral Elements]
7.01.128: Bronchial Valves Treatments: [Bronchial Valves]; Indications: [Prolonged Air Leak, Severe Emphysema with Hyperinflation, Any Situation or Indication]
7.01.130: Axial Lumbosacral Interbody Fusion Treatments: [Axial Lumbosacral Interbody Fusion]; Indications: [Any Relevant Indication, Contraindication: Severe Scoliosis, Contraindication: Severe Spondylolisthesis (Grades 3 and 4), Contraindication: Tumor, Contraindication: Trauma, Contraindication: Vertebral Compression Fractures]
7.01.131: Transcatheter Pulmonary Valve Implantation Treatments: [Transcatheter Pulmonary Valve Implantation]; Indications: [RVOT Conduit with Moderate or Greater Pulmonic Regurgitation, Native or Patched RVOT with Moderate or Greater Pulmonic Regurgitation, RVOT Conduit with Pulmonic Stenosis (Gradient >= 35 mmHg), Native or Patched RVOT with Pulmonic Stenosis (Gradient >= 35 mmHg), All Other Indications]
7.01.132: Transcatheter Aortic-Valve Implantation for Aortic Stenosis Treatments: [Transcatheter Aortic Valve Replacement (TAVR), Cerebral Embolic Protection Device]; Indications: [Severe Symptomatic Native Valve Aortic Stenosis Meeting MN Criteria (NYHA Class II-IV, no Uni/Bi-cuspid Valve), Failed Surgical Bioprosthetic Aortic Valve (ViV) Meeting MN Criteria (Symptomatic NYHA II-IV & High/Prohibitive/Increased Surgical Risk), Contraindication: Unicuspid or Bicuspid Native Aortic Valve, Use During TAVR Procedure, Any Other Indication Not Specifically Listed as Medically Necessary, Patient Does Not Meet All Specified Medical Necessity Criteria for Listed Indications]
7.01.133: Microwave Tumor Ablation Treatments: [Microwave Ablation (MWA)]; Indications: [Primary or Metastatic Hepatic Tumors, Primary or Metastatic Lung Tumors, Lung Tumors: More than one single tumor, Primary or Metastatic Tumors (other than Liver or Lung), Contraindication: Pregnancy, Contraindication: Implanted Electronic Devices, Excludes Splenomegaly, Excludes Ulcers, Excludes Cardiac Applications, Excludes Use as Surgical Coagulation Tool]
7.01.134: Steroid-Eluting Sinus Stents and Implants Treatments: [Steroid-Eluting Sinus Stents and Implants]; Indications: [Postoperative treatment following endoscopic sinus surgery (ESS), Recurrent Sinonasal Polyposis, All other conditions (catch-all investigational rule)]
7.01.137: Magnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux Disease Treatments: [Magnetic Esophageal Sphincter Augmentation]; Indications: [Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease refractory to medical management, Concurrent use with primary bariatric surgery, Unrepaired Hiatal Hernia greater than 3cm]
7.01.139: Peripheral Subcutaneous Field Stimulation Treatments: [Peripheral Subcutaneous Field Stimulation]; Indications: [Chronic Pain (General), Craniofacial Pain, Headache, and Migraine, Trunk and Back Pain, Postherpetic Neuralgia, Lower Extremity Pain, Fibromyalgia, Complex Regional Pain Syndrome (CRPS)]
7.01.142: Surgery for Groin Pain in Athletes Treatments: [Surgery for Groin Pain in Athletes]; Indications: [Sports-related Groin Pain in Athletes (Athletic Pubalgia)]
7.01.143: Responsive Neurostimulation for the Treatment of Refractory Focal Epilepsy Treatments: [Responsive Neurostimulation System]; Indications: [Refractory Focal Epilepsy Meeting Criteria, Three or More Seizure Foci, Primary Generalized Epilepsy, Rapidly Progressive Neurologic Disorder, Any Other Indication Not Explicitly Listed as Medically Necessary]
7.01.144: Patient-Specific Instrumentation (e.g., Cutting Guides) for Joint Arthroplasty Treatments: [Patient-Specific Instrumentation (e.g., Cutting Guides)]; Indications: [Use in Joint Arthroplasty]
7.01.147: Minimally Invasive Ablation Procedures for Morton and Other Peripheral Neuromas Treatments: [Minimally Invasive Ablation Procedures, Intralesional Alcohol Injection, Radiofrequency Ablation, Cryoablation]; Indications: [Morton Neuroma, Other Peripheral Neuromas (Excluding Morton Neuroma)]
7.01.153: Adipose-Derived Stem Cells in Autologous Fat Grafting to the Breast Treatments: [Adipose-Derived Stem Cells in Autologous Fat Grafting to the Breast]; Indications: [Use in Autologous Fat Grafting to the Breast (for Reconstruction), Exclusion: Aesthetic Breast Augmentation (Cosmetic)]
7.01.158: Balloon Dilation of the Eustachian Tube Treatments: [Balloon Dilation of the Eustachian Tube]; Indications: [Chronic Obstructive Eustachian Tube Dysfunction (ETD), Patulous Eustachian Tube Dysfunction (ETD), Extrinsic or Systemic Causes of ETD, Aural Fullness with Normal Exam and Tympanogram, Chronic and Severe Atelectatic Ears, Not Meeting Medically Necessary Criteria for BDET, Concurrent with Sinus Ostial Dilation]
7.01.159: Sphenopalatine Ganglion Block for Headache Treatments: [Sphenopalatine Ganglion Block (Topical Anesthesia)]; Indications: [Any Headache Indication, Migraine, Non-Migraine Headache, Severe Acute Headache, Tension-Type Headache, Cluster Headache, Postdural Puncture Headache]
7.01.15: Meniscal Allografts and Other Meniscal Implants Treatments: [Meniscal Allograft Transplantation, Other Meniscal Implants (e.g., Collagen, Synthetic)]; Indications: [Symptomatic after prior meniscectomy, In combination with treatment of focal articular cartilage lesions, Uncorrected misalignment or instability, Asymptomatic meniscus deficiency, Use of CMI in Medicare population, Any indication or context]
7.01.160: Synthetic Cartilage Implants for Joint Pain Treatments: [Synthetic Cartilage Implants]; Indications: [Articular Cartilage Damage, Arthritis of the First Metatarsophalangeal (MTP) Joint, Articular Cartilage Damage in Joints Other Than the First MTP Joint, Contraindication: Lesion Size > 10 mm or Insufficient Bone]
7.01.163: Absorbable Nasal Implant for Treatment of Nasal Valve Collapse Treatments: [Absorbable Lateral Nasal Implant]; Indications: [Symptomatic Nasal Valve Collapse]
7.01.165: Radiofrequency Coblation Tenotomy for Musculoskeletal Conditions Treatments: [Radiofrequency Coblation Tenotomy]; Indications: [Achilles tendinopathy, Lateral epicondylitis, Patellar tendinopathy, Plantar fasciitis, Shoulder or rotator cuff tendinopathy, Wrist tendinopathy, Any musculoskeletal condition (not specifically listed), Low back pain (as thermal intradiscal procedure, per CMS NCD)]
7.01.168: Cryoablation, Radiofrequency Ablation, and Laser Ablation for Treatment of Chronic Rhinitis Treatments: [Cryoablation, Radiofrequency Ablation, Laser Ablation]; Indications: [Chronic Rhinitis]
7.01.170: Laser Interstitial Thermal Therapy for Neurological Conditions Treatments: [Laser Interstitial Thermal Therapy (LITT) with MRI Guidance]; Indications: [Primary or Metastatic Brain Tumors, Symptomatic Cranial Radiation Necrosis, Drug-Resistant Epilepsy, Contraindication: MRI Contraindicated]
7.01.171: Remote Electrical Neuromodulation for Migraines Treatments: [Remote Electrical Neuromodulation]; Indications: [Acute Migraine Treatment, Migraine Prevention]
7.01.172: Surgical Left Atrial Appendage Occlusion Devices for Stroke Prevention in Atrial Fibrillation Treatments: [Surgical Left Atrial Appendage Occlusion Device]; Indications: [Atrial Fibrillation (AF) for Stroke Prevention, Use during concomitant open or thoracoscopic cardiac procedures, Use as a stand-alone procedure]
7.01.174: Stationary Ultrasonic Diathermy Devices Treatments: [Stationary Ultrasonic Diathermy Devices]; Indications: [Musculoskeletal Pain, Implanted Medical Device, Healing Fracture (Treatment Area), Malignancy (Treatment Area), Pregnancy]
7.01.175: Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia Treatments: [Temporarily Implanted Nitinol Device (iTind)]; Indications: [Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)]
7.01.18: Automated Percutaneous and Percutaneous Endoscopic Discectomy Treatments: [Automated Percutaneous Discectomy, Percutaneous Endoscopic Discectomy, Any Automated Percutaneous or Percutaneous Endoscopic Discectomy]; Indications: [Back Pain and/or Radiculopathy Related to Disc Herniation]
7.01.48: Autologous Chondrocyte Implantation for Focal Articular Cartilage Lesions Treatments: [Autologous Chondrocyte Implantation (ACI)]; Indications: [Knee: All Medical Necessity Criteria Met, Joints other than the knee (e.g., talar/ankle), Other unspecified indications (not meeting knee criteria), Joint instability or misalignment (Contraindication)]
7.01.503: Breast Reduction (Mammaplasty) Treatments: [Reduction Mammaplasty (Breast Reduction)]; Indications: [Macromastia with Symptomatic Physical Functional Impairment, Cosmetic Breast Reduction, Outpatient Site of Service (ASC, Off-Campus, On-Campus), Inpatient Site of Service (Clinical Risk Criteria Met), Inpatient Site of Service (Clinical Risk Criteria Not Met)]
7.01.508: Blepharoplasty, Blepharoptosis and Brow Ptosis Surgery Treatments: [Upper Eyelid Blepharoplasty, Blepharoptosis Repair, Brow Lift, Lower Eyelid Blepharoplasty, Any Eyelid or Brow Surgery]; Indications: [Functional Visual Impairment / Obstruction of Central Vision, Upper Eyelid Excess Skin (Dermatochalasis, Blepharochalasis), Upper Eyelid Ptosis (Blepharoptosis), Brow Ptosis, Children Age 9 or Younger, Obstruction of Vision Causing Occlusion Amblyopia, Cosmetic Improvement Only, Lower Eyelid Ectropion, Entropion, or Trichiasis, Lower Eyelid Excess Tissue Removal for Appearance Only, Bilateral Surgery When Only One Eye Meets Criteria]
7.01.516: Bariatric Surgery Treatments: [Any Covered Bariatric Surgery Procedure, Biliopancreatic Bypass/Diversion with Duodenal Switch, Gastric Bypass with Short-Limb Roux-en-Y, Laparoscopic Adjustable Gastric Banding, Sleeve Gastrectomy, Revision Bariatric Surgery, Reoperation for Inadequate Weight Loss (without technical failure), Routine Cholecystectomy at time of Bariatric Surgery, Hiatal Hernia Repair at time of Bariatric Surgery, Routine Liver Biopsy at time of Bariatric Surgery, Vertical-Banded Gastroplasty, Biliopancreatic Diversion/Bypass without Duodenal Switch, Gastric Bypass using Billroth II (Mini-Gastric Bypass), Laparoscopic Gastric Plication, Long-Limb Gastric Bypass (>150 cm), Single Anastomosis Duodenoileal Bypass with Sleeve Gastrectomy (SADI-S), Two-Stage Bariatric Surgery Procedures, Vagus Nerve Blocking, Any Endoscopic Bariatric Procedure (General), Endoscopic Sleeve Gastroplasty, Endoscopic Closure Device Insertion (e.g., StomaphyX), Intragastric Balloons, Natural Orifice Transluminal Endoscopic Surgery (NOTES) Bariatric, Restorative Obesity Surgery, Endoluminal (ROSE), Stomach Aspiration Therapy (AspireAssist), Transoral Outlet Reduction Endoscopy (TORe), Endoscopically Placed Duodenal-Jejunal Sleeve (EndoBarrier), Open Adjustable Gastric Banding, Laparoscopic Vertical Banded Gastroplasty]; Indications: [Adult with Class III Obesity Meeting MN Criteria, Adult with Class II Obesity and 1+ Comorbidity Meeting MN Criteria, Adult with Class I Obesity and Uncontrolled T2D Meeting MN Criteria, Adolescent with Class III Obesity Meeting MN Criteria, Adolescent with Class II Obesity and 1+ Comorbidity Meeting MN Criteria, Perioperative or Late Complication from Primary Bariatric Procedure, Non-absorption Resulting in Hypoglycemia or Malnutrition (complication), Revision for Pouch Dilation (initial success, compliant), Reoperation for Inadequate Weight Loss (specific criteria met), Routine Cholecystectomy Performed at time of Bariatric Surgery, Hiatal Hernia with Preoperative Diagnosis and Clinical Indications (at time of bariatric surgery), Symptomatic GERD After Sleeve Gastrectomy (meeting criteria), Class III Obesity, BMI less than 35 kg/m² without Type 2 Diabetes, BMI less than 30 kg/m², GERD as Primary Condition Without Meeting Obesity Criteria, Gastroparesis as Primary Condition Without Meeting Obesity Criteria, Individuals less than 18 years of age, Individuals over 65 years of age, Preadolescent Children (under 12 years of age), Performed at the time of bariatric surgery, Contract Limitation: No Benefit for Obesity Surgery, Adolescent (<18) AND contract does not allow, Adolescent (<18) AND facility lacks experienced staff, Contraindicating Mental Health Disorder, Inability to Provide Informed Consent, Inability to Comply with Requirements, Seizure disorder or history (unstable/uncontrolled), Medically Correctable Cause of Obesity, Untreated or Poorly Controlled Substance Abuse, Concurrent or Planned Pregnancy (within 2 yrs), Current Eating Disorder, Use of Device Not FDA Approved for Purpose/Indications, Hiatal Hernia Without Preoperative Diagnosis/Indications (incidental), Routine Liver Biopsy Without Preoperative Signs/Symptoms]
7.01.519: Treatment of Varicose Veins/Venous Insufficiency Treatments: [Endovenous Thermal Ablation (Radiofrequency or Laser), Endovenous Chemical Ablation (Microfoam Sclerotherapy, Varithena), Cyanoacrylate Adhesive Ablation (VenaSeal), Sclerotherapy (General, Liquid or Compounded Foam), Sclerotherapy (Telangiectasia/Spider Veins), Endovenous Cryoablation, Mechanochemical Ablation (MOCA, ClariVein)]; Indications: [Symptomatic Saphenous Veins/Venous Insufficiency Meeting Medical Necessity Criteria, Symptomatic Saphenous Veins/Venous Insufficiency Not Meeting Medical Necessity Criteria, Tributary Veins, Tributary Veins Treated Concurrently or Staged with Saphenous Vein Treatment, Tributary Veins Treated Staged After Saphenous Vein Treatment AND Failed 3+ Months Compression Therapy, Great, Small, or Accessory Saphenous Veins as Indication for Sclerotherapy, Isolated Tributary Veins (without prior or concurrent saphenous treatment) as Indication for Sclerotherapy, Perforator Veins as Indication for Sclerotherapy, Small Telangiectasia (<1mm), Superficial Reticular Veins (1-2mm), Angiomata, Hemangiomata, Any Indication/Condition/Rule Not Otherwise Specified]
7.01.521: Mastectomy for Gynecomastia Treatments: [Mastectomy (Surgical Excision), Liposuction]; Indications: [Malignant (cancer) indications for mastectomy, Non-malignant (not cancer) gynecomastia, Absence of a functional impairment (considered cosmetic), Any Gynecomastia]
7.01.522: Gastric Electrical Stimulation Treatments: [Gastric Electrical Stimulation (Implantable Device)]; Indications: [Gastroparesis (Diabetic or Idiopathic Etiology), Obesity, All Other Indications Not Explicitly Addressed]
7.01.523: Panniculectomy and Excision of Redundant Skin Treatments: [Panniculectomy, Abdominoplasty, Excision of Redundant Skin (Other Areas), Diastasis Recti Treatment]; Indications: [Physical Functional Impairment due to Panniculus, Cosmetic Purposes Only / Absence of Physical Functional Impairment Addressed by Surgery, Diastasis Recti]
7.01.533: Reconstructive Breast Surgery/Management of Breast Implants Treatments: [Any Reconstructive Breast Surgery Technique, Autologous Flap Reconstruction, Autologous Fat Grafting (Reconstruction), Breast Implant Insertion (Reconstruction), Nipple/Areola Reconstruction or Tattooing, Revision of Reconstructed Breast, Reduction Mammaplasty, Mastopexy, Breast Augmentation with Implant (General), Breast Implant Explantation (Removal)]; Indications: [Need for Breast Reconstruction (General), Prior Mastectomy/Partial Mastectomy for Disease, Prior Mastectomy/Partial Mastectomy for Injury/Trauma, Prior Prophylactic Mastectomy, Achieve Symmetry with Contralateral Breast, Original Implant Placed for Reconstructive Purposes, Baker Class III or IV Contracture, Documented Rupture (Reconstructive Implant), Extrusion (Implant-related), Infection (Implant-related), Malignancy Involving Breast/Implant, Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), Original Implant Placed for Cosmetic Purposes, Interval Malignancy/Disease after Cosmetic Implant (Requires Mastectomy/Partial Mastectomy), No Interval Malignancy/Disease after Cosmetic Implant, Pain without Rupture/Contracture (Implant-related), Patient Anxiety (Implant-related), Baker Class III Contracture (Cosmetic Implant), Saline Rupture (Cosmetic Implant), Systemic Symptoms (Unproven Link to Implants), Prophylactic Explantation for BIA-ALCL Risk, Prophylactic Explantation for B cell Lymphoma Risk, Inpatient Site of Service Criteria Met, Inpatient Site of Service Criteria Not Met, Cosmetic Surgery (General Exclusion)]
7.01.542: Lumbar Spinal Fusion in Adults Treatments: [Lumbar Spinal Fusion (Any Approach/Type), Single-Level Lumbar Fusion, Multiple-Level Lumbar Fusion, Lumbar Fusion Revision for Implant/Instrumentation Failure, Lumbar Fusion for Pseudarthrosis]; Indications: [Any Indication Not Specifically Listed, Spinal Stenosis, Severe Degenerative Scoliosis (Adults), Spondylolisthesis (except Isthmic), Isthmic Spondylolisthesis, Recurrent, Same Level, Disc Herniation, Pseudarthrosis (Following Spinal Fusion), Implant/Instrumentation Failure (Following Spinal Fusion), Instability (Due to Fracture, Dislocation, Infection, Abscess, Tumor), Iatrogenic or Degenerative Flatback Syndrome, Adjacent Level Disease After Prior Fusion, Chronic Nonspecific Low Back Pain Without Radiculopathy, Degenerative Disc Disease, Disc Herniation (Initial), Facet Syndrome, Initial Discectomy/Laminectomy for Neural Structure Decompression, Smoking within 6 Weeks Prior to Scheduled Surgery]
7.01.546: Spinal Cord and Dorsal Root Ganglion Stimulation Treatments: [Spinal Cord Stimulation (Any Type), Standard/Conventional Spinal Cord Stimulation, High-Frequency Spinal Cord Stimulation, Dorsal Root Ganglion Stimulation (Any Type)]; Indications: [Failed Back Surgery Syndrome, Complex Regional Pain Syndrome (Any Type), Arachnoiditis, Phantom Limb/Stump Pain, Peripheral Neuropathy, Chronic Post-Surgical Pain, Groin Pain, Lumbar Spinal Stenosis, Non-Surgical Low Back Pain, Central Deafferentation Pain, Nociceptive Pain, Critical Limb Ischemia, Refractory Angina Pectoris, Chronic Pelvic Pain, Cancer-Related Pain, Heart Failure, Chronic Pain of Ischemic Origin, Replacement due to Device Failure or Changed Patient Need, Replacement of Functioning Standard SCS with High-Frequency SCS]
7.01.547: Implantable Bone-Conduction and Bone-Anchored Hearing Aids Treatments: [Implantable Bone-Conduction/Bone-Anchored Hearing Aid (Percutaneous or Magnetic), Non-Implanted Transcutaneous Bone-Conduction Hearing Aid (Headband/Softband Use), ADHEAR Non-Invasive Bone Conduction Hearing Device, Any Bone Conduction or Bone-Anchored Hearing Aid Component]; Indications: [Unilateral Conductive or Mixed Hearing Loss, Bilateral Conductive or Mixed Hearing Loss, Single-Sided Sensorineural Deafness and Normal Hearing in the Other Ear, Bilateral Sensorineural Hearing Loss, Unilateral or Bilateral Conductive Hearing Loss (ADHEAR Criteria), Replacement Parts and Upgrades, Other Uses Not Explicitly Listed as Medically Necessary]
7.01.548: Hysterectomy for Non-Malignant Conditions Treatments: [Hysterectomy (Any Approach, with or without Salpingo-oophorectomy), Hysterectomy (Reviewed only for Medical Necessity), Hysterectomy (Reviewed for Medical Necessity and Site of Service)]; Indications: [Non-Malignant Gynecological Conditions (General Scope), Abnormal Uterine Bleeding (Premenopausal), Abnormal Uterine Bleeding (Postmenopausal), Adenomyosis, Chronic Pelvic Inflammatory Disease (PID), Endometriosis, Genetic Predisposition to Gynecologic Cancer (Prophylactic Hysterectomy/Salpingo-oophorectomy), Chronic Pelvic Pain, Symptomatic Pelvic Organ Prolapse (Stage II or greater), Symptomatic Uterine Fibroids (Leiomyomata), Medical Necessity Criteria Not Met, Site of Service: Medically Necessary Outpatient Settings, Site of Service: Medically Necessary Inpatient Setting (Due to Specific Risk Factors), Site of Service: Inpatient Setting (Risk Factors Not Met)]
7.01.549: Knee Arthroscopy in Adults Treatments: [Any Knee Arthroscopy Procedure, Arthroscopic Partial Meniscectomy, Arthroscopic Meniscus Repair, Arthroscopic ACL Repair or Reconstruction, Arthroscopic PCL Repair or Reconstruction, Arthroscopic Debridement, Drainage, or Lavage, Arthroscopic Loose Body or Foreign Body Removal, Arthroscopic Osteochondral Defect Repair (Technique Dependent), Arthroscopic Lateral Retinacular Release, Arthroscopic Synovectomy, Arthroscopic Popliteal (Baker) Cyst Excision, Arthroscopic Lysis of Adhesions, Diagnostic Knee Arthroscopy]; Indications: [Meniscal Tear, ACL Tear, PCL Tear, Rheumatoid Arthritis, Septic Joint, Osteomyelitis, Septic Prosthetic Joint, Postoperative Arthrofibrosis, Intra-articular Joint Pathology (Unknown Etiology), Mechanical Symptoms with Loose Body or Foreign Body, Osteochondral Defect, Chondromalacia Patellae (Patellar Compression Syndrome), Symptomatic Popliteal (Baker) Cyst, Hemophilic Joint Disease, Localized Pigmented Villonodular Synovitis, Other Chronic Inflammatory Conditions, Osteoarthritis of the Knee, Severe Osteoarthritis (Outerbridge Grades III/IV), Degenerative Meniscal Tear without Mechanical Symptoms, Outpatient or ASC Site of Service, Inpatient Hospital Site (Criteria Met), Inpatient Hospital Site (Criteria NOT Met)]
7.01.550: Knee Arthroplasty in Adults Treatments: [Total Knee Arthroplasty, Unicompartmental Knee Arthroplasty, Knee Arthroplasty Replacement/Revision, Patellofemoral Knee Arthroplasty]; Indications: [Degenerative Joint Disease (DJD), Osteoarthritis (OA), Rheumatoid Arthritis (RA), Traumatic Arthritis, Osteonecrosis, Distal Femur Fracture Repair in Individual with Osteoporosis, Failure of Previous Proximal Tibial or Distal Femoral Osteotomy, Hemophilic Arthroplasty, Limb Salvage for Malignancy, Reason for Knee Arthroplasty Revision/Replacement, Exclusion: Patellofemoral Knee Arthroplasty]
7.01.551: Lumbar Spine Decompression Surgery: Discectomy, Foraminotomy, Laminotomy, Laminectomy in Adults Treatments: [Lumbar Discectomy, Foraminotomy, or Laminotomy, Lumbar Laminectomy, Any Lumbar Spine Decompression Surgery]; Indications: [Rapid Progression of Neurologic Impairment, Lumbar Disc Herniation (Non-Emergent), Spinal Stenosis (Non-Emergent), Surgery Site: Ambulatory Surgery Center, On-Campus Outpatient, Off-Campus Outpatient, Surgery Site: Inpatient Hospital (Inpatient Risk Criteria Met), Surgery Site: Inpatient Hospital (Inpatient Risk Criteria Not Met), Patient Age Under 19]
7.01.554: Surgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome Treatments: [Uvulopalatopharyngoplasty (UPPP), Palatopharyngoplasty (General), Hyoid suspension, Surgical modification of the tongue (General), Maxillofacial surgery, Adenotonsillectomy, Hypoglossal nerve stimulation (HNS), Laser-assisted uvulopalatoplasty (LAUP), Palatal stiffening procedures, Radiofrequency volumetric tissue reduction of the palate, Radiofrequency volumetric tissue reduction of the tongue, Tongue base suspension (Minimally Invasive), Endoscopically assisted nasomaxillary expansion, Other minimally invasive surgical procedures for OSA or UARS]; Indications: [Obstructive Sleep Apnea Syndrome (OSA), Snoring in the absence of documented OSA, Upper Airway Resistance Syndrome (UARS), Obstructive Sleep Apnea in Pediatric Individuals with Down Syndrome, Other indications for Hypoglossal Nerve Stimulation (HNS), Complete concentric collapse at the soft palate level, Does not meet specific Medical Necessity criteria for this procedure/indication, No adequate CPAP trial or intolerance]
7.01.555: Facet Joint Denervation Treatments: [Non-Pulsed Radiofrequency Denervation, Other Facet Denervation Methods, Diagnostic Medial Branch Block, Therapeutic Medial Branch Block]; Indications: [Chronic Facet Joint Pain, Contraindication: Prior Spinal Fusion at Treatment Level, Failed 3+ months of Conservative Management, Successful Trial of Controlled Medial Branch Blocks, Repeat RF Denervation Procedure, Diagnostic MBB after prior successful RF Denervation, Any other Indication or Scenario]
7.01.557: Gender Transition/Affirmation Surgery and Related Services Treatments: [Mastectomy or Breast Reduction (Female to Male/Non-binary), Initial Augmentation Mammoplasty (Male to Female), Additional Breast Augmentation (after initial), Genital Surgery (Male to Female/Non-binary), Genital Surgery (Female to Male), Other Gender Transition/Affirmation Surgery (Facial, Body, etc.), Hair Transplantation/Grafting, Hair Removal (Laser or Electrolysis), Medical Tattooing, Fertility Preservation Procedures, Surgery to Correct/Repair Complications, Revise/Redo due to Complications, Revision Surgery (Appearance Dissatisfaction, No Pain/Impairment), Correction of Incomplete or Incorrect Surgery (Not due to Complications), Reversal of Gender Transition/Affirmation Surgery, Uterine Transplantation, Penile Transplantation, Voice Therapy, Hormone Therapy, Counseling/Psychotherapy and Psychiatric Medication Treatment, Any Gender Transition/Affirmation Service]; Indications: [Gender Dysphoria, Female to Male Patient, Male to Female Patient, Non-binary or Gender Neutral Patient, Any Gender Transition/Affirmation Related Context, Hair Removal Location: Facial, Body, or Extremity (Not Genital), Goal: Feminization or Non-binary Transition, Goal: Masculinization, Reason for Revision: Appearance Dissatisfaction without Pain/Functional Impairment, Type of Surgery: Breast/Chest or Genital, Type of Surgery: Non-breast/chest, Non-genital, or Additional Breast Augmentation, Any Indication or Rule Context, Age 18 years or older, Mental Health Recommendation Criteria Met, Not For Reasons Unrelated to Transition, Criteria Met for Hair Removal Prior to Genital Surgery, Criteria Met for Facial/Body/Extremity Hair Removal (Feminization/Non-binary), Criteria Met for Medical Tattooing, Significant Deformity Not Part of Normal Anatomy (allowing revision MN), Original Surgery Would Have Been Covered If On Plan, Complication Causes Pain, Functional Impairment, or Serious Condition, Serious Medical Barrier to Completion or Serious Medical Condition Necessitating Reversal, Complication is Causing or Likely to Cause a Medical or Surgical Emergency, Member Plan Includes Assisted Reproduction Benefit, Site of Service for Elective Surgical Procedures, Inpatient Site of Service Criteria Met, Inpatient Site of Service Criteria Not Met]
7.01.558: Rhinoplasty and Other Nasal Procedures Treatments: [Rhinoplasty, Radiofrequency ablation treatment for nasal airway remodeling (VivAer), Nasal swell body reduction, Elective Surgical Procedure]; Indications: [Nasal deformity secondary to cleft lip or cleft palate or other congenital craniofacial deformity, Nasal deformity secondary to trauma that is causing a significant functional impairment (e.g., nasal airway obstruction), Clinical findings of collapsed internal or external nasal valve (nasal vestibular stenosis), Nasal Obstruction, To prevent development of nasal obstruction after removal of large cutaneous defect, For the sole purpose of changing the appearance of the nose (Cosmetic), Site of Service: Outpatient Hospital/Medical Center or Ambulatory Surgical Center, Site of Service: Inpatient Hospital/Medical Center without specific increased risk factors, Site of Service: Inpatient Hospital/Medical Center with specific increased risk factors]
7.01.559: Sinus Surgery in Adults Treatments: [Functional Endoscopic Sinus Surgery (FESS), Balloon Sinus Ostial Dilation (BOD), Any Sinus Surgery or Procedure in Policy]; Indications: [Recurrent acute bacterial rhinosinusitis, Chronic rhinosinusitis with or without polyposis, Revision surgery for chronic rhinosinusitis, Multiple nasal polyps, Cerebrospinal fluid (CSF) leak closure, Choanal atresia repair, Dacryocystorhinostomy (DCR), Epistaxis control, Excision of selected tumors and nasal masses, Foreign body removal, Optic nerve decompression, Orbital decompression, Recurrent sinusitis in people who have cystic fibrosis or severe asthma, Silent sinus syndrome, Sinus disease has eroded into the bone, Sinus disease in the immune compromised, Sinus disease for invasive fungal disease, Sinus disease for allergic fungal sinus disease, Sinus disease related to Wegener's granulomatosis, Sinus disease related to hereditary hemorrhagic telangiectasia, Sinus disease related to scarring or osteoneogenetic changes, Inpatient Site of Service, Outpatient Site of Service, Criteria for increased risk met for inpatient site, Adult patients only (age 19+), Absence of sinonasal symptoms and positive findings on CT/Endoscopy, Headache alone (without CRS/RARS criteria), Sleep apnea alone (without CRS/RARS criteria), Any applicable indication]
7.01.560: Cervical Spine Surgeries: Discectomy, Laminectomy, and Fusion in Adults Treatments: [Anterior Cervical Fusion, Posterior Cervical Fusion, Cervical Discectomy (with or without Fusion), Cervical Laminectomy, Any Cervical Spinal Fusion, Any Covered Elective Cervical Spine Surgery]; Indications: [Degenerative cervical spondylosis with kyphosis causing cord compression, Infection of cervical spine, Ossification of posterior longitudinal ligament (OPLL) associated with myelopathy, Posttraumatic cervical instability, Spine fracture and/or dislocation with instability, Tumor of cervical spine, Cervical radiculopathy, Spondylotic myelopathy, Cervical pseudarthrosis (failed union), Degenerative spinal segment adjacent to prior surgery, Cervical spine injury with acute radiculopathy/myelopathy, Revision surgery for implant/instrumentation failure, Atlas and axis fractures, Bilateral locked facets, Cervical instability in individual with Down syndrome, Cervical instability in skeletal dysplasia or connective tissue disorders, Disruption of posterior ligamentous structures, Facet fractures with dislocation, Klippel-Feil syndrome, Ossification of posterior longitudinal ligament (OPLL) without kyphosis with associated myelopathy, Part of stabilization procedure at cervicothoracic junction (C7-T1), Part of stabilization procedure with laminectomy at C2, Subluxation and cord compression in rheumatoid arthritis, Multilevel spondylotic myelopathy without kyphosis, Symptomatic unstable cervical spondylosis, Cervical herniated disc, Spinal stenosis, Other causes of spinal cord or nerve root compression, Smoking within 6 weeks prior to surgery, Site of Service: Preferred Outpatient Location, Site of Service: Inpatient (Increased risk criteria met), Site of Service: Inpatient (Increased risk criteria not met)]
7.01.562: Intraoperative Neurophysiologic Monitoring Treatments: [Intraoperative Neurophysiologic Monitoring (Any Modality), Intraoperative Neurophysiologic Monitoring (Primary Modalities), Somatosensory-Evoked Potentials, Motor-Evoked Potentials (Transcranial Electrical Stimulation), Brainstem Auditory-Evoked Potentials, Electromyography (Intraoperative), Electroencephalography (Intraoperative), Electrocorticography, Motor-Evoked Potentials (Transcranial Magnetic Stimulation), Train of Four Monitoring, Visual-Evoked Potentials]; Indications: [Any Indication/Context, Spinal, intracranial, or vascular surgical procedures, Aortic, thoracic, or abdominal aneurysm repair, Aortic cross-clamping, Arteriovenous malformation repair of the spinal cord, Brachial plexus surgery, Cerebral vascular surgery, Clipping of intracranial aneurysms, Cortical localization, Decompression of facial nerve, Interventional neuroradiology, Intracranial arteriovenous malformation, Location of the hypoglossal nerve during implantation of a hypoglossal nerve stimulator, Multilevel cervical fusion (anterior, posterior, artificial disc arthroplasty), Parotid tumor resection, Pelvic fracture surgery, Release of a tethered cord, Repair of coarctation of the aorta, Resection of acoustic neuroma, Resection of fourth ventricular cyst, Resection of intracranial vascular lesions, Resection of skull base tumor (including posterior fossa tumor), Resection of spinal cord tumor, cyst, or vascular lesion, Resection of tumor involving a cranial nerve, Resection of tumor involving the facial nerve, Scoliosis correction with instrumentation, Surgical stabilization of spine fractures, Stereotactic surgery of the brain or brain stem, thalamus, or cerebral cortex, Thalamus tumor resection or thalamotomy, Thyroid/parathyroid surgery, Thoracic to L1-L2 lumbar spine surgery, Anterior cervical spine surgery, Surgery on the peripheral nerves, Decompression, neurectomy, radiosurgery, or rhizotomy of the trigeminal nerve, Epidural injections, Facet joint injections or medial branch blocks, Lumbar spine surgery below L1/L2, Placement of an intrathecal pain pump, Placement or removal of spinal cord or dorsal root ganglion stimulators, Radiofrequency facet ablation/denervation procedures, Routine cervical spine surgery, Sacroiliac injections, Esophageal surgeries, Baseline neurophysiologic studies for procedures listed as Not Medically Necessary for IONM]
7.01.563: Ablative Treatments for Occipital Neuralgia, Chronic Headaches, and Atypical Facial Pain Treatments: [Any Ablative Procedure for Headache/Facial Pain, Chemical Neurolysis (Chemodenervation), Cooled Radiofrequency Ablation, Cryoneurolysis (Cryoablation), Pulsed Radiofrequency, Radiofrequency Ablation (RFA)]; Indications: [Any of the listed Headache or Facial Pain Conditions, Chronic Migraines, Chronic Tension-Type Headaches, Cluster Headaches, Cervicogenic Headaches, Occipital Neuralgia, Persistent Idiopathic Facial Pain (PIFP)]
7.01.564: Pulsed Radiofrequency Treatments: [Pulsed Radiofrequency]; Indications: [Various Chronic Pain Syndromes, Anterior cutaneous nerve entrapment syndrome (abdominal pain), Carpal tunnel syndrome, Chronic facial and head pain (persistent idiopathic facial pain (PIFP)/spheno-palatine ganglion), Coccydynia, Complex regional pain syndrome (reflex sympathetic dystrophy), Diabetic peripheral neuropathy, Discogenic pain, Facet joint pain (cervical, lumbar, thoracic, sacro-iliac)/zygapophyseal joint pain, Frozen shoulder (adhesive capsulitis), Headaches (e.g., cervicogenic, migraines, cluster, tension), Inguinal neuralgia, Intercostal neuralgia (post-surgical thoracic pain), Low back pain, Lumbo-sacral radicular pain (e.g., dorsal root ganglion), Meralgia paresthetica (burning pain in the outer thigh related to lateral femoral cutaneous nerve entrapment), Metacarpal or metatarsal joint pain of the hands and feet, Morton's neuroma, Myofascial pain syndrome (gastrocnemius/trapezius muscle), Neck pain (cervical radicular pain), Occipital neuralgia, Ophthalmic neuralgia, Orchialgia (testicular pain/spermatic cord), Osteoarthritis pain of the knee (genicular nerve, saphenous nerve, intra-articular) or hip, Pelvic pain (e.g., superior hypogastric plexus treatment for interstitial cystitis), Peripheral neuromas, Piriformis syndrome (buttock pain and/or pain in the back of the lower extremity related to sciatic nerve irritation), Plantar fasciitis (medial calcaneal nerve), Post herpetic neuralgia (ophthalmic neuralgia), Pudendal neuralgia, Sacro-iliac joint pain, Shoulder pain (suprascapular nerve) (hemiplegic shoulder pain after stroke), Tarsal tunnel syndrome (compression neuropathy from entrapment of the posterior tibial nerve), Trigeminal neuralgia (Gasserian ganglion), Vulvodynia]
7.01.565: Ablation of Peripheral Nerves to Treat Pain Treatments: [Any Peripheral Nerve Ablation for Pain, Radiofrequency Ablation of Peripheral Nerves, Cryoneurolysis of Peripheral Nerves, Chemical Neurolysis of Peripheral Nerves]; Indications: [Knee Osteoarthritis Pain, Plantar Fasciitis Pain, Occipital Neuralgia, Cervicogenic Headache, Total Knee Arthroplasty Pain, Intercostal Neuralgia, All Other Peripheral Nerve Pain Conditions, Facet Joint Pain Exception]
7.01.567: Surgical Treatments for Lymphedema and Lipedema Treatments: [Lipectomy or Liposuction, Group of Investigational Lymphedema Surgical Treatments, Lymphatic Microsurgical Preventing Healing Approach (LYMPHA), Reverse Lymphatic Mapping (ARM)]; Indications: [Lipedema, Lymphedema, Staged Procedures (Large Volume Aspirate), Treatment of Lipedema in Trunk or Back, Retreatment of Previously Treated Area, Lymphedema Prevention in Breast Cancer Patients, Used During Surgery (for Mapping)]
7.01.573: Hip Arthroplasty in Adults Treatments: [Total Hip Arthroplasty (Initial), Hip Arthroplasty Revision, Any Hip Arthroplasty Procedure]; Indications: [Severe Hip Arthritis or Avascular Necrosis, Disabling Hip Pain or Functional Disability, Acute Hip Fracture, Malignancy of Hip Joint/Pelvis/Proximal Femur, Non-union or Malunion of Articular Fracture, Qualifying State for Primary THA (Arthritis/AVN, Symptoms, Imaging, Failed Cons Tx), Other/Non-Qualifying Hip Conditions/Indications, Active Hip Infection or Systemic Bacteremia, Active Skin Infection or Open Wound at Surgical Site, Permanent/Irreversible Muscle Weakness Preventing Ambulation, Rapidly Progressive Neurological Disease, Neuropathic (Charcot) Joint, Aseptic Loosening of Prosthetic Components, Bearing Surface Wear with Symptoms/Reaction, Prosthetic Component Instability, Displaced Periprosthetic Fracture, Prosthetic Component Failure or Recall, Periprosthetic Infection, Progressive/Substantial Periprosthetic Bone Loss, Recurrent/Irreducible Dislocation, Recurrent Disabling Pain w/ Leg Length Inequality or Audible Noise, Adult Patients (Age 19+), Patients Under Age 19]
7.01.574: Implantable Peripheral Nerve Stimulation for the Treatment of Chronic Pain and Other Conditions Treatments: [Implantable Peripheral Nerve Stimulation]; Indications: [Any Indication, Chronic Pain or Other Conditions, Severe Intractable Chronic Pain of Peripheral Nerve Origin, Bladder Dysfunction, Urgency Urinary Incontinence, Refractory Non-Specific Chronic Low Back Pain associated with Multifidus Dysfunction, Chronic Hemiplegic Shoulder Pain, Mononeuropathies of the Upper Extremity, Lower Extremity Neuropathic Pain, Lower Extremity Post-Amputation Pain, Chronic Intractable Pain Responsive to PNS, Trial Stimulation, Permanent Placement]
7.01.582: Bioengineered Skin and Soft Tissue Substitutes Treatments: [AlloDerm, AlloMend, Cortiva, DermACELL, DermaMatrix, FlexHD, FlexHD Pliable, Graftjacket Regenerative Tissue Matrix / Graftjacket Skin Substitute, AlloPatch, Apligraf, Dermagraft, Integra Dermal Regeneration Template / Omnigraft, IntegraFlowable Wound Matrix, mVasc, TheraSkin, Oasis Wound Matrix, OrCel, Epicel, BEAR (Bridge-Enhanced ACL Repair) Implant, ReCell, Suprathel, Cytal / MatriStem, Helicoll, Keramatrix / Kerasorb, Kerecis Omega3 Wound, Permacol, PriMatrix / PriMatrix Dermal Repair Scaffold, SurgiMend / SurgiMend PRS, Strattice Reconstructive Tissue Matrix, Integra Bilayer Wound Matrix / Integra Meshed Bilayer Wound Matrix, Integra Matrix Wound Dressing / Avagen, TransCyte, AC5, ACell UBM Hydrated Wound Dressing / ACell UBM Lyophilized Wound Dressing, AlloSkin, Aongen Collagen Matrix, Apis, Architect ECM, PX, FX, ArthroFlex / Flex Graft, AxoGuard Nerve Protector (AxoGen), BellaCell HD, Biobrane / Biobrane-L, bio-Connekt Wound Matrix, CollaCare / CollaCare Dental, Collagen Wound Dressing (Oasis Research), CollaGUARD, CollaMend, CollaWound, Coll-e-derm, Collexa, Collieva, Conexa, Coreleader Colla-Pad, CorMatrix, Cymetra (Micronized AlloDerm), DeNovoSkin, Derm-Maxx, Dermadapt Wound Dressing, Derma-gide, DermaPure, DermaSpan, DressSkin, Durepair Regeneration Matrix, Endoform Dermal Template, ENDURAGen, Excellagen, ExpressGraft, E-Z Derm, FlowerDerm, GammaGraft, hMatrix, Hyalomatrix / Hyalomatrix PA, InnovaMatrix AC, FS, XL, PD, InteguPly, Keroxx, MatriDerm, Matrix HD, Microderm biologic wound matrix, Microlyte matrix, Mediskin, MemoDerm, Mirragen Advanced Wound Matrix, Miro Products (Miroderm, Miro3d, Mirodry, Mirotract), MyOwn skin, Myriad matrix / Myriad morcells, Neomatrix, Novosorb Biodegradable Temporizing Matrix (BMT) / SynPath, Ologen Collagen Matrix, Omeza Collagen Matrix, PermeaDerm B, C, Glove, Phoenix Wound Matrix, ProgenaMatrix, Puracol / Puracol Plus Collagen Wound Dressings, PuraPly / PuraPly AM / PuraPly XT, Puros Dermis, RegenePro, Repliform, Resolve matrix, Repriza, Restrata / Restrata minimatrix, Supra SDRM, SkinTE, StrataGraft, Surederm, Symphony, Talymed, TenoGlide Tendon Protector Sheet, TenSIX Acellular Dermal Matrix, TheraForm Standard / Sheet, TheraGenesis, Tissue Mend, TruSkin, Tutomesh Fenestrated Bovine Pericardium, Veritas Collagen Matrix, XCelliStem, XCM Biologic Tissue Matrix, XenMatrix AB, Skin cell suspension autograft preparation and application, Unspecified Skin Substitute Product]; Indications: [Breast reconstructive surgery, Chronic, non-infected, full-thickness diabetic lower-extremity ulcers, Chronic, non-infected, partial or full-thickness lower-extremity skin ulcers due to venous insufficiency, Dystrophic epidermolysis bullosa (mitten-hand deformity), Second- and third-degree burns, Complete rupture of the ACL, Tendon repair (excluding ACL), Surgical repair of hernias or parastomal reinforcement, Acute or infected wounds/ulcers, Any indication other than the specific ones listed as Medically Necessary for a product from the MN list, Any indication]
7.01.583: Amniotic Membrane and Amniotic Fluid Treatments: [Any Amniotic/Placental Product or Application, Affinity Amniotic Membrane Graft, AmnioBand Membrane Graft, Biovance Amniotic Membrane Graft, EpiCord Amniotic Membrane Graft, Epifix Amniotic Membrane Graft, Grafix Amniotic Membrane Graft, Corplex, Theracor, Allacor Amniotic Products, Human amniotic membrane grafts for ophthalmic use, Injection of micronized or particulated human amniotic membrane, Injection of human amniotic fluid, All other amniotic/placental products (Investigational)]; Indications: [Any Indication/Condition, Nonhealing diabetic lower-extremity ulcers, Ophthalmic conditions, Osteoarthritis, Plantar fasciitis, Lower extremity ulcers due to venous insufficiency, Repair following Mohs micrographic surgery, All other indications (Not Explicitly Addressed), Application exceeding reasonable size, Diabetic ulcer applications beyond 12 weeks]
7.01.584: Nerve Repair for Peripheral Nerve Injuries Using Synthetic Conduits or Allografts Treatments: [Synthetic Conduits or Nerve Allografts for Peripheral Nerve Repair]; Indications: [Peripheral Nerve Injury Requiring Repair (Including Nerve Gaps)]
7.01.586: Cochlear Implant Treatments: [Any Cochlear Implant, Unilateral Cochlear Implantation, Bilateral Cochlear Implantation, Hybrid Cochlear Implant, Cochlear Implant Component Replacement, Cochlear Implant External Component Aesthetic Upgrade]; Indications: [Bilateral Severe-to-Profound Sensorineural Hearing Loss, Single-Sided Deafness (SSD), Asymmetrical Sensorineural Hearing Loss (AHL), Bilateral High-Frequency SNHL with Residual Low-Frequency Hearing, Tinnitus, Absence of Cochlear Development, Cochlear Ossification, Lesions of Auditory Nerve, Central Auditory Pathway, or Brainstem, Active or Chronic Infection of Ear or Mastoid, Tympanic Membrane Perforation, Component Replacement Due to Functional Failure, Component Replacement Due to Condition Change, Component Upgrade Solely for Technology Advancement, Component Upgrade Solely for Aesthetic Improvement]
7.01.587: Open and Thoracoscopic Approaches to Treat Atrial Fibrillation and Atrial Flutter (Maze and Related Procedures) Treatments: [Maze or Modified Maze Procedure with Concomitant Cardiac Surgery, Open Maze or Modified Maze Procedure without Concomitant Cardiac Surgery, Stand-Alone Minimally Invasive, Off-Pump Maze Procedure, Hybrid Ablation (Endocardial/Epicardial)]; Indications: [Symptomatic Atrial Fibrillation or Atrial Flutter]
7.01.588: Percutaneous Electrical Nerve Stimulation and Percutaneous Neuromodulation Therapy Treatments: [Percutaneous Electrical Nerve Stimulation, Percutaneous Neuromodulation Therapy, Percutaneous Electrical Nerve Stimulation or Percutaneous Neuromodulation Therapy]; Indications: [Chronic Pain Conditions (for Treatment), Diagnostic Assessment for Suitability of Ongoing Stimulation]
7.01.589: Artificial Intervertebral Disc: Lumbar Spine Treatments: [Artificial Intervertebral Disc Implantation (Lumbar), Removal of Lumbar Total Disc Arthroplasty, Revision/Replacement of Lumbar Total Disc Arthroplasty]; Indications: [Symptomatic single level lumbar degenerative disc disease (L3-L4, L4-L5, or L5-S1), Skeletally mature individuals up to age 60, Symptoms for at least 6 months unresponsive to 3 months of nonoperative conservative management, Device approved by FDA for single level use, Active infection, Anatomical deformity (e.g., ankylosing spondylitis), Disc implantation at more than one level, History of lumbar disc replacement, History of rheumatoid arthritis, lupus, or other autoimmune disorder, Lumbar scoliosis, Lumbar artificial disc combined with lumbar spinal fusion (hybrid surgery), Malignant tumor, Metabolic bone disease (e.g., osteoporosis, osteopenia), Multilevel degenerative disc disease, Nerve root compression or spinal stenosis, Pars interarticularis defect with spondylolysis or isthmic spondylolisthesis, Significant facet arthropathy at the operative level, Spinal instability with spondylolisthesis greater than Grade 1, Previous fusion at another lumbar level, Spinal fracture, All other indications not listed as medically necessary]
7.01.590: Shoulder Arthroplasty Treatments: [Total Shoulder Arthroplasty, Reverse Shoulder Arthroplasty, Shoulder Hemiarthroplasty, Revision Shoulder Arthroplasty]; Indications: [Degenerative Joint Disease, Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Avascular Necrosis, Proximal Humerus Fracture Malunion or Non-union, Reconstruction After Tumor Resection, Failed Hemiarthroplasty, Post-traumatic Joint Destruction, Glenohumeral Osteoarthritis with Irreparable Rotator Cuff Tear, Pseudoparalysis from Irreparable Rotator Cuff Tear, Massive Rotator Cuff Tear Arthropathy, Avascular Necrosis or Osteonecrosis of Humeral Head without Glenoid Involvement, Shoulder Fracture Not Repairable or Reconstructible, Failed Total Shoulder Arthroplasty with Non-repairable Rotator Cuff Tear, Inadequate Glenoid Bone Stock to Support Prosthesis, Proximal Humerus Fracture Not Amenable to Internal Fixation, Aseptic Loosening of Prosthetic Component, Bearing Surface Wear with Symptoms, Prosthetic Component Instability, Displaced Periprosthetic Fracture, Prosthetic Component Failure or Recall, Migration of Humeral Head Prosthesis, Periprosthetic Infection, Recurrent Prosthetic Dislocation, Persistent Shoulder Pain of Unknown Etiology Unresponsive to Conservative Care, Active Joint Infection or Systemic Bacteremia, Active Skin Infection or Open Wound at Surgical Site, Allergy to Implant Components, Deltoid Deficiency, Inadequate Bone Stock for Prosthesis Implantation, Neuropathic (Charcot) Arthropathy of the Shoulder, Paralytic Disorder of the Shoulder, Rapidly Progressive Neurological Disease]
7.01.591: Interspinous Fixation (Fusion) Devices Treatments: [Interspinous Fixation (Fusion) Devices]; Indications: [Any Indication, Use in combination with interbody fusion, Use alone for decompression, Spinal Stenosis, Spondylolisthesis, Degenerative Disc Disease, Exception: Small Pedicles preventing screw placement]
7.01.592: Surgical Treatment of Femoroacetabular Impingement Treatments: [Arthroscopic Femoroacetabular Impingement (FAI) Surgery]; Indications: [Femoroacetabular Impingement (FAI) Meeting Medical Necessity Criteria, Hip Arthroscopic Labral Repair (Alone or Adjunct to FAI Surgery), Advanced Osteoarthritis (Tönnis Grade 2 or 3), Severe Chondral (Cartilage) Damage (Outerbridge Grade IV), All Other Situations Not Meeting Medical Necessity Criteria]
7.01.593: Vagus Nerve Stimulation Treatments: [Implanted Vagus Nerve Stimulation, Non-Implantable/Transcutaneous Vagus Nerve Stimulation, Any Vagus Nerve Stimulation]; Indications: [Medically Refractory Seizures, Major Depressive Disorder (Unipolar Depression), Bipolar Depression, Depression with Psychotic Features, History of Vagotomy, Current or Planned Therapeutic Diathermy, Other Investigational Conditions, VNS in Conjunction with Transcranial Magnetic Stimulation (TMS), VNS in Conjunction with Other Neuromodulation Modalities, VNS in Conjunction with Ketamine or Psychedelic Drugs, Any Indication]
7.01.594: Percutaneous Revascularization Procedures for Lower Extremity Peripheral Arterial Disease Treatments: [Percutaneous Revascularization Procedures (General), Balloon Angioplasty, Stenting, or Atherectomy, Balloon Angioplasty, Stent Procedures, Atherectomy, Intravascular Lithotripsy]; Indications: [Functionally Limiting Claudication (Chronic Symptomatic PAD), Chronic Limb-Threatening Ischemia (CLTI), Acute Limb Ischemia (ALI), Asymptomatic Peripheral Arterial Disease (PAD), Access in Support of Other Procedures, Any Covered Indication (General)]
7.01.595: Carpal Tunnel Release Surgical Techniques Treatments: [Open Carpal Tunnel Release, Endoscopic Carpal Tunnel Release, Thread Carpal Tunnel Release, US-guided Percutaneous Needle Release]; Indications: [Carpal Tunnel Syndrome, Repeat surgery after previous failure, Criteria not met]
7.01.596: Adjunctive Techniques for Screening, Surveillance, and Risk Classification of Barrett Esophagus and Esophageal Dysplasia Treatments: [Wide-area transepithelial sampling with three-dimensional computer-assisted analysis (WATS3D), TissueCypher, Esopredict, EsoCheck Cell Collection Device, EsoGuard, BarreGen]; Indications: [Barrett Esophagus (General), Barrett Esophagus without Dysplasia (NDBE), Barrett Esophagus with Indefinite for Dysplasia, Barrett Esophagus with Low-Grade Dysplasia (LGD), Barrett Esophagus with High-Grade Dysplasia (HGD), Esophageal Adenocarcinoma (EAC), At-Risk Population for BE Screening, Screening for BE, Surveillance for BE, Risk Stratification/Prognosis for Progression]
7.01.63: Deep Brain Stimulation Treatments: [Any Deep Brain Stimulation System/Procedure, Deep Brain Stimulation of the Thalamus, Deep Brain Stimulation of Globus Pallidus or Subthalamic Nucleus]; Indications: [Tremor due to Parkinson's disease, Essential Tremor, Parkinson's Disease Meeting GPi/STN Medical Necessity Criteria, Primary Dystonia Meeting Medical Necessity Criteria, Post-traumatic dyskinesia, Tardive dyskinesia/dystonia, Chronic cluster headaches, Alcohol addiction, Alzheimer disease, Anorexia nervosa, Chronic Pain (excluding headache), Depression, Epilepsy, Tremor due to Multiple Sclerosis, Obsessive-compulsive disorder, Tourette syndrome, Huntington's Disease, Chronic Facial Pain, Other Psychiatric or Neurologic Disorders (Not listed elsewhere), Any Indication (Not Specified Elsewhere), Poor Surgical Risk / Unstable Medical Problems, Conditions Requiring Repeated MRI, Dementia Interfering with Cooperation, Botulinum Toxin Injection within 6 Months, Non-idiopathic Parkinson's or Parkinson's Plus Syndromes, Current Psychosis, Current Alcohol or Other Drug Abuse, Movement Disorder due to Structural Lesions, Previous Movement Disorder Surgery]
7.01.69: Sacral Nerve Neuromodulation/Stimulation Treatments: [Sacral Nerve Neuromodulation (Any), Sacral Nerve Neuromodulation Trial, Sacral Nerve Neuromodulation Permanent Implantation]; Indications: [Urge Incontinence, Urgency-Frequency Syndrome, Nonobstructive Urinary Retention, Overactive Bladder (OAB), Chronic Fecal Incontinence, Contraindication: Neurologic Condition (for UI/UR), Contraindication: Anorectal Malformation/IBD (for FI), Stress Incontinence, Urge Incontinence due to Neurologic Condition (Investigational), Other Investigational Urinary/Voiding Applications, Chronic Constipation, Chronic Pelvic Pain, Any Indication/Context]
7.01.72: Percutaneous Intradiscal Electrothermal Annuloplasty, Radiofrequency Annuloplasty, Biacuplasty, and Intraosseous Basivertebral Nerve Ablation Treatments: [Percutaneous Intradiscal Electrothermal Annuloplasty, Intradiscal Radiofrequency Annuloplasty, Intradiscal Biacuplasty, Intraosseous Basivertebral Nerve Ablation]; Indications: [Chronic Discogenic Back Pain, Vertebrogenic Back Pain]
7.01.78: Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions Treatments: [Osteochondral Autografting, Fresh Osteochondral Allografting, Autologous Minced or Particulated Cartilage, Allogeneic Minced or Particulated Cartilage, Decellularized Osteochondral Allograft Plugs, Reduced Osteochondral Allograft Discs, Any Osteochondral Grafting Procedure (Autograft or Allograft)]; Indications: [Focal Articular Cartilage Lesion (General), Symptomatic full-thickness knee cartilage defect meeting specific criteria for autograft, Full-thickness knee cartilage defect where autografting is inadequate, Large (>1.5cm²) or cystic (>3.0cm³) osteochondral lesions of the talus, Osteochondral lesion of the talus after failed prior marrow stimulation, Focal articular cartilage lesions in other joints, Misalignment and instability of the joint, Procedure performed at outpatient hospital or ASC site of service, Procedure performed at inpatient hospital site of service, Patient meets criteria for increased risk justifying inpatient stay, Patient does not meet criteria for increased risk justifying inpatient stay]
7.01.83: Auditory Brainstem Implant Treatments: [Auditory Brainstem Implant (Any Type/Use), Unilateral Auditory Brainstem Implant, Bilateral Auditory Brainstem Implant, Penetrating Electrode Auditory Brainstem Implant (PABI)]; Indications: [Any Indication/Use Context, Neurofibromatosis Type 2 (NF2) with Deafness from Bilateral Auditory Nerve Neurofibroma Resection, Other Conditions (Non-NF2 Related) Causing Deafness]
7.01.84: Semi-Implantable and Fully Implantable Middle Ear Hearing Aids Treatments: [Semi-Implantable and Fully Implantable Middle Ear Hearing Aids, Semi-Implantable Middle Ear Hearing Aid, Fully Implantable Middle Ear Hearing Aid]; Indications: [Sensorineural Hearing Loss, Conductive Hearing Loss, Mixed Hearing Loss, Aural Atresia, Adult patients (>= 18 years), Desire alternative to acoustic hearing aid, Prior experience with appropriately fitted hearing aids, Normal middle ear anatomy, Psychologically and motivationally suitable with realistic expectations, Pure-tone air-conduction thresholds within specific limits, Word recognition score >= 50%, Unaided speech discrimination test score >= 40%, Normally functioning eustachian tube, Normal tympanic membrane, Adequate space for implant (CT scan)]
7.01.85: Electrical Stimulation of the Spine as an Adjunct to Spinal Fusion Procedures Treatments: [Noninvasive Electrical Bone Growth Stimulation, Invasive Electrical Bone Growth Stimulation, Semi-invasive Electrical Bone Growth Stimulation, Any Electrical Bone Growth Stimulation Type]; Indications: [Lumbar Spinal Fusion (Adjunctive Use), High Risk for Lumbar Spinal Fusion Failure (Context), Failed Lumbar Spinal Fusion, Cervical Spinal Fusion (Adjunctive Use), Failed Cervical Spinal Fusion]
7.01.92: Cryoablation of Tumors Located in the Kidney, Lung, Breast, Pancreas, or Bone Treatments: [Cryoablation]; Indications: [Localized renal cell carcinoma <= 4 cm, Need to preserve kidney function for RCC, Individual is not a surgical candidate (any site), Renal cell carcinomas in individuals who ARE surgical candidates, Early-stage non-small cell lung cancer, Poor surgical candidate for NSCLC, Palliation for central airway obstructing lesion (Lung), Bone cancer and bone metastases, Lung tumors and lung metastases (other than MN criteria), Malignant or benign tumors of the breast, Pancreatic cancers]
7.01.95: Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors Treatments: [Radiofrequency Ablation]; Indications: [Primary or metastatic liver tumors (Any use), Osteolytic bone metastases (failed or poor candidates for standard treatment), Osteoid osteomas (cannot be managed successfully with medical treatment), Localized renal cell carcinoma <= 4cm (meeting medical necessity criteria), Isolated peripheral non-small-cell lung cancer <= 3cm (meeting medical necessity criteria), Malignant nonpulmonary tumor(s) metastatic to the lung <= 3cm (meeting medical necessity criteria), Breast tumors (Any use), Lung cancer (not meeting medical necessity criteria), Renal cell cancer (not meeting medical necessity criteria), Osteoid osteomas (can be managed successfully with medical treatment), Painful bony metastases (as initial treatment), All other tumors outside the liver (Any use)]
7.03.01: Kidney Transplant Treatments: [Kidney Transplant]; Indications: [End-Stage Renal Disease, Kidney Retransplant After Failed Primary Transplant, Any other indication not listed as Medically Necessary, Known current malignancy, Recent malignancy with high risk of recurrence, History of cancer with a moderate risk of recurrence, Systemic disease that could be exacerbated by immunosuppression, Untreated systemic infection, Other irreversible end-stage diseases not attributed to kidney disease, Psychosocial conditions or chemical dependency affecting ability to adhere to therapy]
7.03.02: Allogeneic Pancreas Transplant Treatments: [Any Pancreas Transplant Type, Pancreas Transplant after Prior Kidney Transplant, Combined Pancreas and Kidney Transplant, Pancreas Transplant Alone, Pancreas Retransplant]; Indications: [Insulin-Dependent Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus with Uremia, Severely Disabling/Life-Threatening Complications of Hypoglycemia Unawareness and Labile Diabetes, Failed Primary Pancreas Transplant, All Other Situations, Contraindication: Known Current Malignancy, Contraindication: Recent Malignancy with High Recurrence Risk, Contraindication: Untreated Systemic Infection, Contraindication: Other Irreversible End-Stage Disease, Contraindication: History of Cancer (Moderate Risk), Contraindication: Systemic Disease Exacerbated by Immunosuppression, Contraindication: Psychosocial/Chemical Dependency Affecting Adherence, Contraindication: Partial Pancreatic Tissue or Islet Cells Transplant]
7.03.04: Isolated Small Bowel Transplant Treatments: [Any Small Bowel Transplant Type, Small bowel transplant using cadaveric intestine, Small bowel transplant using a living donor, Small bowel retransplant]; Indications: [Intestinal Failure (Meeting MN Criteria), Failed Primary Small Bowel Transplant, Intestinal Failure (Tolerating TPN), Contraindication: Known Current Malignancy, Contraindication: Recent Malignancy with High Recurrence Risk, Contraindication: Untreated Systemic Infection, Contraindication: Other Irreversible End-Stage Diseases, Contraindication: History of Cancer with Moderate Recurrence Risk, Contraindication: Systemic Disease Exacerbated by Immunosuppression, Contraindication: Psychosocial or Chemical Dependency Issues, Rule: Cadaveric Intestine Not Available, Rule: Living Donor Transplant in Other Situations]
7.03.05: Small Bowel, Liver and Multivisceral Transplant Treatments: [Small Bowel and Liver Transplant, Multivisceral Transplant, Any Small Bowel, Liver or Multivisceral Transplant (Including Retransplant)]; Indications: [Intestinal Failure with TPN complications and impending end-stage liver failure, Failed Primary Small Bowel, Liver or Multivisceral Transplant, All Other Situations Not Meeting Medically Necessary Criteria, Malignancy (Current or History with significant recurrence risk), Systemic Disease Exacerbated by Immunosuppression, Untreated Systemic Infection, Other Irreversible End-Stage Disease (Not from Intestinal Failure), Psychosocial Condition or Chemical Dependency Affecting Adherence, Procedure Expected to be Futile, Post-Transplantation Care Expected to Worsen Comorbidities]
7.03.07: Lung and Lobar Lung Transplant Treatments: [Lung Transplant (Single or Double), Lobar Lung Transplant, Lung or Lobar Lung Retransplantation, Any Lung or Lobar Lung Transplant or Retransplant]; Indications: [Irreversible, Progressively Disabling, End-Stage Pulmonary Disease, Candidate for Retransplantation (Meeting Initial Criteria), Any Other Situation Not Outlined as Medically Necessary, Contraindication: Known Current Malignancy, Contraindication: Recent Malignancy with High Risk of Recurrence, Contraindication: Untreated Systemic Infection, Contraindication: Other Irreversible End-Stage Diseases (Not Lung), Contraindication: History of Cancer with Moderate Risk of Recurrence, Contraindication: Systemic Disease Exacerbated by Immunosuppression, Contraindication: Psychosocial/Chemical Dependency Affecting Adherence, Contraindication: Severe Coronary Artery Disease, Contraindication: Colonization with Highly Resistant/Virulent Infection]
7.03.08: Heart/Lung Transplant Treatments: [Heart/lung transplant, Heart/lung retransplantation, Any Heart/Lung Transplant Type]; Indications: [End-stage cardiac and pulmonary disease, All other situations not meeting Medical Necessity criteria, Known current malignancy, Recent malignancy with high risk of recurrence, Untreated systemic infection, Other irreversible end-stage diseases (not cardiac/pulmonary), History of cancer with moderate risk of recurrence, Systemic disease exacerbated by immunosuppression, Psychosocial/chemical dependency issues affecting adherence]
7.03.09: Heart Transplant Treatments: [Human heart transplantation, Heart retransplantation]; Indications: [End-stage heart failure, End-stage heart failure in adults meeting specific medically necessary criteria, End-stage heart failure in pediatric individuals meeting specific medically necessary criteria, Conditions considered inadequate indications for cardiac transplantation in adults unless other criteria are met, Failed primary heart transplant requiring retransplantation consideration, All other situations not specifically outlined as medically necessary, Known current malignancy, Recent malignancy with high risk of recurrence, Untreated systemic infection, Other irreversible end-stage diseases not attributed to heart or lung disease, History of cancer with a moderate risk of recurrence, Systemic disease that could be exacerbated by immunosuppression, Psychosocial conditions or chemical dependency affecting ability to adhere to therapy, Fixed pulmonary hypertension or severe pulmonary disease, UNOS Status 7, Age over 70 years (relative contraindication), Body mass index >= 35 kg/m² (relative contraindication), Diabetes with end-organ damage or poor glycemic control (relative contraindication), Irreversible renal dysfunction (relative contraindication), Clinically severe symptomatic cerebrovascular disease (relative contraindication), Peripheral vascular disease (relative contraindication), Frailty (relative contraindication), Active tobacco smoking during previous 6 months (relative contraindication), Retransplantation within first six months after previous transplantation with immunologic complications]
7.03.11: Total Artificial Hearts and Implantable Ventricular Assist Devices Treatments: [Implantable Ventricular Assist Device (FDA Approved), Total Artificial Heart (FDA Approved), Percutaneous Ventricular Assist Device, Non-FDA Approved Ventricular Assist Device or Total Artificial Heart]; Indications: [Bridge to Heart Transplantation, Destination Therapy, Postcardiotomy Setting or Bridge to Recovery, End-stage Heart Failure (Adult, meeting specific criteria for Destination Therapy), Biventricular Failure (meeting specific criteria for TAH Bridge to Transplant), Cardiogenic Shock, High-Risk Cardiac Procedures (e.g., PCI), Acute Decompensated Heart Failure, Ventricular Tachycardia (VT) Ablation, Any other application or indication not specifically listed as Medically Necessary, Contraindication: Chronic irreversible hepatic, renal, or respiratory failure, Contraindication: Systemic infection, Contraindication: Coagulation disorders, Contraindication: Inadequate psychosocial support, Contraindication: Uncorrected valvular disease]
7.03.12: Islet Transplantation for Chronic Pancreatitis and Donislecel-jujn for Type 1 Diabetes Treatments: [Autologous Pancreas Islet Transplantation, Allogeneic Pancreas Islet Transplantation with Donislecel-jujn (Lantidra)]; Indications: [Chronic Pancreatitis (Adjunct to Pancreatectomy), Type 1 Diabetes Mellitus, Contraindication: Seizure Disorder or History, Contraindication: Prior Portal Thrombosis, Contraindication: Liver Disease, Contraindication: Renal Failure, Contraindication: Prior Renal Transplant Recipient, Contraindication: Type 1 Diabetes Well-Controlled with Insulin, Contraindication: Preventable Severe Hypoglycemia, Contraindication: Active Alcoholism, Contraindication: Pancreatic Cancer, Contraindication: End-Stage Systemic Illness, Contraindication: Psychiatric/Socioeconomic Status Hindering Care, All Other Situations (for Donislecel-jujn), Any Indication or Context]
7.03.13: Composite Tissue Allotransplantation of the Hand and Face Treatments: [Composite Tissue Allotransplantation of the Hand and/or Face]; Indications: [Severe Facial Disfigurement (due to burns or trauma), Hand or Upper-Extremity Amputation, Any Indication]
7.03.509: Liver Transplant and Combined Liver-Kidney Transplant Treatments: [Liver Transplant (Cadaver or Living Donor), Liver Retransplantation, Combined Liver-Kidney Transplantation]; Indications: [End-Stage Liver Failure (General), Alcoholic Liver Disease, Viral Hepatitis (A, B, C, non-A, non-B), Autoimmune Hepatitis, α1-Antitrypsin Deficiency, Hemochromatosis, Nonalcoholic Steatohepatitis, Protoporphyria, Wilson Disease, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis (with secondary cirrhosis), Biliary Atresia, Budd-Chiari Syndrome, Inborn Errors of Metabolism, Trauma and Toxic Reactions (Liver), Familial Amyloid Polyneuropathy, Primary Hepatocellular Carcinoma, Polycystic Liver Disease with Massive Hepatomegaly, Unresectable Hilar Cholangiocarcinoma, Pediatric Nonmetastatic Hepatoblastoma, Advanced Irreversible Kidney Disease (for Combined Transplant), Primary Graft Nonfunction (for Retransplant), Hepatic Artery Thrombosis (for Retransplant), Chronic Rejection (for Retransplant), Ischemic Type Biliary Lesions (after DCD for Retransplant), Recurrent Non-Neoplastic Disease (causing graft failure for Retransplant), Intrahepatic Cholangiocarcinoma, Neuroendocrine Tumors Metastatic to Liver, Alagille Syndrome, Pediatric Acute Liver Failure, Pediatric Hepatic Tumors (General), Hemangioendothelioma, Cystic Fibrosis-Associated Liver Disease, Urea Cycle Disorders, Immune-Mediated Liver Disease (Pediatric), Other Pediatric Metabolic/Genetic Disorders, HIV Infection (Controlled), Hepatitis C Virus (HCV) Infection, All Other Indications Not Listed, Hepatocellular Carcinoma Extended Beyond Liver, Ongoing Alcohol or Drug Abuse, Known Current, Recent, or Extrahepatic Malignancy, Untreated Systemic Infection or Sepsis, Other Irreversible End-Stage Diseases, Psychosocial Issues Affecting Adherence, Tobacco Consumption, MELD Score < 15, Anatomic Abnormality Precluding Transplant, Fulminant Hepatic Failure, Hemangiosarcoma, Pediatric Persistent Viremia]
8.01.01: Adoptive Immunotherapy Treatments: [Adoptive Immunotherapy (General), Cytotoxic T Lymphocytes, Cytokine-Induced Killer Cells, Tumor-Infiltrating Lymphocytes, Dendritic Cells, Genetically Engineered T Cells]; Indications: [Any other cancer or indication not explicitly addressed, Epstein-Barr virus-associated cancers, Cytomegalovirus-associated cancers, Nasopharyngeal carcinoma, Renal cell carcinoma, Gastric cancer, Colorectal cancer, Hepatocellular carcinoma, Non-small-cell lung cancer, Melanoma, Glioblastoma multiforme, Medullary thyroid cancer, Pancreatic cancer, Hodgkin and non-Hodgkin lymphoma, Prostate tumors, Neuroblastoma]
8.01.11: Transcatheter Arterial Chemoembolization (TACE) to Treat Primary or Metastatic Liver Malignancies Treatments: [Transcatheter Arterial Chemoembolization (TACE)]; Indications: [Unresectable Hepatocellular Carcinoma (Confined, No PVT, Not Child-Pugh C), Hepatocellular Carcinoma (Bridge to Transplant, Specific Criteria Met), Symptomatic Metastatic Neuroendocrine Tumor (Liver Mets, Criteria Met), Liver-Dominant Metastatic Uveal Melanoma, Hepatocellular Carcinoma (Neoadjuvant/Adjuvant Therapy in Resectable HCC), Hepatocellular Carcinoma (In Combination with Radiofrequency Ablation - RFA), Unresectable Cholangiocarcinoma, Liver Metastases from Other Primary Tumors, Hepatocellular Carcinoma (Uses Not Meeting Medically Necessary Criteria), Recurrent Hepatocellular Carcinoma, Hepatocellular Carcinoma (Pre-Transplant Use, Other than Bridge)]
8.01.15: Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Treatments: [Allogeneic Hematopoietic Cell Transplantation, Autologous Hematopoietic Cell Transplantation]; Indications: [Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (Any Risk/Stage), Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with markers of poor-risk disease, Richter transformation (Transformation to high-grade lymphoma), Purine analogue relapsed and/or refractory CLL/SLL, CLL/SLL refractory to small-molecule therapy, T cell, prolymphocytic leukemia, B cell, prolymphocytic leukemia, As part of clinical trials]
8.01.17: Hematopoietic Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome Treatments: [Autologous Hematopoietic Cell Transplantation, Tandem Autologous Hematopoietic Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Initial Allogeneic Hematopoietic Cell Transplantation, Tandem Autologous followed by Reduced-Intensity Conditioning Allogeneic HCT]; Indications: [Multiple Myeloma, POEMS Syndrome, Disseminated POEMS Syndrome, Multiple Myeloma - Newly Diagnosed, Multiple Myeloma - Relapsed or Refractory, Rule: Failure to achieve near-complete/VGPR after first Auto HCT, Rule: Individual did NOT receive initial Auto HCT, Rule: Relapse after Auto HCT with >18 mo remission, Rule: Relapse after Auto HCT with <24 mo relapse or high risk features, Rule: In the context of a clinical trial]
8.01.23: Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer Treatments: [Any Hematopoietic Cell Transplant, Autologous Hematopoietic Cell Transplant, Allogeneic Hematopoietic Cell Transplant]; Indications: [Advanced Stage Epithelial Ovarian Cancer]
8.01.24: Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults Treatments: [Hematopoietic Cell Transplantation (Any Type), Autologous Hematopoietic Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation]; Indications: [Solid Tumors (Miscellaneous), Cancer of the bile duct, Cancer of the fallopian tubes, Cervical cancer, Colon cancer, Esophageal cancer, Gall bladder cancer, Lung cancer (any histology), Malignant melanoma, Nasopharyngeal cancer, Neuroendocrine tumors, Pancreatic cancer, Paranasal sinus cancer, Prostate cancer, Rectal cancer, Renal cell cancer, Soft tissue sarcomas, Stomach cancer, Thyroid tumors, Tumors of the thymus, Tumors of unknown primary origin, Uterine cancer, Use in NIH-approved clinical trials (Autologous HCT)]
8.01.25: Hematopoietic Cell Transplantation for Autoimmune Diseases Treatments: [Autologous Hematopoietic Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Any Hematopoietic Cell Transplantation Type]; Indications: [Systemic Sclerosis/Scleroderma, Multiple Sclerosis, Systemic Lupus Erythematosus, Juvenile Idiopathic or Rheumatoid Arthritis, Chronic Inflammatory Demyelinating Polyneuropathy, Type 1 Diabetes, Other Specified Autoimmune Diseases, Any Autoimmune Disease (General), Systemic Sclerosis: Meeting Medical Necessity Criteria, Systemic Sclerosis: Not Meeting Medical Necessity Criteria, Contraindication: Severe/Irreversible Organ Involvement]
8.01.26: Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Treatments: [Allogeneic HCT with Myeloablative Conditioning, Allogeneic HCT with Reduced-Intensity Conditioning, Autologous Hematopoietic Cell Transplantation, Any Hematopoietic Cell Transplantation Type]; Indications: [Acute Myeloid Leukemia (General), AML in First Complete Remission, Poor or Intermediate Risk, AML refractory to standard induction, achieving CR with intensified chemo, AML relapsed after CR1, achieving CR2 or beyond with intensified chemo, AML relapsed after prior autologous HCT, achieving CR with intensified chemo & medically able, AML in CR1 or beyond AND medically unable to tolerate myeloablative conditioning, AML in CR1+, OR relapsed AML responsive to intensified chemo, AND not candidate for allo, Any AML scenario not meeting explicit MN criteria]
8.01.28: Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma Treatments: [Autologous Hematopoietic Cell Transplantation, Tandem Autologous Hematopoietic Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation]; Indications: [Central Nervous System (CNS) Embryonal Tumors (General), Previously Untreated CNS Embryonal Tumors with Response or Stable Disease to Induction Chemotherapy, Recurrent CNS Embryonal Tumors, Ependymoma, Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor (PNET)]
8.01.29: Hematopoietic Cell Transplantation for Hodgkin Lymphoma Treatments: [Autologous Hematopoietic Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Tandem Autologous Hematopoietic Cell Transplantation, Second Autologous HCT after Prior Autologous HCT, Any Hematopoietic Cell Transplantation Type]; Indications: [Hodgkin Lymphoma, Primary Refractory or Relapsed Hodgkin Lymphoma, Newly Diagnosed Hodgkin Lymphoma in First Complete Remission (Consolidation), Other Uses of HCT in Hodgkin Lymphoma]
8.01.30: Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia Treatments: [Allogeneic HCT (Myeloablative Conditioning), Allogeneic HCT (Reduced-Intensity Conditioning), Autologous HCT]; Indications: [Chronic Myeloid Leukemia]
8.01.36: Extracorporeal Photopheresis Treatments: [Extracorporeal Photopheresis]; Indications: [Organ Rejection After Solid Organ Transplant, Cardiac Allograft Rejection, Prophylactic Prevention of Rejection After Cardiac Transplantation, Other Solid Organ Rejection or Prevention (e.g., Lung, Liver, Kidney), Graft-Versus-Host Disease (GVHD), Acute or Chronic GVHD: Previously untreated or responding to established therapies, Cutaneous T-cell Lymphoma (CTCL), Late stage (III/IV) Cutaneous T-cell Lymphoma, Early stage (I/II) Cutaneous T-cell Lymphoma that is progressive and refractory to established nonsystemic therapies, Early stage (I/II) CTCL: Previously untreated or responsive to established nonsystemic therapies, Autoimmune Diseases (Cutaneous or Visceral Manifestations), All Other Indications]
8.01.42: Hematopoietic Cell Transplantation for Primary Amyloidosis Treatments: [Autologous Hematopoietic Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation]; Indications: [Primary Systemic (AL) Amyloidosis]
8.01.502: Home Nutritional Support Treatments: [Oral Enteral Nutrition/Supplements for Defined Conditions, Specialized Oral Infant Formulas for Non-Covered Indications, General Food and Nutritional Supplements (Explicitly Non-Covered Examples), Relizorb Immobilized Lipase Cartridge, Enteral Formulas (Tube Administered)]; Indications: [Inborn Errors of Metabolism (General), Histidinemia, Homocystinuria, Maple Syrup Urine Disease (MSUD), Phenylketonuria (PKU), Tyrosinemia, Eosinophilic Gastrointestinal Associated Disorders (EGID), Washington Fully-Insured Members Policy Context, Conditions Other Than Inborn Errors of Metabolism or EGID (for infant formulas), Cow's Milk Allergy, Food Allergies (General), Gluten Sensitive Enteropathy (Celiac Disease), Intolerance to Soy Formulas, Lactose Intolerance, Multiple Protein Intolerances, Prematurity or Low Birth Weight, Protein or Fat Maldigestion, Sensitivities to Intact Protein, Any Indication (General Rule), Pancreatic Insufficiency Due to Cystic Fibrosis, Any Indication Other Than Pancreatic Insufficiency Due to Cystic Fibrosis]
8.01.519: Nonpharmacologic Treatment of Hyperhidrosis Treatments: [Any Nonpharmacologic Treatment for Hyperhidrosis, Endoscopic Transthoracic Sympathectomy, Surgical Excision of Axillary Sweat Glands, Axillary Liposuction, Iontophoresis, Microwave Treatment, Radiofrequency Ablation, Aluminum Chloride 20% Solution, Lumbar Sympathectomy, Tympanic Neurectomy, Botulinum Toxin, Topical Anticholinergic Medications, Oral Anticholinergic Medications, Brella Sweat Control Patch]; Indications: [Hyperhidrosis (General), Primary Focal Hyperhidrosis (General Criteria), Primary Focal Hyperhidrosis - Axillary Region, Primary Focal Hyperhidrosis - Palmar Region, Primary Focal Hyperhidrosis - Plantar Region, Primary Focal Hyperhidrosis - Craniofacial Region, Severe Secondary Gustatory Hyperhidrosis, Absence of a Functional Impairment, Conservative Treatment Failed, Age 18 or Greater]
8.01.520: Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia Treatments: [Autologous Hematopoietic Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation (Standard Conditioning), Reduced-intensity conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation]; Indications: [Childhood Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia, Childhood ALL in First Complete Remission (CR1) at high risk of relapse, Childhood ALL in Second or greater remission (CR2+), Adult ALL in First complete remission (CR1) any relapse risk level, Adult ALL in Second or greater remission (CR2+), Relapsing ALL after a prior autologous HCT or prior chemotherapy, Adult ALL with refractory disease, Individuals unable to tolerate a standard myeloablative conditioning regimen]
8.01.521: Radioembolization for Primary and Metastatic Tumors of the Liver Treatments: [Radioembolization]; Indications: [Primary Hepatocellular Carcinoma (Unresectable, Limited to Liver), Primary Hepatocellular Carcinoma (Bridge to Liver Transplantation), Primary Intrahepatic Cholangiocarcinoma (Unresectable), Hepatic Metastases from Neuroendocrine Tumors (Diffuse, Symptomatic, Systemic Therapy Failed), Hepatic Metastases from Colorectal Carcinoma, Melanoma (Ocular/Cutaneous), or Breast Cancer (Unresectable, Refractory to Systemic Therapy), Other Hepatic Metastases (Not Explicitly Medically Necessary), Inability to Catheterize the Hepatic Artery, Fulminant Liver Failure, Significant Nontarget Deposition to GI Organs (Uncorrectable), Unfavorable Pulmonary Shunt Fraction, Active Hepatic Infection, Pregnancy, Excessive Tumor Burden in the Liver, Elevated Bilirubin (> 2 mg/dL, Non-obstructive), Prior Radiation Therapy to Liver or Upper Abdomen, Concurrent Systemic Therapies]
8.01.529: Hematopoietic Cell Transplantation for Non-Hodgkin Lymphomas Treatments: [Autologous Hematopoietic Cell Transplant (Any Conditioning), Allogeneic Hematopoietic Cell Transplant (General), Reduced-Intensity Conditioning (RIC) Allogeneic HCT, Myeloablative Autologous HCT, Myeloablative Allogeneic HCT, Tandem Transplant, Any Hematopoietic Cell Transplant Type]; Indications: [Non-Hodgkin Lymphoma (General), NHL B-cell aggressive subtype (except mantle cell), Mantle cell NHL B-cell subtype, NHL B-cell indolent subtypes, Mature T-cell or NK (peripheral T-cell) lymphoma (General), Mature T-cell or NK (peripheral T-cell) lymphoma (High-Risk Subtypes), Mature T-cell or NK (peripheral T-cell) lymphoma (Not High-Risk Subtypes), Hepatosplenic T-cell lymphoma, Any B-cell NHL subtype, All NHL with low or low-intermediate IPI score, Salvage therapy for individuals not in complete remission after first line chemotherapy, Consolidate complete remission in chemotherapy sensitive first or subsequent relapse, Consolidate complete remission in individuals with age-adjusted IPI predicting high or high-intermediate risk of relapse, Consolidate a first complete remission, As initial therapy without completion of full course standard induction chemotherapy (B-Cell NHL), Consolidate a first complete remission for indolent B-cell NHL, Consolidate a first complete remission in high-risk subtypes (Mature T-cell/NK), Salvage therapy (Mature T-cell/NK lymphoma), Consolidate a first CR or partial response (Hepatosplenic T-cell), As initial therapy without full induction chemotherapy (Hepatosplenic T-cell), Tandem transplants for any NHL, Consolidate a first complete remission for All NHL with low or low-intermediate IPI score]
8.01.52: Orthopedic Applications of Stem Cell Therapy (Including Allografts and Bone Substitutes Used with Autologous Bone Marrow) Treatments: [Mesenchymal Stem Cell Therapy, Allograft Bone Products Containing Viable Stem Cells, Allograft or Synthetic Bone Graft Substitutes Combined with Autologous Blood or Bone Marrow, Intramuscular Autologous Bone Marrow Cell Therapy, Autologous Cellular Implant Derived from Adipose Tissue]; Indications: [All Orthopedic Applications, Cartilage Defects, Meniscal Defects, Osteonecrosis, Osteoarthritis, Osteoarthritis of the Knee, Osteoarthritis of the Hip, Osteoarthritis of the Hand, Glenohumeral Joint Osteoarthritis (Shoulder), Degenerative Disease of the Lumbar Spine, Rheumatoid Arthritis, Use in Joint Fusion Procedures]
8.01.531: Hematopoietic Cell Transplantation for Waldenström Macroglobulinemia Treatments: [Autologous hematopoietic cell transplantation, Allogeneic hematopoietic cell transplantation]; Indications: [Waldenström Macroglobulinemia, Waldenström Macroglobulinemia, Chemosensitive (Salvage Therapy), Waldenström Macroglobulinemia, Refractory]
8.01.532: Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors Treatments: [Any Hematopoietic Cell Transplantation, Any Autologous HCT Type, Single Autologous HCT, Tandem or Sequential Autologous HCT, Allogeneic HCT]; Indications: [Germ-Cell Tumors (Any Context), Germ-Cell Tumors (Any Salvage or Refractory), Testicular Tumors (Salvage or Platinum-Refractory), Germ-Cell Tumors (First-Line Treatment)]
8.01.539: Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms Treatments: [Any Allogeneic Hematopoietic Cell Transplantation, Myeloablative Allogeneic Hematopoietic Cell Transplantation, Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation]; Indications: [Myelodysplastic Syndromes, Myeloproliferative Neoplasms]
8.01.53: Cellular Immunotherapy for Prostate Cancer Treatments: [Sipuleucel-T Therapy]; Indications: [Asymptomatic or Minimally Symptomatic Castration-Resistant Metastatic Prostate Cancer, Hormone-Responsive Prostate Cancer, Moderate to Severe Symptomatic Metastatic Prostate Cancer, Visceral Metastases (Liver, Lung, Brain), Any Other Situation Not Meeting Criteria]
8.01.540: Cranial Electrotherapy Stimulation and Auricular Electrostimulation Treatments: [Cranial Electrotherapy Stimulation, Auricular Electrostimulation]; Indications: [Any Indication or Situation, Pain, Insomnia, Depression, Anxiety, Weight Loss, Opioid Withdrawal Symptoms, Functional Constipation, Parkinson Disease, Addiction, Tic Disorders, Context: Practice of Acupuncture]
8.01.55: Stem Cell Therapy for Peripheral Arterial Disease Treatments: [Stem Cell Therapy for Peripheral Arterial Disease]; Indications: [Peripheral Arterial Disease (PAD) / Critical Limb Ischemia (CLI)]
8.01.61: Focal Treatments for Prostate Cancer Treatments: [Focal Laser Ablation, High-Intensity Focused Ultrasound (HIFU), Cryoablation, Radiofrequency Ablation (RFA), Photodynamic Therapy, Irreversible Electroporation (IRE), Magnetic Nanoparticle Ablation, Water Vapor Thermotherapy]; Indications: [Localized Prostate Cancer]
8.01.62: Electronic Brachytherapy for Nonmelanoma Skin Cancer Treatments: [Electronic Brachytherapy for Nonmelanoma Skin Cancer]; Indications: [Nonmelanoma Skin Cancer]
8.01.63: Chimeric Antigen Receptor Therapy for Leukemia and Lymphoma Treatments: [Any Chimeric Antigen Receptor T-Cell Therapy, Aucatzyl (obecabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Yescarta (axicabtagene ciloleucel)]; Indications: [B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Aggressive Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, Other Applications/Unspecified Indications, Repeat Treatment, Burkitt Lymphoma, Active Infection (Hepatitis B, C, Uncontrolled), Grade 2 to 4 Graft-versus-host Disease, Genetic Syndrome associated with Bone Marrow Failure (except Down Syndrome), Received Allogeneic Cellular Therapy within 6 weeks prior, Active Central Nervous System ALL, Primary Central Nervous System Lymphoma]
8.01.66: Chimeric Antigen Receptor Therapy for Multiple Myeloma Treatments: [Abecma (idecabtagene vicleucel) IV, Carvykti (ciltacabtagene autoleucel) IV]; Indications: [Relapsed or Refractory Multiple Myeloma (R/R MM), Active Infection, Inflammatory Disorders, Prior CAR T-cell therapy, Considering or received any other gene therapy, Repeat Treatment, All other uses or conditions not specified as Medically Necessary]
8.03.01: Functional Neuromuscular Electrical Stimulation Treatments: [Functional Neuromuscular Electrical Stimulation]; Indications: [Restore Function Following Nerve Damage or Injury, Ambulation in Spinal Cord Injury, Upper Extremity Function Loss (Nerve Damage), Foot-Drop, Exercise in Spinal Cord Injury, Use as Home Exercise Equipment, Cardiac Pacemaker, Severe Scoliosis or Osteoporosis, Skin Disease or Cancer at Stimulation Site, Irreversible Contracture, Autonomic Dysreflexia]
8.03.09: Vertebral Axial Decompression Treatments: [Vertebral Axial Decompression]; Indications: [Any Indication, Low Back Pain, Herniated Lumbar Disc, Degenerative Lumbar Disc Disease, Incapacitating Low Back Pain]
8.03.501: Chiropractic and Other Manipulation Services Treatments: [Standard Chiropractic Care (CMT/SMT), Active Therapeutic Movement (ATM2), Advanced Biostructural Correction (ABC), Applied Spinal Biomechanical Engineering, Arvigo Techniques of Maya Abdominal Therapy (ATMAT), Atlas Orthogonal Technique, BioEnergetic Synchronization Technique (BEST), Biogeometric Integration (BGI), Chiropractic Biophysics Technique, Coccygeal Meningeal Stress Fixation Technique, Cranial Manipulation, Craniosacral Therapy (Upledger), Digital Analysis of Posture, Digital Radiographic Mensuration Analysis, Directional Non-Force Technique, Dry Hydrotherapy, Graston Technique, Manipulation for Infant Colic, Manipulation for Internal Disorders (Applied Kinesiology), Manipulation Under Anesthesia (MUA), Moire Contourographic Analysis, Network Technique (Network Spinal Analysis), Neural Organizational Technique, Neurocalometer/Nervoscope, Paraspinal EMG/Surface Scanning EMG, Sacro-Occipital Technique (SOT), Spinoscopy, Thermography, Thermomechanical Massage, Webster Technique (Breech Position), Wobble Chair]; Indications: [Neuromusculoskeletal Condition (Expected to Resolve/Improve), Non-Neuromusculoskeletal Condition, Treatment Without Neuromusculoskeletal Diagnosis, Condition Not Resolving or Improving, Maintenance or Preventive Therapy, Idiopathic Scoliosis (for Curve Correction), Solely for Asymptomatic Spinal Goals, Simple Pain Without Documented Cause, Any Indication/Context]
8.03.502: Physical Medicine and Rehabilitation – Physical Therapy and Medical Massage Therapy Treatments: [Physical Medicine and Rehabilitation - Physical Therapy and Medical Massage Therapy]; Indications: [Physical functional impairment or disability interfering with ADLs, Chronic Pain (Intractable, Moderate to Severe), Chronic Diseases or Conditions (Moderate to Severe, Lasting >= 3 months), Homebound Status, Flat Feet, Criteria for Medical Necessity Not Met, Duplicate Therapy, Maintenance Therapy Program, Non-skilled Therapy Services, Plan of Care Requirements Not Met, Services Provided by Unqualified Provider]
8.03.503: Occupational Therapy Treatments: [Occupational Therapy]; Indications: [Physical functional impairment or disability interfering with activities of daily living (ADLs), Home-based therapy (individual is homebound), Duplicate therapy (same treatment/diagnosis as PT), Maintenance therapy programs, Non-skilled services]
8.03.505: Speech Therapy Treatments: [Speech Therapy (General), Voice therapy for gender transition/affirmation]; Indications: [Communication impairment or swallowing disorders (General), Gender transition/affirmation, Self-correcting communication dysfunctions (Developmental), Duplicate therapy, Non-skilled services, Maintenance programs]
9.02.500: Orthodontic Services for Treatment of Congenital Craniofacial Anomalies Treatments: [Craniofacial Treatment Services (Orthodontics, Surgery, Appliances)]; Indications: [Certain Congenital Craniofacial Anomalies, Developmental Malocclusion Not Related to Severe Congenital Craniofacial Anomaly]
9.02.501: Orthognathic Surgery Treatments: [Orthognathic Surgery, Orthognathic Surgical Splints, Endoscopically-Assisted Nasomaxillary Expansion, Condylar Positioning Devices]; Indications: [Congenital Anomalies or Deformities, Traumatic Injury or Tumor Removal (Restoration of Function), Maxillary/Mandibular Skeletal Deformities with Masticatory Malocclusion, Severe Malocclusion Contributing to TMJ Syndrome Symptoms, Airway Dysfunction and Obstructive Sleep Apnea (OSA), Cosmetic Purposes, Obstructive Sleep Apnea (OSA) Treated with Endoscopic Nasomaxillary Expansion, Any Indication (General Rule), Orthognathic Surgical Splint Quantity (> 2), All Other Indications Not Explicitly Listed]
9.02.502: DENTAL BENEFIT COVERAGE GUIDELINE – 9.02.502 Periodontics Treatments: [X-ray imaging for periodontal diagnosis, Counseling for periodontal disease, Prophylaxis and sealants for periodontal disease, Periodontal tissue regeneration (Osseous, Soft Tissue, Biologics), Collagen plugs or tape for periodontal treatment]; Indications: [Periodontal disease]
9.02.503: Computerized Diagnostic Imaging for Complex Maxillofacial Procedures Treatments: [Computerized Diagnostic Imaging (Any Type), 2D/3D Oral/Facial Photographs, Cone Beam Computed Tomography (CBCT), Maxillofacial Magnetic Resonance Imaging (MRI), Maxillofacial Ultrasound, Sialoendoscopy, Intraoral Tomosynthesis, Interpretation of Diagnostic Image, Treatment Simulation Using 3D Image Volume, Digital Subtraction of Images, Fusion of 3D Image Volumes, 3D Printing of 3D Dental Surface Scan]; Indications: [Complex Maxillofacial Procedures/Problems, Routine Pre-treatment Screening, Substitute for Traditional Dental X-rays, Recall and/or Periodic Examinations, For Planned Therapy, Implants, Complex Third Molar Extractions, Temporomandibular Joint (TMJ) Surgical Planning, Orthognathic Surgical Planning, For Diagnostic Purposes, Suspicion of Head and Neck Neoplasms, Head and Neck Trauma, For Post-treatment Care, Consideration of Retreatment of Endodontic Procedures, Consideration of Retreatment of Implant Placement]
9.02.506: Dental Restorations Treatments: [Any Dental Restoration, Fillings (Amalgam and Composite), Crowns, Inlays and Onlays, Cosmetic Restorations and Veneers, Gold Foil Restorations, Other Specified D2XXX Procedures]; Indications: [Any Dental Issue or Need, Meet Specific Criteria for Crowns/Inlays/Onlays, Cosmetic Purpose Only, To Increase Vertical Dimension, On Malformed Teeth (e.g., Peg Laterals), Supporting Medically Necessary Treatment, Determined Not Dentally Necessary by Dental Review]
9.03.507: Fundus Photography Treatments: [Fundus Photography]; Indications: [Fundus abnormalities, progression of known disease, or eye injury response, Abnormal electro-oculogram or oculomotor studies, Abnormal retinal function studies, Abnormal visually evoked potential, Age-related macular degeneration, Anti-malarial therapy when fundus changes noted during standard screening, Autoimmune disease involving the eye, Benign neoplasm of the eye, adn...]
9.03.508: Orthoptic Training for the Treatment of Vision or Learning Disabilities Treatments: [Orthoptic Training / Vision Therapy (General), Office-Based Vergence/Accommodative Therapy, Neuro-visual (Optometric) Rehabilitation]; Indications: [Symptomatic Convergence Insufficiency, Learning and Reading Disabilities (including ADD, Dyslexia, Dysphasia), Slow Reading, Neurological Conditions after Brain Injury Affecting Visual System, All Other Conditions (including Visual Disorders other than CI)]
